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ABSTRACT
Tï70 methods for the measurement of cyclic AICP, 
enzymic radioisotopic displacement and protein binding 
(saturation) assay, were established.
Vitamins B%2 and C were found, in vitro studies, 
to be more effective inhibitors of cyclic AMP phospho­
diesterase than theophylline.
Plasma and urinary levels of cyclic A1<!P were found 
to exhibit a diurnal variation in normal volunteers. The 
majority gave a plasma pattern with a maximum at 24.00h 
and a minimum at l6.00h. The minority plasma pattern 
showed a peak at 12.00h. The urinary excretion gave a 
pattern in the majority with a maximum between 04.00 - 
OS.OOh and a minimum between 12,00 — l6.00h. The minority 
showed a peak urine value between 12.00 - l6,00h and a 
trough between 24*00 - 04*00h.
A further pattern was noted in menstrual cycle with 
a mid-cycle peak. This was absent in males, and was lost 
in secondary eunenorrhoea, pregnancy and after prolonged 
ingestion of oral contraceptives. The amplitude was more 
pronounced in pre-menstrual tension syndrome, suggesting 
the possibility of overswing.
IV
Muscular activity produced a transient increase in 
plasma cyclic AT.îP, but this was not reflected in the 
urinary level. Limited studies on dietary change 
showed no significant influence.
Patients suffering from endogenous depression showed 
low plasma and urinary levels of cyclic AI'IP. On clinical 
improvement urinary levels returned to the normal range.
The urinary excretion of cyclic AÎ-ÎP in endogenous depression 
showed a peak between 08.00 - 12.00 h. On clinical 
improvement the pattern became bimodal with peaks between 
04*00 — 08,00h and 16,00 - 20.00h, ' The reactive depression
group showed a bimodal pattern (peaks between 24*00 - 04.00h 
and 12.00 — l6.00h) both before and after clinical 
improvement.
Electro-convulsive therapy caused a marked rise in 
both plasma and urinary levels of cyclic AMP on the day of 
treatment. The plasma concentration doubled and remained 
elevated for up to 90 min after electrical stimulation. 
Patients who did not respond to E.C.T. in terms of cyclic 
AMP increase also showed no clinical improvement.
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1.1. Cyclic Aie
A heat stable factor mediating the glycogenolytic 
effect of adrenaline and glucagon in the liver, was 
discovered by Rail (1957)* This was later
identified (Sutherland and Rail, 1957? Lipkin et al.,
1959) as adenosine 3*,5* cyclic monophosphate, commonly 
referred to as cyclic AÎ^ÏP (Figure 1.1.). This nucleotide 
occurs throughout the animal kingdom (Robison et al., 1971)? 
in micro-organisms (Perlman and Pastan, 1971? Pastan, 1972; 
Ashworth, 1974) and in plant tissues (Rewton, 1974?
Po-Chao Lin, 1974)*
•  Carbon atom 
® Nitrogen atom  
O Oxygen atom
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Figure 1.1. One of the two conformations for cyclic AMP 
in the crystalline state (Watenpaugh et al., 1968).
1.2. Biogenesis of Cyclic AI4P
Figure 1.2. illustrates the reaction by which cyclic 
AIvIP is produced fx*ora ATP under the catalytic influence of 
adenyl cyclase (Rail and Sutherland, -1962). This ensyme 
system is found in the plasma membrane of vertebrates 
(Rodbell, 19725 Bitensky & Gorman, 1972), and requires a 
divalent cation (Mg** or Mn**) as co-factor (Robison et al.,
1971)* The apparent %  value ranges from O.O8 - O.50 mM 
depending upon the tissue preparation (Hardman et al., 1971a).
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Figure 1.2. The adenyl cyclase reaction.
The adenyl cyclase reaction is reversible under certain 
conditions (Greengard et al., 1972) indicating that cyclic AI4P 
is itself an energy rich molecule. Measurement of the free 
energy of hydrolysis of cyclic AI^IP to Al'IP gives a value of 
48 kj/mol as compared with the value of 36 kJ/mol for the 
hydrolysis of ATP to ADP.
1.2.1. Distribution of Adenyl Cyclase
Adenyl cyclase has been found in all animals so far 
studied as well as in micro-organisms and in plants 
(Table 1.1.).
Adenyl cyclase activity has been detected in a 
multiplicity of mammalian tissues and some of these are 
listed in Table 1.2. together with hormones which affect 
the enzyme activity. The enzyme appears to be absent from 
the erythrocytes of some mammals (Sutherland et al., 1962), 
but is present in the nucleated red blood cells of birds 
and frogs (Davoren & Sutherland, 1963; Rosen & Rosen, 1969) 
The brain, and especially the grey matter, contains the 
highest adenyl cyclase activity of the mammalian tissues 
studied (Robison jet aA., 1970); this activity probably 
having a post-synaptic location (Mcllwain, 1971)*
1.2.2. Properties of Adenyl Cyclase
Adenyl cyclase preparations from a variety of tissues 
have lipoprotein characteristics, show lability and are 
sensitive to certain hormones (Robison ejb al., 1970).
This last aspect is of key importance and seems to develop 
at different times for different tissues (Schmidt et al., 
I97O; Palmer ejt , 1972b). Catecholamines (beta 
component) and a number of polypeptide hormones (excluding 
insulin and melatonin), activate the adenyl cyclase system 
leading to an increase in the intracellular concentration 
of cyclic Aî^îP in the target tissues (Table 1.3. )• This
Table 1.1. Species distribution of adenyl cyclase
Mammals 
Birds
Amphibians
Fish
Insects
Liver fluke 
Bacteria 
Slime molds 
Plants
Robison, Butcher & Sutherland (1971).
Langslow (l971); Riddick, Kregenow 
& Or1off (1971).
Rosen (1971); Bockaert, Roy &
Jard (1972).
Menon & Smith (1971)•
Sutherland, Rail and Menon (1962),
Segmented worms Sutherland, Rail and Menon (1962).
Sutherland, Rail and Menon (1962). 
Pastan (1972).
Ashworth (l974).
Newton (1974).
aspect will be discussed later (l,4.) in greater detail.
The prostaglandins, a group of complex lipids with 
hormonal activities (Horton, 1972), can increase cyclic 
AIvIP in a variety of tissues (e.g. heat*t, thyroid, platelets) 
through activation of adenyl cyclase, with PGE compounds 
being more effective than PGP (Shio .et , 1971;
Harwood et al., 1972). This action does not appear to 
involve specific receptors on the plasma membrane.
Prostaglandins may, however, cause a decrease in cyclic At«ÎP 
levels possibly by interfering with ATP binding to adenyl 
cyclase. Such inhibitory effects are encountered in 
lipolysis, in vasopressin-induced water movement in renal 
tubules, in dopamine-induced hyperpolarisation of postganglionic 
neurones in superior cervical ganglia (McAfee & Greengard,
1972) and in noradrenaline-induced inhibition of the spontaneous 
discharge of cerebellar Purkinje cells (Horton, 1972). Again 
the PGS compounds show more potent inhibition than the PGP 
series. Currently it .is not possible to predict whether the 
effects of prostaglandins on a particular tissue will be to 
inhibit or to stimulate cyclic AîuP formation (Shio et al»,
1971).
Fluoride can markedly stimulate adenyl cyclase activity 
in a variety of preparations from multicellulai' organisms 
(Rail & Sutherland, 1958) but not in bacteria (Tao & Lipman, 
1969). In the developing rat brain fluoride has little 
influence for the first 5 days postpartum, then stimulation
Table 1.2. Distribution and Hormonal Sensitivity of Mammalian 
Adenyl Cyclase
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Tissue
Liver
Skeletal
muscle
Cardiac
muscle
Hormone affecting 
Adenyl Cyclase
Reference
Kidney
Bone
Glucagon and adrenaline Park and Exton (1972).
Brain
Adrenal
Corpus Luteura
Ovary
Testis
Thyroid
Parotid
Adrenaline
Catecholamines
Glucagon
Triiodothyronine
Vasopressin
Parathyroid
Parathyroid
Calcitonin
Catecholamines
ACTE
LH and prostaglandins 
LH .
LH and PSH 
TSH
Prostaglandins 
Catecholamines _
Mayer and Stull (l97l)* 
Robison jet al. (1971)5
Levey (l971a).
Mayer et (l9?0):
Levey %T971b).
Levey (l971o).
Major and Kilpatrick (1972).
Melson ^  al, (l970); 
l>îarcus et al. (1971 )•
Chase et al. (1969)5 
Aurbach ejt al. (1972).
Murad et al. (1970).
Rail (1972)5 
Skolnick ^  al» (1973).
Grahame-Smith _et al, (1967)5 
Al banc and Brown ^ 974).
March (l970a,b). .
Dorrington and Baggett (1969)
Hollinger (1970)5 
Kuehl ^  al. (1970).
Major and Kilpatrick (1972).
Field et (1969).
Schramm and Nairn (1970)5 
Selinger and Schramm (1971)*
Pineal Catecholamines Weiss and Strada (1972).
Table 1.2. (Contd.)
Tissue Hormone affeoting
Adenyl Cyclase
Lung Adrenaline
Spleen Adrenaline
Adipose Adrenaline, Glucagon
TSH, AGTH, LH, Secretin
Brown Adipose Catecholamines
Platelets Prostaglandins
Reference
Leucocytes
Erythrocytes
Uterus
Pancreas
Anterior
pituitary
Vascular 
smooth muscle
Catecholamines and 
Prostaglandins
None demonstrated
Catecholamines
None demonstrated
Hypothalamic releasing 
factors (e.g. TRH)
None demonstrated 
Hair follicles Diliydrotestosterone
Klainer at (1962); 
Kaliner al. (1971 )«
Klainer .et al. (1962).
Rodbell (1972).
Butcher and Baird (1969).
Cole et aJ. (l97l);
Harwood et al. (1972).
Scott (1970);
Bourne and Melson (1971)»
Sheppard and Burghardt (1969)
Triner et al. (1971)=
Cohen and Bitensky (1969 )•
Steiner et al. (l970);
Bowers and Robison (1971 )•
Klainer et al. (1962).
Adachi and Kano (l970).
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becomes apparent reaching a maximum after a further 10 to 
15 days (Sclimidt _et al., 1970). Fluoride stimulation 
only occurs with homogenized tissues (i.e. broken cells) 
and not with intact cells (Oye & Sutherland, I966). It 
is probable that fluoride bypasses the hormone receptor 
and acts directly on the catalytic side of the cyclase 
(Drummond et al., 1971)» This direct action being possible 
only when the plasma membrane is disrupted (Rodbell, 1972).
Studies on cations indicate that Mn++ can replace Mg"*"^' 
in some preparations (Birnbaumer et al.. I969). Ca'**’^' is
inhibitory in general (Rasmussen, 1970) although it may be 
required for optimal cyclase activity in adrenal cortex 
(Bar & Hechter, I969) and brain (Bradham _et aJ., 1970).
Cu"^ "^  and Zn’*"*' are strongly inhibitory and Go"^ "^  causes some 
inhibition (Birnbaumer .et , 19^9), whereas Ha’*' and E* have 
little effect in homogenates. In brain slices (Sattin &
Rail, 1967) and rat diapliragm muscle (Lundholm et al.,
1967 ) an increase in the ratio of to Ha"*" can lead to an 
increase in cyclic AI'IP level. Rodbell (1972) has discussed 
the implications of a changing ionic microenvironment on the 
adenyl cyclase system and has reported (Rodbell et al.,
1971) a need for the presence of GTP to achieve glucagon 
activation of liver plasma membrane adenyl cyclase. This 
allosteric modulation by GTP has also been reported for the 
prostaglandin activation of adenyl cyclase in human platelet 
membranes (Harorood et al., 1973; Krishna et al., 1972), 
and the oxytocin stimulation of adenyl cyclase in frog bladder
Table 1.3* Some Hormones That Mediate Their Action Through 
Cyclic AMF
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Hormone
Catecholamines 
(beta component)
Glucagon
ACTH
Vasopressin
Luteinizing hormone
PSH
Melanocyte stimulating 
hormone
Tissue
Liver
Pat
Muscle
Heart
Parotid gland
Uterus
Leukocytes
Cerebellum
Liver
Pat
Heart
Pancreatic islets 
Adrenal Cortex 
Pat
Toad Bladder 
Kidney
Pituitary gland 
Corpus luteum 
Ovary 
Testis - 
Testis
Prog skin
Effect of Hormone
On tissue On Adenyl 
cyclic AI'/p Cyclase
Increase
Increase
Increase
Increase
Increase
Increase
Unsettled
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Unsettled
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Unsettled
Stimulation
Stimulation
Unsettled
Stimulation
Unsettled
Stimulation
Stimulation
Stimulation
Stimulation
Increase Unsettled
Table 1.3» (Contd.)
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Hormone Tissue
Effect of Hormone
On tissue 
cyclic AMP Cyclase
Parathyroid hormone
Calcitonin
Thyrotropin releasing 
factor
Insulin
Melatonin
Catecholamines 
(alpha component)
Kidney
Bone
Kidney
Bone
Increase
Increase
Increase
Increase
Stimulation
Stimulation
Stimulation
Unsettled
Pituitary gland Increase Unsettled
Fat Decreased Unsettled
Liver Decreased Unsettled
Frog skin Decreased Unsettled
Pancreatic islets Decreased Unsettled
Platelets Decreased Unsettled
Frog skin Decreased Unsettled
13
epithelial cells (Bockaert et al,, 1972), More recently 
the suggestion has been made that cyclic AI'EP can modify 
adenyl cyclase activity by a kinase-dependent phosphorylation 
(Constantopoulos & Najjar, 1973) and in brain a low molecular 
weight activator of adenyl cyclase has been reported 
(Kauffman & Johnson, 1973).
1,3. BreakdoT-m of Cyclic AI-IP - Phosphodiesterase
Cyclic 3*5* - nucleotide phosphodiesterase was first 
demonstrated by Sutherland and Rail (1958). It is found 
mainly in the soluble fraction of the cell and catalyses the 
hydrolysis of cyclic AMP to 5 *-AI^ 3P (Figure 1,3.).
Phosphodiesterase(s) is widely distributed in nature 
including bacteria (ide, 1971)j slime molds (Ashworth, 1974) 
and plants,
H jO
NH
,CH2
fb o s P b S ro -p -o  -C  H 
diesterase ’ I
0- OH OH
Figure 1,3. The reaction catalysed by phosphodiesterase,
A table (l,4«) showing the range of values in dog tissue; 
has been adopted from Butcher and Sutherland (1962),
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Table 1.4» Tissue distribution of Mammalian phosuhodiesterase
Tissue pmol cyclic /dlP converted to 5 * AIÆP
per min per g fresh weight %30^0)
Brain cortex 41
Brain stem 15
Adrenal 12
Kidney medulla 7
Kidney cortex 6
Snail intestine (whole) 6
Cardiac ventricle 5
Spleen 4
Liver 4
Pancreas 4
Cardiac auricle 4
Cerebellum 3
Lung 3
Testis 2,5
Sartorius muscle 2
Aorta 1.5
Femoral artery 1
Diaphragm muscle 1
Femoral nerve 0.5
Erythrocytes 0
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Gel filtration, electrophoresis and kinetic studies 
have indicated the presence of isoenzymes (Thompson &
Appleman, 1971? Russell et al.. 1973 ). Rat brain, kidney 
and fat pad supernatants contain in the raol.wt. region 
400,000 a phosphodiesterase with a higher affinity for 
cyclic GPjP ( %  of 1 X 10"’^ H) than cyclic AI^IP (K^ i of 1 x 10"'^ M), 
In the mol.wt. region 200,000 from the same tissues an enzyme 
can be located which does not catalyse cyclic GÎÎP hydrolysis 
but has a %  for cyclic AICP of p % 10~^M. Liver contains 
detectable levels of the high mol.wt. enzyme only. It is 
possible that the lower mol.wt. form is associated with the 
membrane bound adenyl cyclase in an organised control system. 
The high mol.wt. form may be associated with the apparently 
soluble guanyl cyclase (Tata, 1973). Other reports of tissues 
containing multiple forms of phosphodiesterase include cerebrum 
(Fertel ^  , 1973), gastric mucosa (Sung et al., 1972),
human platelets (Pichard _et , 1973) and testis (Catt et al.,
1972).
Phosphodiesterase requires divalent cations for maximal
activity. For the bovine brain preparation, Mg"*"*" and Mn++
(l.O mM), Co"*"^  (O.l mM) and Zn (O.Ol niM) are effective, Ca**”’'
and Ba*^**' are ineffective, while Cu'*"^  and Hg"*"*" are inhibitory, 
added
In the elDsence of j cations about 30^ activity is found, which is 
suppressed by the addition of 1 mM EDTA.
A number of substances have been found to alter 
phosphodiesterase activity. Cheung (l970) reported that
16
nucleotide triphosphates are inhibitors at a concentration 
of 3 niî'î with ATP the most-effective (75^). Cyclic GMP 
was found to inhibit the action of phosphodiesterase in 
heart, and activate it in liver (Beavo et al., 1970;
Hardman, 1972). There is some evidence that triiodothyronine 
(Mandel & Kuehl, 19&7) cyclic AMP (De Lorenzo jet , 1973) 
and db cyclic AllP (Pastan, 1972) have an inhibitory effect 
on phosphodiesterase activity. A calcium dependent protein 
activator of phosphodiesterase has been found in brain '
(Eakiuchi ^  , 1972) and heart (Teo ejt 1973). Cyclic
AÎVÎP modulates the activa tor-enzyme interaction by enhancing 
the affinity of the enzyme for the activator. There would 
seem to be no equivalent in mammalian tissue to the potent 
protein inhibitor secreted by slime mold (Ashworth, 1974).
Methyl xanthines and especially theopîiylline have been 
the most widely used inhibitors of phosphodiesterase (Stanfield 
al., 1971), although recently some much more potent compounds 
have been available (e.g. ICI 63,197 and Squibb SQ 20,009).
A wide range of drugs have been checked for their inhibitory 
activity (Usunov & Weiss, 1971; Weinryb et al., 1972), and 
these include the tricyclic antidepressants (Beer^et ad., 1972) 
and -tetrahydrocannabinol (Moffat jet al., 1972).
Activation of cyclic nucleotide phosphodiesterase may be 
achieved by imidazole, nicotinic acid (Abdulla & Hamadah, 1970), 
imidazole acetic acid (Roberts and Simonsen, 1970) and ammonium 
ions (Hair, I966). It has been suggested that the therapeutic
17
effects of a number of the drugs quoted above may be 
mediated by the cyclic AMP system (Beer ^  al., 1972).
1.4» The Second Messenger. H;vn30thesis
The presence of cyclic AI»ÎP in most animal cells and 
the fact that many hormones increase the intracellular 
concentration of cyclic AICP in their target tissues (Table 1.3.), 
led to the development of the ’’second messenger” concept of 
hormone action (Sutherland ^  > 1968), This is represented
in figure 1.4. Rodbell (1972) has suggested that the adenyl 
cyclase system is composed of a regulatory sub-unit on the 
outer surface of the plasma membrane and a catalytic sub-unit 
with its active centre directed towards the interior of the 
cell. He proposed a discriminator (i.e. hormone receptor) - 
transducer - amplifier (adenyl cyclase) model.
To account for hormone-tissue selectivity, the regulatory 
sub-unit is made up of receptors specific for different hormones. 
Rodbell (1972) has reviewed evidence for a single discriminator 
in the majority of target tissues - see for example the work of 
Reik ^  (1970) on liver parenchyma and reticulo-endothelial
cells. In the fat cell, however, there would seem to be 
several receptors a/f fee ting a single adenyl cyclase (Birnbaumer 
& Rodbell, 1969). The receptor is protein in character and 
phospholipids may be involved in the linking of it to the 
appropriate hormone (Rodbell et al., 1968). Rodbell (l97l) 
and Levey (1973) provided evidence for the involvement of 
phospholipids in the coupling mechanism (transduction) of
18
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discriminator to cyclase. Storm and Dolginow (1973) 
have shoim that receptor interaction at the extracellular 
surface produces a conformational change in the cyclase, 
and thus an increase in its activity, at the intracellular 
surface.
The localization of the enzyme in the cell membrane
is also thought to regulate its activity. Disruption of
membrane function in brain by homogenization (Krishna et al,$
of
1971) leads to a loss[hormonal sensitivity while the enzyme
becomes fully active catalytically. Similar observations 
have been made with the use of digitonin in retina (Bitensky 
& Gorman, 1972) and in hepatomas where normal membrane function 
is absent (Chayoth et al., 1972). Adenyl cyclase is thought, 
therefore, to be intrinsically active (Bitensky cc Gorman,
1972) and under physiological conditions this activity is 
regulated by membrane components which exercise inhibitory 
constraint. This constraint is decreased by appropriate 
hormonal interaction or by a change in membrane organisation 
such as may occur in neoplasia.
The switch-on, switch-off mechanism for the cyclase may 
involve co-operative interactions between free and bound 
receptors on the membrane as discussed by de Meyts
al. (1973).
1.3» Mechanism of Action of Cyclic AtÆP
The discovery of a cyclic Aî-ïP-dependent protein kinase 
in rabbit skeletal muscle (Walsh et al., I968), lead to the
20
hypothesis that the diverse actions of cyclic MÏP may he 
mediated through regulation of the activity of a family of . 
protein kinases (Kuo and Greengard, 1969a, h). The latter 
authors demonstrated a tenfold rise in protein kinase 
activity by the presence of 5 cyclic AI«IP in a variety of 
mammalian tissues. There is now evidence for the wide 
distribution of cyclic GllP-dependent protein kinases in the 
animal kingdom (Kuo & Greengard, 1970)# Even though the 
two groups of enzymes have been found in the same tissue they 
act independently of each other (Greengard and Kuo, 1970; 
Greengard, 1971)* Protein phosphokinase may employ ATP or 
GTP as phosphorylator and there is evidence for ATP inhibiting 
the GTP requiring enzyme (Davis & Lazarus, 1974)# Thus the 
ratio of ATP to GTP concentration in the membrane may have a 
regulatory function (Tata, 1973)#
It has been suggested that the cyclic MIP stimulated 
protein kinase system is composed of two sub-units, a regulatory 
sub-unit to which cyclic AMP binds and a catalytic sub-unit, 
which is inhibited by the regulatory sub-unit (Gill & Garren,
1971)* Ifhen cyclic AICP binds to the regulatory sub-unit the 
catalytic sub-unit becomes freely active catalysing the 
phosphorylation of its substrate, thus resulting in the 
physiological response, Walsh 8. Ashby (1973) have extended 
this scheme and introduced the concept of an inhibitor protein' 
which binds to the catalytic sub-unit after dissociation of 
the holoenzyme into its respective sub-units. It has been 
suggested that inhibitor protein and regulatory sub-unit
21
modulate catalytic sub-unit activity by an identical 
mechanism#
The identification of natural substrates for the 
protein kinases in various tissues is at present under 
investigation. However, a limited number of substrates 
are at present knovm, e.g. phosphorylase kinase and 
glycogen synthetase in skeletal muscle (Pastan & Perlman,
1971)j lipase in adipose tissue (Huttunen et al., 1970; 
Soderling ^  , 1973), histones and protamine in liver
(Langan, 1968), brain (Miyamoto et al., I969) and testis 
(Garberset al., 1973). High cyclic M üF levels were found 
in seminal fluid (Broadus et al., 1971) and spermatozoa 
contain an active cyclic AlS^-dependent protein kinase 
(Hoskins , 1972) which may be involved with mobility
(Tash & Marin, 1973) and fertilization (Morton & Albagli,
1973). The activity of this kinase is affected by oestrogens 
and androgens (Bernard à Wasserman, 1972; Ichii et al.^
1973). Evidence for the involvement of cyclic AI-IP in the 
stimulation of protein phosphorylation has been adduced for
a variety of tissues including liver membrane ( Shlatz and 
Marinetti, 1972)^ muscle troponin (Pratje and Hulmeyer, 1972), 
retina (Kuhn et al., 1973), erythrocyte membrane (Rubin and 
Rosen, 1973), pancreatic islet tissue (Montague and Howell,
1972), heart (La Raia et al., 1973) and brain (Wei1er and 
Rodnight, 1970; Johnson et al., 1971^)
Some hormones, such as insulin, may lower the level of 
cyclic Al^iP, but there is no clear role for cyclic AfnP activated
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protein kinase in such cases. The mode of action of the 
adenohypophyseal lactogenic hormone - the protein prolactin - 
has been investigated by Majumder and Turkington (1971)•
They suggest that the action concerns the increased production 
of protein kinase rather than its activation by cyclic MIP. 
This kinase rather than cyclic AMP is the rate limiting 
material in the control of the rate of casein production.
There have been no reports on the role of cyclic AI5P in the 
luteotrophic and steroid secretory effects of prolactin in 
ovarian tissue (Major and Kilpatrick, 1972). Prolactin may 
enhance the intrinsic capability of a tissue (e.g. prostrate) 
to bind steroids (Farnsworth, 1972).
Steroid hormones also seem to bypass cyclic AÎ'îP by 
entering within the cell rather than through an intermediary. 
Szego (1972) has suggested, however, that cyclic AI»IP may be 
involved in the transport of oestrogen from the cell surface 
into the nucleus. Steroids stimulate protein synthesis and 
effects have been reported both at the level of transcription 
and translation (Bitenskj'’ & Gorman, 1972). At the
transcriptional level the steroid may bind to a receptor 
protein which is involved in activating R M  polymerase prior 
to the function of RRA on the D M  template. This is akin to
the sigma or initiation.factor in E. coli. It is also akin
to a proposed mode of action of cyclic AI5P in bacteria 
(Pastan, 1972). Thus cyclic AÎ-ÎP x’eceptor protein in E. coli 
stimulates transcription in the Lac operon probably by binding 
to D M  enabling R M  polymerase to bind and initiate
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transcription (Anderson et al., 1971). Langan (1971) has 
proposed a role for cyclic AÎ«iP at the transcriptional level 
in eukaryotes, possibly via the stimulation of histone 
phosphorylation. Glucagon or dibutyryl cyclic AÎ5P can 
cause a marked rise in tyrosine transaminase activity in 
liver. This rise is inhibited by actinomycin D (Langan,
1971). At the translational level Gill and Garren (l970) 
suggested that a cyclic AIÆP—dependent protein kinase 
phosphorylates ribosoraal protein. This is supported by the 
findings of Chuah and Oliver (1971 ) that cyclic AI5P is 
involved in the release of tyrosine transaminase from 
polysomes.
1.6. Extracellular Levels
In addition to the rates of formation and degradation 
of cyclic AfCP the rate at which it is extruded from the cell 
may be a factor in the regulation of its internal concentration. 
Very little is known about how this extrusion process works 
but at least one cell type - the avian erythrocyte (Davoren 
and Sutherland, 1963), appears able to pump cyclic jITÆP out 
against a concentration gradient and E. coli may have a 
similar capability (Makraan and Sutherland, 1963). Endogenous 
cyclic AÎÆP can function extracellularly in promoting aggregation 
and differentiation of the cellular slime mold (Bonner et al., 
19725 Ashworth, 1974). Studies on cells in tissue culture 
indicate that exogenous cyclic Al# (usually ' - dibutyryl
cyclic AMP, which is more lipophilic and thus crosses membranes
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more readily) can increase contact inhibition of human 
fibroblasts and thus decrease mobility and growth (Johnson 
et al., 1972; Pastan, 1972; Burger et al., 1972). Cyclic 
AÎÎP and cyclic GI# may be involved in cell division (Hadden
, 1972). Extracellular cyclic AICP has been reported 
both to stimulate (ishizuka et al., 1971) and inhibit 
(Bosing-Schneider & Kolb, 1973) the induction of antibody 
synthesis. Watson et al., (1973) provided further evidence 
which suggests that cyclic Al# and cyclic GÎCP mediate the 
intracellular signals which determine whether antigen- 
sensitive cells follow an inductive (antibody synthesis) or 
non-inductive (paralytic) pathway. Cyclic Al# alone is 
postulated to mediate paralysis whereas both cyclic AMP and 
cyclic GMP present in an optimum ratio are required for 
induction. Cyclic Al# has been shown to suppress the 
tumorigenicity of virus-transformed skin cells (Reddi & 
Constantinides, 1972). It has been suggested by Korinek 
^  al., (1973) that the antitumor activities of cyclic AMP 
are associated with an increase in BHA-dependent RHA 
polymerase activity.
In mammalian body fluids the highest level is found in 
seminal plasma (3-3 % 10”^M; Gray, 197G). In blood plasma 
the level is much lower (1-3 x 10“%I; Broadus ^  al• > 1971)* 
Normally humans excrete 2-9 pmol of cyclic Al# in a 24 h 
urine. The rat excretes more cyclic AMP relative to body 
weight than does man, the former achieving 33O-8OO pmol/min/kg
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whereas the latter is in the range 20-90 pmol/min/kg.
Extreme fluctuations in urine volume cause little if any .
change in the total amount of the nucleotide excreted
(Hardman et al., 1969; Owen & Moffat , 1973)» Cyclic AÎ#
and cyclic GI# are the only nucleotides so far found in
urine; cyclic pyrimidine nucleotides are either absent
from urine or too low to measure (Broadus et al., 197l)«
The mechanism of renal plasma clearance of cyclic Al# and
cyclic GÎ# and the source(s) of these compounds in the urine
were investigated by Broadus et al. (l970a,b). The renal
clearance of inulin, intravenously administered tritiated-
cyclic nucleotides and endogenous cyclic nucleotides were
.
measured in normal humans. The clearances of inulin and
[^h] - cyclic Al# were found to be equal, thus indicating that
the mechanism of renal clearance of plasma cyclic Al# was
simple glomerular filtration. The clearance of endogenous
cyclic Al#, however, exceeded both inulin and j - cyclic
Al# clearances, suggesting that the kidney adds a variable
quantity of cyclic Al# to that filtered from plasma. Thus,
in humans, under basal conditions approximately O^fo ot the
urinary cyclic Al# is derived by glomerular filtration of plasma
while the other 30^ is nephrogenous. In contrast to cyclic
AB#, urinary cyclic GI# appears to be derived from plasma by
simple glomerular filtration. Cyclic Al# has also been found
in cerebrospinal fluid (0.5 - 3*0 x 10"'%!, Steiner ^  al.,
—8
1970a; Broadus ejk , 1971), gastric juice (2 x 10“" M,
Robison et al., 1971), amnio tic fluid ( 25 x 10“‘^ H, Broadus
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ejk , 1971), bile (actual level not reported, Levine et al.,
1969) and milk (8 - 80 x 10“%!, Kobata al., I96I). It 
has also been measured in' extracellular media from 
perfused liver (Hardman et al., 1971a) and adrenals (Albano & 
Brown, 1974).
The plasma cyclic nucleotide represents a dynamic pool 
in a steady state (Broadus et al., 1971). The half-time for 
the disappearance from plasma of injected radioactive cyclic 
AMP is about 2 min in rat (Chase & Aurbach, 1967), rather 
longer in man (about 30 min, Broadus 1971), however,
Barling £t , (1974) have reported 14-16 min half-life after 
a pulse of endogenous cyclic Al# caused by PTH infusion.
About 15^ of the injected labelled nucleotide appears in the 
urine in the short terra (Chase & Aurbach, 1967), indicating 
that extrarenal factors account for the removal of most of the 
material from plasma. Metabolism of the nucleotide by the 
formed elements of blood may account for part of this extra- 
renal removal, but in vitro studies suggest that this is too 
slow to be a major factor (Broadus ^  , 19704/b). The
apparent volume of distribution of the labelled cyclic Al# is 
significantly greater than the extracellular space (Broadus 
^  al., 1970a). Under appropriate hormonal stimulation both 
the liver and kidney are capable of adding cyclic Al# to plasma 
(Broadus et al., 1971), but the sources of the normal plasma 
level of this nucleotide are far from clear. In their chapter 
in Annual Review of Physiology (l97l) Hardman, Robison and 
Sutherland conclude “Unfortunately, too little is known about
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the sources and hormones responsible for the normal levels 
of cyclic nucleotides in plasma and urine to permit more 
than speculative conclusions regarding abnormal levels.
Studies are badly needed”.
1.7. Role of Cyclic At# and Cyclic GMP in Mammals
Most of the knoïfn functions of cyclic Al# are given in 
table 1.5. Besides mediating the actions of several 
hormones (table 1.3.) cyclic Al# regulates the release of 
most of the others (e.g. steroid hormones). Sometimes a 
hormone is both released by cyclic Al# and then acts via the 
nucleotide, e.g. ACTH, TSH and possibly glucagon (Chesney & 
Scofield, 1969). Some hormones released by cyclic j^# do 
not act directly via the nucleotide, e.g. steroids.
Pathological conditions involving a fault in the control of
■ \
cyclic Al# production (e.g. pseudo-hypoparathyroidism) and 
function, are described later (Section I.IO). Evidence 
implicating cyclic AT# in the control of the immune response 
(Section 1.6), in the regulation of visual processes (Bitensky 
et al., 1971; Miller, 1973), possibly in the control of 
balding in males (Adachi & Kano, 1970), the control of some 
of the effects of ions and especially Ga"^ "^  (Lundholm et al., 
1967? Ifemra ^  , 1968) and other nucleotides (Sa.ttin & Rail,
1970) is now available.
Guanyl cyclase, the enzyme responsible for cyclic GMP 
formation is found in all mammalian tissues with the exception 
of whole blood (white & Aurbach, 1969; Hardman & Sutherland, 
1969), the highest levels in rat tissue being in the lung and
Table 1.5* Relationships between the metabolic actions of 
hormones and cyclic AI#
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Hormone
Adrenaline
Noradrenaline
Glucagon
ACTH
Principal Responses
Glycogenolysis (liver, muscle, heart) 
Heart force
Rate of heart centraxetion
Stimulation of enzyme secretion
Lipolysis in fat cells
Insulin secretion
Melanophore stimulation
Discharge frequency of Purkinje cells 
(brain)
Acetyl-choline release (nerve) 
Melatonin synthesis (pineal) 
Glycogenolysis (liver, heart)
Heart force
Rate of heart contraction
Gluconeogenesis
Enzyme synthesis
Ketogenesis
Urea and K"** transport
Lipolysis (adipose tissue)
Steroid synthesis (adrenal)
Adrenal growth 
Phosphorylase activation 
Protein kinase activation 
Lipolysis (adipose tissue)
Table 1.5. (Contd)
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Hormone
LE
FSE
TSH
Growth hormone
Vasonressin
Oxytocin
MSH
Prarathyroid hormone
Pancreozymin
Principal Responses
Steroid synthesis (corpus luteum)
Glucose uptake
Glycogenolysis
Ovarian amino acid uptake
Thyroid growth and cell division
Uptake of 1“
Organification of I and thyroid 
hormone production
Release of thyroid hormones
Phosphorylase activity
Glucose uptake
Lipolysis
Glucose metabolism in adipose tissue
H2O transport
Urea transport
ITa*^ transport
Enzyme secretion
Melanophore expansion (frog skin) 
Ca^ "*" uptake (intestine)
Mobilization of skeletal Ga'
Protein synthesis in bone 
Gluconeogenesis (kidney)
Phosphaturia (renal cortex)
Ca^’* resorption (bone)
Amylase secretion
.2+
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Table 1.5. (Contd.)
Hormone
Secretin
Gastrin
Testosterone
Progesterone
Oestrogen
Thyroid hormones
Principal Responses
Pancreatic secretion 
Lipolysis
Enzymes of seminal vesicles 
Oviduct protein (avidin) synthesis 
Uterus (enzyme sj^mthesis)
Pineal activity 
Metabolic rate 
Heart rate 
Lipolysis
Spermatozoal activity
Reproduced from Major and Kilpatrick (l972)*-
J1
small intestine (Gray et al., 1970).
Initially cyclic GMP was considered to mimic cyclic 
AIvIP; on these lines it seemed relatively unimportant in 
that it had lower potency in, for example, a cell free 
system and its endogenous level in plasma and urine is an 
order of magnitude lower than cyclic Al# (Hardman ^  ,
1971b). It is now realised that cyclic GI# formation is 
under a separate control mechanism from cyclic Al# (Kuo 
a t ^ . ,  1971; Steiner 1972; Ferrendelli et al.,
1972: Thompson et al., 1973)* The two cyclic nucleotides
may show reciprocity in their intracellular levels (llliano 
et al., 1973) but this does not always follow (Ferrendelli 
at , 1973). It is suggested that these two nucleotides 
antagonise the intracellular effects of each other, the 
so-called *Yin-Yang' hypothesis (Estensen e^ al., 1973).
This concept of mutual antagonism is supported by studies on 
cell growth and differentiation (Hadden et al,, 1972;
Boring j^al., 1972; Vorhees ^  , 1973; Hr am & Tomkins,
1973). It has also been suggested that the nature of the 
primary messenger interaction with the receptor site of 
“purine nucleotide cyclase" can select the nucleotide 
specificity (i.e. either ATP or GTP as substrate) of this 
enzyme (iQiano et al., 1973). This ’induced specificity* 
could explain the reciprocal relationship between the intra­
cellular levels of the two cyclic nucleotides.
Cyclic GI#-dependent protein kinases have been 
demonstrated in tissues from lobster and other arthropoda
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(Kuo & Greengard, 1970; Kuo ^  , 1971) and in bovine
(Greengard & Kuo, 1970; Kuo et al., 1971) and rat cerebellum
(Hoffman & Sold, 1972). Physiological roles for such 
kinases have not yet been proposed; however, the 
démonstration that they do occur in nature would suggest that 
a unitary hypothesis for cyclic GI# action, similar to that 
proposed for cyclic M #  by Greengard ^  (l972) is
feasible, protein phosphorylation being the primary event.
Cyclic GI# has been shown to be involved in the 
initiation of DNA synthesis in haemopoietic stem cells (%ron,
1973), the regulation of DrîA synthesis in lymphocytes (Hadden 
^  , 1972), the mediation of lymphocyte transformation
(Estensen _et al., 1973; llliano et al., 1973), the regulation -
of the pleiotypic effects of cyclic AMP at the microtubular
level (Kram & Tomkins, 1973), the mechanism of cholinergic 
transmission (George et al., 1970; Eichhorn et al., 1974), 
the immuiie response (Watson ^  1973), and possibly in
photoreceptor function (Goridis & Virmaux, 1974).
1.8. Regulation of Cyclic Al# Levels in Brain Tissue and its
Role in Heur0transmission
Phosphodiesterase(s) (Table I.4) and adenyl cyclase 
show a much higher activity in the brain than in other 
mammalian organs (Robison e^ , 1971). The activity of 
adenyl cyclase is some 20 times higher than that found in 
other mammalian tissues, most of it being associated with the 
grey matter (Weiss & Kidman, I969). De Robertis (1967)
suggested a presynaptic location for adenyl cyclase, whereas
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Weiss & Costa (1967) proposed a postsynaptic location for 
the enzyme. Most of the brain phosphodiesterase is 
associated with the microsomal and synaptosomal fractions 
(Cheung & Salaganicoff, 1966; Be Robertis ^  , 1967;
Johnson ^  , 1973).
The level of cyclic Al# in any tissue is a balance 
between the activities of these enzymes, yet in brain, 
despite the fact that the total activity of phosphodiesterase 
is some 100 times greater than that of adenyl cyclase, this 
tissue still has the highest content of cyclic AMP in 
mammalian tissue (Ebadi et al., 1971). This is due to the 
control mechanisms governing the activities of the two enzymes 
(Rasmussen et al., 1972; Bitensky & Gorman, 1972a) and their 
distinct subcellular localisations (be Robertis ^  al., 1967; 
Greengard ^  , 1972).
Daly ^  al., (1972) proposed a model for a cyclic AJ#- 
generating system in brain (Figure 1.5). Basically the 
system consists of a small compartmentalised pool of adenine 
nucleotides which serve through the action of adenyl cyclase 
as precursors of cyclic Al#, which in turn evokes a physio­
logical response or re-enters the adenine nucleotide pool via 
the action of phosphodiesterase. The activity of the adenyl 
cyclase is governed by receptors which may either control 
independent pools or may interact with one pool of adenine 
nucleotides. Incubation of brain tissues with J -
adenine provides evidence that such small compartmentalized 
pools of s,denine nucleotides do exist and serve as precursors 
for cyclic Al# (Shimizu ^  1970; Daly at , 1972).
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Under control conditions cyclic /il-îP accounts for less than
0.3$ of the pool, which consists primarily of ATP and to 
a lesser extent ADP and 5* AI«IP. However, under stimulatory 
conditions as much as 40$ of the labelled adenine nucleotides 
in the pool could be converted into cyclic AMP in guinea pig 
cerebral cortical slices and 78$ in human cerebral slices 
(Shimizu 1970; Kodama et al., 1973; Mcllwain, 1974).
The compartmenta.lized pools are remarkably stable and do not 
mix with the remaining 90$ or so of adenine nucleotides in 
the brain tissue. Thus the endogenous levels of cyclic AI4P 
after maximal stimulation represents less than 10% of the 
total adenine nucleotides in brain tissue.
»
Both adenine and adenosine can serve as precursors of
cyclic AMP in brain tissue (Mcllwain, 1974) with adenine
the
showing a much higher incorporation intoj cyclic AI^IP pool than 
the nucleoside. The incorporation of adenine involves 
phosphoribosyl transferase activity which has been shoim to 
be associated to a large extent with the cyclic AICP precursor 
pools of cerebral cortical tissues (Schimizu & Daly, 1972); 
for adenosine, a kinase is required which is less specifically 
associated with cyclic A&ÎP precursor pools. Kuroda and 
Mcllwain (1973) have confirmed by subcellular fractionation 
studies different distributions of label after pre-incubation 
of cerebral tissue with - adenine and P^] “
adenosine.
The cyclic AMP-generating system responds to a number 
of substances with an enhanced accumulation of cyclic AfÆP.
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Several ‘biogenic amines can be shown to modulate this 
system in cerebral cortical slices. Adrenaline and 
noradrenaline are effective presumably by interaction - 
with (X - and P - receptors (the analogue isoproterenol 
which specifically interacts with p - receptors is much 
less effective); dopamine is inactive. Histamine (and 
the terminal N - and - dimethyl derivatives) is 
markedly active whereas the ring N - methyl derivative, a 
natural metabolite, is inactive. Serotonin elicits a 
similar response to the active catecholamines. There is 
evidence for adenosine as a regulatory amine as well as a 
precursor for adenine nucleotides; this regulatory side is 
blocked by 5 '-deoxyadenosine and 3 *~deoxyadenosine - the 
latter blocking the stimulatory effect of both adenosine 
and histamine. The relative magnitude of effects evoked 
by these simines with regard to accumulation of cyclic A33P 
varies greatly from species to species and from one brain 
region to another (Huang & Daly, 1972; Daly et al., 1972;
Skolnick et al., 1973; Schultz & Daly, 1973). In addition 
depolarizing agents (Schimizu et al,, 1970; Huang et al..
1972), electrical stimulation (KaMiuchi et al., 19&9), 
tricyclic drugs such as the antidepressants imipramine, 
desipramins, protryptyline and the tranquillizer chlorpromazine 
(Kodama et al., 1971I Huang & Daly, 1972), have been 
demonstrated to enhance accumulation of cyclic AÎ«5P in cerebral 
slices. These are postulated to exert their action on the cyclic
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AMP-generating system via release of adenosine, which then 
interacts with an adenosine-sensitive regulatory unit for 
adenyl cyclase (Huang & Daly, 1972).
Radioautography of guinea pig cerebral cortical slices 
which were labelled by incubation with -adenine
indicated that a major portion of the radioactive nucleotides 
in the slice are associated with synaptic structures. No 
radioactivity is associated with cell bodies, axons or glial 
cells (Daly et ^1., 1972). Thus the precursor pools appear 
to be associated with synaptic structures. This is further 
supported by evidence that adenyl cyclase (Mcllwain, 1974) 
and the catabolic enzyme being immediately adjacent to the 
synaptic membrane (Plorendo ^  al., 1971) are.associated with 
postsynaptic nerve endings. The above evidence suggests a 
possible role of cyclic AMP in regulating physiological 
responses in the hypothetical model of figure 1.5* This is 
further supported by the finding of a parallel distribution 
of cyclic AI'iP stimulated protein kinases (Johnson et al., 
1971a, 1972a), Haas et al., (1972) have also suggested that 
cyclic AMP might play a role in the maturation of nervous 
tissue and nerve regeneration. In fact the protein nerve 
growth factor may act via the stimulation of adenyl cyclase.
Greengard et a]. (1972 ) proposed a hypothesis for the role 
of cyclic AMP in the physiology of synaptic transmission in 
sympathetic ganglia (figure 1.6). According to his 
hypothesis, activity in the presynaptic fibres leads to 
depolarization (excitation) of postganglionic neurons with
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FIGURE 1.6: MODEL FOR SYNAPTIC TRANSMISSION ( Greengard , 1972.)
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the generation of impulses in the postganglionic axons.
Activity in the presynaptic fibres leads to acetylcholine 
mediated excitation of dopamine-containing interneurons 
resulting in the release of dopamine (Keen & McLean, 1972; 
Greengard et al., 1972 ) which then activates (muscarinic 
adrenergic mechanism; Schorderet et al., 1972) adenyl 
cyclase in the plasma membrane of the postganglionic neurons 
and, thereby, causes the accumulation of cyclic AMP in these 
neurons. The newly formed cyclic AICP activates a protein 
kinase leading to the phosphorylation of a protein constituent 
of the plasma membrane (Weller & Rodnight, 1970, 1973).
This causes an alteration in the movement of ions across the 
membrane, resulting in hyperpolarization. Thus cyclic AMP 
mediates dopaminergic transmission and, thereby, modulates 
cholinergic transmission in the ganglion. Greengard's 
hypothesis is supported by measurements of synaptic potentials 
and changes in resting membrane potentials of superior cervical 
ganglia (McAfee & Greengard, 1972). Both dopamine and 
db-cyclic M3P cause a h^rperpolarization of post ganglionic 
neurons, which is inhibited by PGEq. Db-cyclic GI5P causes 
a depolarization of postganglionic neurons suggesting that 
cyclic GMP mediates synaptic transmission of muscarinic 
cholinergic synapses.
Adrenergic transmission is also believed to be mediated 
by cyclic AMP. Gilman and Wirenberg (l97l) found that 
noradrenaline or isoproterenol caused a marked rise in cyclic 
AI-'IP in glial tumor cells in tissue culture. Hoffer et al.,
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(1972) provided evidence for a noradrenaline synapse in the 
mammalian cerebellum and suggested that the effect of 
noradrenaline on the postsynaptic Purkinje cells is mediated 
by cyclic AtîP. These investigators have observed that 
noradrenaline or cyclic AI^ P causes hyperpolarization in 
Purkinje cells and this is potentiated by phosphodiesterase 
inhibitors. However, Lake and Jordan (1974) were unable to 
mimic the strongly depressant action of noradrenaline on 
spontaneously firing Purkinje cells by the microiontophoretic 
application of cyclic AI'ÎP. They have therefore challenged the 
hypothesis that cyclic AMP is the second messenger for 
noradrenaline in the cerebellum. Yarborough et al,, (1974) 
present data indicating that the inhibitory effects of 
biogenic amines involve changes in calcium ions flux, and 
Rasmussen et al., (1972) have suggested that calcium serves 
to couple hoi'mone-receptor interactions to physiological 
effects in a variety of peripheral systems.
Breckenridge , (1967) and Goldberg and Singer
(1969) proposed that cyclic AMP mediates the presynaptic
action of adrenaline on the nerve endings in the skeletal
neuromuscular junction by potentiating the release of
acetylcholine. Both db-cyclic AMP and methylxanthines mimic
the effects of catecholamines on end plate potentials, 
et ah
However, Greengard^(1972) and Ginsborg and Hirst, (1972) 
have results opposed to the role of cyclic Al# in neuro­
muscular transmission.
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Injection of catecholamines into the cerebral ventricles 
of cannulated rats increased the content of cyclic Al^lP ijn vivo 
(Buckard, 1972). Gessa et , (l970) injected db-cyclic AI^îP 
into various regions of the brain of cannulated rats and cats 
and elicited specific responses (Table 1.6). Pre—treatment 
with reserpine, which destroys noradrenaline stores in nerve 
cells or with chlorpromazine, which blocks adrenergic receptor 
sites, did not prevent this cyclic AI^IP response indicating a 
postsynaptic site of action.
1.9. Cyclic G%{P and the Nervous System
The situation with regard to cyclic AIBP and neurotrans­
mission is far from clear and cyclic GIW studies are even more 
in their infancy. The highest concentrations of cyclic G&ÎP in 
rat brain occur in the cerebellum (Steiner et al,, 1972).
Early observations in the rat heart and brain showed that 
acetylcholine and oxotremorine which increases myocardial 
acetylcholine content, produced marked increases in the cyclic 
GI'IP content of the tissues (George et al., 1970; Ferrendelli
, 1970); thus cyclic GMP may be involved in cholinergic 
transmission (Hardman et al., 1971)• Lee et al., (1972) and 
îCebabian (1972) found that the increase in cyclic GÎ'îP elicited 
by acetylcholine was muscarinic in nature. McAfee and 
Greengard (1972) using the lipid soluble db-cyclic Gl^iP showed 
that this nucleotide mimicked the physiological effects of 
acetyl-choline in superior cervical ganglia, giving further 
support to the role for cyclic GMP in cholinergic transmission.
Table 1.6. Behavioural and vegetative effects observed after 
the injection of db-cyclic MiP in the cat brain
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Site of Injection Effects
Cisterna magna Scratching, convulsions (miosis, 
mydriasis, salivation, defecation, 
micturition).
Lateral ventricle Psychomotor stimulation, 
convulsions.
Third ventricle Psychomotor stimulation, 
convulsions.
Hypothalamus (anterior) Psychomotor stimulation, 
convulsions, adrenergic effects.
Hypothalamus (posterior) Psychomotor stimulation, 
convulsions, cholinergic effects.
Formatio reticularis 
raesencephali
Catatonia, psychomotor stimulation, 
contraversive turning of the head.
Amygdala Contraversive circling movement, 
Jacksonian convi.ilsions, 
convulsions, rage.
Gaudate nucleus No effects.
Putarnen
Pallidum,
No effects. 
No effects.
Cerebellum (fastigial 
nucleus) Non-rapid eye movement sleep.
Reproduced from Gessa et , (l970).
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In cerebellar slices from rat (Kuo ejk al., 1972) the acetyl­
choline dependent increase in cyclic GÎ-îP, was matched by a 
decrease in cyclic AI'iP content, while noradrenaline-induced 
increase in cerebellar cyclic MOP content was found to 
decrease cyclic GMP levels,
A study in mouse cerebellar slices on drugs (e.g. 
amphetamine) which affect non aminergic transmitter mechanisms 
and motor activity in vivo (Perrendelli al., 1972), showed 
that increases in the cyclic GÎ'IP levels in vitro could be 
correlated with the pharmacological actions of these drugs.
Perrendelli ^  , (1973) ha,ve found that the depolar­
ising agents veratridine and ouabain and elevated concentrations 
of caused marked increases in the cyclic GÎCP content of 
mouse cerebellar slices, reaching about thirty times the basal 
levels. Atropine has no effect on these increases and acetyl­
choline does not mimic them, indicating that the cholinergic 
mechanism is not involved. Also in contrast to the cholinergic- 
mediated increases in cerebellar cyclic GMP content these 
depolarising agents increase the cyclic AI'IP content. The 
depolarisation induced increase in cyclic GBD? level involves 
calcium flux and synaptic transmission (Blaustein, 1971)•
These preliminary investigations of the effect of depolar­
ising agents and acetylcholine on mouse and rat cerebellar 
cyclic GMP content would suggest that the complexity of these , 
responses may be similar to those observed with cyclic AIÆP in 
guinea pig neocortex (Daly et , 1972); however, in view of 
the paucity of data available at the moment this observation
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is somewhat speculative. It is increasingly clear that 
the content of cyclic Al^îP and cyclic Gî-ÎP in nervous tissue 
are to a certain extent under separate control mechanisms 
(Kuo al*, 1972) but whether the "Yin-Yang” hypothesis 
(Sstensen et al., 1973) is applicable to nervous tissue 
remains to be seen.
1.10. Cyclic iUIP in Clinical conditions
Cyclic AI"IP has been implicated in a variety of 
clinical conditions with perhaps the most detailed studies 
being made on pseudohypoparathyroidism, a rare hereditary 
disease in which parathyroid hormone appears incapable of 
stimulating cyclic AJvîP formation in the target tissues 
in vivo (chase et al. , 196921^ Marcus dli; 1971;
Murad and Pak, 1972). It would seem that the lesion lies 
in the receptor rather than in the catalytic centre.
Other disorders in which cyclic AMF has been implicated 
include bronchial asthma (Szentivanyi, 1968; Alston et al.,
1974)? allergic skin reactions (Burton & Graves, 1972), 
diabetes insipidus (Pichman & Brooker, 1972), diabetes 
raellitus (Cerasi and Luft, 1970), and thyrotoxicosis 
(Bitensky & Gorman, 1972).
Some bacterial infections may also involve cyclic iiMP, 
and an especially interesting example is cholera. The 
toxin produces an apparently irreversible increase in 
adenyl cyclase activity, leading to prolonged high levels 
of cyclic AÜCP in intestinal epithelia; this in turn leads 
to the debilitating loss of fluids and electrolytes 
characteristic of this disease (Kimberg et al., 1971?
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Bennett _et al. 1975 ), Tumors and transformed cells
have intracellular levels of cyclic M ’lP significantly 
lower than corresponding normal cells (Sheppard, 1972) 
and db-cyclic AMP reduces the rate of growth of transformed 
cells (Johnson , 1972). Burger et al., (1972)
proposed that a reduced level of cyclic AI^ÎP may trigger 
the mitotic cycle and Korinèk ^  , (l973) suggested that
cell division control involves a change in cell surface which 
in turn requires mRNA synthesis induced by cyclic AJ'îP.
Finally cyclic AJviP has been implicated in affective disorders 
(mania and depression).
1.11. Cyclic AI^IP and its Correlation with affective disorders
Abdulla and Hamadah (l970) showed that 24-hour cyclic 
Al’iP levels were high in manic and low in depressed patients 
(table 1.7). These authors put forward the hypothesis that 
cyclic .AMP is the driver rather than the passenger in affective 
disorders, i.e. depressive illness is due to a severe fall in 
cyclic AMP concentration in the cells of 8,11 tissues including 
those of the central nervous system, Evidence supporting 
this hypothesis includes the demonstration that chlorproma,zine 
and tricyclic antidepressants inhibit phosphodiesterase 
activity in vitro, thus increasing cyclic AI^IP concentration 
(Abdulla and Hamadah, 1970; Rarasden, 1970). Kodama et al.,
(1971) reported that the tricyclic antidepressants stimulated 
cyclic AI€P formation in brain slices.
Paul et ale, (l970) in a study on 47 patients divided
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them into four groups on the basis of their 24-hourly 
cyclic MIP excretion. Their results are summarised in 
table 1.8.
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Table 1.8.
Group n
Urinary cyclic Aî^IP 
pmol/24h ±
Normal 10 5.64 +. 0.68
Psychotic depression 7 3.64 ±  0.19
Neurotic depression 25 6.7 0 + 0.37
Manic 5 9.9 4 + 1.88
No correlation between age, sex and cyclic AMP 
excretion was found. Paul et al., (l971a.) reported a 
marked elevation in urinary cyclic Aî«îP at the time of the 
switch from depression into mania.
It has been suggested that changes in urinary cyclic 
AMP reflect exercise rather than the clinical status of 
depression or mania (Eccleston et al., 1970). However, 
Paul ^ ^ l . j  ( 1971b) found that there was no significant 
difference in cyclic AI# excretion between 10 hyperkinetic 
children and an age-matched control group. They a,lso 
reported that physically active and inactive depressed 
patients show similar (low) levels of cyclic AI'IP. No 
significant difference in urinary cyclic AMP levels were 
found in the psychotic phases of two patients with periodic
48
catatonia, one of whom exhibited profound stupor, whereas 
the other exhibited violent and destructive episodes 
(perry et al., 1973). Prolonged physical activity in 
normal controls was found either to have no effect (Paul 
et al., 1971b; Owen, 1975 ), or cause only an
insignificant increase in cyclic AI<ÎP excretion (Williams
, 1972). However, Heath et al., (l973) reported a 
rise in plasma and urinary cyclic AÎ5P after exercise (see 
Chapter 3).
Broi-m ^  al., (1972) studied four patients - manic- 
depressive receiving amitriptyline, chlorpromazine or 
haloperidol and EOT (4)5 IB^manic-depressive as lA but no 
EOT but chloramphenicol for a urinary infection; 10,manic 
receiving phenothiazines and lithium carbonate; ID (the 
only male) receiving lithium carbonate after an episode of 
schizophrenic excitement. There was no obvious correlation 
between cyclic AH# and mood for this diverse group. Patient 
10 showed a 70^ decrease in cyclic Aî^îP excretion coincident 
with the commencement of lithium therapy. Jenner et al.,
(1972) also reported a failure to obtain a correlation between 
cyclic AI# excretion and 'mood* in a “number of depressed and 
manic-depressive patients",. However, they found a marked 
correlation in a patient with a regular 48-hour cycle of 'mood'. 
They suggested that cyclic AÎ-CP changes were secondary to ADH 
variation and thus reflected pituitary or hypothalamic 
function. Lithium carbonate was effective in the control of 
this patient. Dousa and Hechter, (1970) implied that the
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therapeutic effect of lithium in the treatment of mania 
may he due to inhibition of cyclic Al# formation,
Paul et al., (l971h) reported that lithium treatment of 
manic and manic depressive patients can cause changes in 
urinary cyclic AMP, which followed the direction of 
clinical change; and L-dopa administration to depressed 
patients is paralleled by dose related increases in 
urinary cyclic AMP.
Hansen (l972) has reported that cyclic Al# in 
blood is significantly lower in a group of depressed 
patients compared with controls. He suggests, however, 
that this is a reflection of changes in ATP concentration.
His measurement procedure was individualistic and this 
is indicated by normal blood levels of cyclic Al# reported 
as 2.3 (Jg/ml ( 3 orders of magnitude higher than other 
workers). Robison et al., (1970a) found no correlation 
between clinical condition and cyclic Al# level in 
cerebrospinal fluid pooled from a manic group, or a 
depressed group, or a 'neurological* control group,
Cramer £t ^., (l972, 1973) supported this lack of correlation 
in a study of 'baseline* cerebrospinal fluid samples.
However, administration of 'probenecid* led them to conclude 
that the “turnover" of cyclic Al# in brain is significantly 
greater in the manic group than in the depressed or the 
'neurological * control group.
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1.12. Affective Disorders
1.12,1. Definition
The term "affective disorders" is used for a group
of mental diseases with a primary disturbance of affect
(emotional-mental status) from which all other symptoms
seem more or less directly derived (Slater & Roth, 1969)#
The most important characteristics of the affective
disorders are: anxiety and irritability; periodicity,
i.e. elevation and depression of mood alternating with
free intervals in which there is a complete return to
normality; and the capacity for recovering’from a single
attack without impairment of mental integrity. \
There are two major subgroups of primary affective
disorders; the unipolar, or depressive disease and the
bipolar or manic-depressive disease (in which periodic
attacks of mania occur). This classification is based
*
on genetic (Cadoret et al., 1970; Perris, 1971) and 
general background. It includes evaluation of personality 
and temperament (Slater and Roth, 1969) and emotional 
status post-parturn (Baker et al., 1971). Response to 
drugs and other forms of treatment (Murphy £t al., 1971; 
Goodwin et al., 1972; Buchsbaum et al,, 1971) and 
biochemical findings (Punner et al., 1971, 1972; Murphy 
& Weiss, 1972). Mania and involutional melancholia 
(depressions of later life) are also included in the 
affective group of mental illnesses, whereas mental 
^Also see Becket (1974).
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conditions, in which the affective disturbances are mainly 
secondary alterations, are excluded.
Unipolar affective disorders are further subdivided 
into endogenous (or psychotic) depression and reactive (or 
neurotic) depression (Slater & Roth, 19^9). Many 
psychiatrists regard the two conditions as extremes of the 
same disease state (Rosenthal & Gudeman, 1967a?b),
However, the presence Of qualitative differences, differential 
response to treatment and distinct clinical features provide 
evidence for the existence of two types of illness. Slater 
and Roth (19^9) stated that the clinical features, which 
significantly correlate with the diagnosis of endogenous 
depression are: early morning wakening, depression worse in
the morning, qualitative change in affect, marked degree of 
psychomotor retardation, duration of symptoms of one year or 
less, age 40 years or above, depression regarded as being of 
considerable depth, failure of concentration, weight loss of 
3 kg or more and a history of previous attacks. On the 
other hand the clinical features characteristic of reactive 
depression are: responsiveness of depression to environmental
change (i.e. attacks occur in response to stress), self-pity 
and inadequacy, hysterical features, initial insomnia, 
depression worse in the evening, sudden onset, irritability, 
liypochondriasis, obsessionality and variability of illness.
As might be expected, there is an overlap in the symptoms of 
endogenous and reactive forms of depression.
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1.12.2. Incidenôe - Basic Personality - Physical 
Constitution - Heredity
Estimations of the incidence of mental illnesses 
have been made from samples of the general population of 
several countries. The tendency in recent years is to 
find larger numbers of people suffering from affective 
diseases. At present the life-time expectation of 
developing such an illness in Western Europe is as high 
as l6fé in women and 8fc in men (Coppen, 1973). Ethnic 
variations have also been noted, for example, affective 
disorders were found to be commoner in people of Jewish 
stock and in the Hutterites of America (Slater & Roth,
1969), There is also some evidence that affective 
disturbances are more frequent in professional people than 
in the general population (Helgason, I964). The 
distribution of onset of manic-depressive, reaction by age in 
the United Kingdom is shown in figure 1.7*
Kretschmer, (1936) demonstrated an affinity between 
affective illnesses, basic personality and body type.
The pyknic or ectomorphic physique (short, fat) is 
associated with cycloid (changeable) temperament and with 
an increased risk of manic-depressive psychosis. The 
endocrine system, with its evident influence on bodily 
habits and its subjection to a biological periodicity has 
been held responsible by some for the fluctuation of mood 
in affective diseases (Slater & Roth, 1969). The menstrual, 
cycle provides a further perturbation and thus may explain
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an increased risk in pre-menopausal females (figure 1.7), as 
may the stress of pregnancy and its aftermath.
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Figure 1.7. First admissions for manic-depressive reaction 
(from Slater & Roth, 1969)*
Heredity is believed to play an important part in the 
aetiology of affective disorders (Winokur et al.. 1971; 
Rorzab , 1971; Gershon et al., 1971? Baker et al.,
1972; Bunney et al., 1972bj Hies ^  , 1973). The
following lines of evidence provide support for this views 
there is an increased history of depression among the family 
members of depressed patients compared to the general
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population; there is an increased concordance of 
monozygotic (75^0 over dizygotic twins (38^). The 
involvement of a single autosomal dominant gene has been 
suggested (Hopkinson, 19^4? Tfinokur & Clayton, 19^7)«
More recently evidence has been built up for a polygenic, 
rather than dominant gene, transmission of the depressive 
trait (Baker et al., 1972; Perris, 1971)• However, 
mania could be attributable to a dominant gene (Slater 
& Roth, 1969).
1.13. Biochemical aspects of Affective Disorders
Affective disorders can now be described as truly 
psychosomatic conditions. The view that biochemical 
changes are of primary importance in their aetiology, is 
at present widely accepted, though social and psychological 
factors are also of great importance. The mode of 
interaction of these environmental events with the 
biochemistry of the nervous system to produce the syndromes 
of depression and mania is far from clear. Txfo major 
areas of research have involved cations (especially Ha"^ , )
and biogenic amines.
1.13*1. Cations and Hater
Early work on electrolyte and body fluids balance in 
affective disorders produced controversial results.
Retention of sodium during depression and diuresis of 
sodium during mania were reported by Strcm-Olsen et al., 
(1958) and Crammer (1959). However, Russell (1960) could
55
not detect any change in water, sodium or potassium 
balance during clinical improvement from depressive 
illness.
The introduction of isotope-dilution techniques
enabled estimates to be made of the distribution of
electrolytes - the relative concentrations of sodium and
potassium in cells and in the extracellular space. The
most consistent finding was an increase in residual sodium
(mostly intracellular sodium plus a small amount of
exchangeable bone sodium) both in depression and mania,
the increase amounting to about 50^ of the normal in the
former, and to the highly significant 200^ in the latter.
The values returned to the normal range on recovery
(Coppen, 1970; Singh, 1970; Baer et 1970),
However, Glen and Bellinger (1973) found
the intracellular concentration of erythrocyte sodium to
be within normal limits for both manic and depressed
et al.
patients, and Mendelj (1971) reported low sodium concentrations 
in erythrocytes from manies. Extracellular sodium was 
found to be within the normal range during either a depressed 
or a manic phase,- but on recovery there was a significant 
reduction in its concentration (Copuen et al., 1966).
The decrease was more marked in mania.
The values for total body potassium, intracellular 
potassium and the intra-/extraoellular ratio for E*, 
obtained from depressive and manic patients were reported 
to be consistently lower than normal both during illness
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and on recovery '(Coppen, 1970; Singh, 1970). Baer 
jet (1970), however, could not show any measurable
change in body potassium with recovery, thus confirming 
earlier findings of Gibbons (1960). Furthermore, body 
K**" in patients was not found to differ significantly from 
that of a control population (Baer ^  ad., 1970; Glen & 
Bellinger, 1973).
Sodium is extruded from the cell by means of the 
sodium pump, which is associated with Ha*^ , E^-stimulated 
ATPase. It has been suggested that the cause of the 
increased intracellular sodium, in affective disorders, 
could reside in a genetically inherited enzymatic membrane 
defect which reduces the ability of the membrane to remove 
sodium from the cell (Singh, 1970; Bunney et al., 1972a;
Dick et al., 1972; 1974; Naylor et al., 1973; Glen and 
Reading, 1973). Glen ^  al., (1968, I969) reported that 
active transport of Na"^  across the duct walls of the 
parotid gland is significantly diminished in depressed 
patients compared to healthy individuals. Maizels (1968) 
and Glen et al., (1972) have shoi-m that Li'*' pan
stimulate Na"*" efflux from the erythrocyte. Calcium and 
magnesium ions are known to be involved in membrane transport 
systems and Li'*' treatment of affective disorders has also 
been found to increase the plasma concentration of these 
ions (Mel1erup et al., 1973; Lyttkens et al., 1973).
The distribution of body water has also been 
investigated. An increase in the total body water and
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extracellular water, was observed during recovery from 
depression (Coppen, 1970), whereas no significant change 
was found on recovery from a manic episode (Singh, 1970)« 
Studies on the brains of suicides by Shaw et al.,
(1969) indicated that electrolyte changes could occur in 
the CNS. Support for this was provided by Kjeldsen et al., 
(1973) who showed that Li^ decreases Na"*^ and concentrations 
in brain-cortex slices. The significance of electrolyte 
changes in mental disorders is controversial. However, 
alterations in the balance of electrolytes in the central
nervous system could result in a reduced rate of protein 
synthesis (Coppen, 1970) and changes in the transport of 
biogenic amines, amino acids and sugars (Bunney et al., 1972b), 
It has been shown by many investigators that lithium 
salts are effective both in the treatment of affective 
disorders (Johnson et al., 1971? f^ rien £t al,, 1972;
Coppen, 1973; Samuel & Gottesfeld, 1973), and in their 
prophylaxis (Baastrup et al., 1970; Ooppen at al., 1971;
Hullin et al., 1972; Prien et al., 1973;
Coppen, 1973)» Although a considerable volume of basic 
biological information has been obtained on the effect of 
lithium cations, the site and the mode of its action in 
patients suffering from an affective Illness is still unknotm.
Theories of action include interference with the electrolyte
balance in body fluids and tissues (Murphy and Bunney, 1971; 
Kjeldsen et al., 1973; Jenner, 1973; Shaw, 1973; Samuel &
Gottesfeld, 1973); change in the metabolism of biogenic
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amines and other‘neurotransmitters (Colburn et al., 1967,
Katz & Kopin, 1970; Shaw et al., 1972; Gershon, 1972;
Shaw, 1973; Samuel & Gottesfeld, 1973; Friedman and 
Gershon, 1973; Gottesfeld et al., 1971;
); change in hormonal levels (Platman et al., 1970;
Sachar et al., 1970; Murphy et al., 1970; Kfulik, 1971;
Noyes et al., 1971; Mannisto et al., 1971; Barrow et al., 
1971; Temple ^  al.,, 1971) or energy supply in the CNS 
(De Feudis, 1971, 1972; Mellerup et , 1970, 1973; 
S h o p s i n ^ ^ . ,  1972; Schou, 1973; Samuel & Gottesfeld,
1973).
In comparison with the many studies of effects of Li'*'
on nerve endings relatively little work has been carried out
on its possible interference with conditions in the synaptic
cleft and at the postsynaptic receptor site. It has been
suggested that Li"*" is bound by the mucopolysaccharides of
the synaptic cleft and thus may produce significant alterations
in transmission properties (Schou, 1973)« There is evidence
that the cyclic AI>iP system is involved in the mechanism
et al.,
underlying postsynaptic receptor response (Greengard |^ 1972 ). 
Lithium inhibits adenyl cyclase activity, vitro, in 
rabbit cerebral cortex and rat hypothalamus (Dousa & Hechter,
1970; Porn & Valdecasas, 1971; Palmer et al., 1972a) but 
stimulates adenyl cyclase activity in glial tissue (Schimmer, 
1971). In humans 24-hour urinary excretion of cyclic AIviP 
has been found to increase in mania and decrease in depression 
(section 1.11). Paul et al., (l971b) reported that lithium
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treatment of manic and manic-depressive patients can cause 
changes in urinary cyclic Aî^îP which parallel the direction 
of clinical change. Jenner (l972) have reported
that the mood change in a patient who showed a regular 
switch (48—hour cycle) from mania to depression was 
paralleled by changes in urinary ADH and urinary cyclic AÎ‘ïP. 
The peptide hormone and the cyclic nucleotide both 
decreased in depression and increased in mania. Lithium 
was very effective as a prophylactic agent in this patient. 
7Hien the lithium salt was replaced by a placebo the 48-hour 
rliythm of illness returned (Jenner, 1973)*
Lithium inhibition of adenyl cyclase system has been 
reported in thyroid (Burke, 1970; Williams et al., 1971), 
kidney (Dousa & Hechter, 1970; Forrest ^  al., 1971;
Harris & Jenner, 1971, 1972; Jenner, 1973; ITraae et al., 
1972; Geisler ^  , 1972), fat cells (Sirnbaumer et al.,
1969), ovary (Smith et al., 1971) and toad bladder (Rotenberg 
1971 ; Harris & Jenner, 1972).
1.13.2. Endocrine Functions
Endocrine studies in affective disorders have 
concentrated on adrenocortical and thyroid activity.
Adrenocortical Activity
Depression was long ago noted to be prevalent in
#
patients diagnosed as having Cushing * s syndrome (Glaser, 1953; 
Spillane, 1951) whereas euphoria occurred in patients 
receiving exogenous corticosteroids (Glaser, 1953; Lids
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, 1952). In more recent studies patients suffering 
from depressive illness were shoTm to have high morning 
plasma cortisol levels which fell on recovery (Bridges &
Jones, 1966; Coppen, 1970; Carpenter & Bunney, 1971&).
There is evidence that the hypothalamic-pituitary control 
mechanism in adrenocortical activity is normal in depressed 
patients (Carpenter & Bunney, 1971a; Shopsin & Gershon,
1971). However, Carpenter and Bunney, (l971a) suggested 
that the cortisol production rate and the metabolic 
clearance rate are proportionately elevated during a 
depressed phase, thus maintaining normal plasma concentration. 
On recovery the clearance rate continues to be elevated 
whereas the production rate falls, resulting in significantly 
lower plasma concentrations. During a manic phase normal 
morning and evening plasma levels were obtained but the 
evening values fell on recovery (Carpenter & Bunney, 1971b).
Few other steroids have been investigated in affective 
disorders. The plasma levels of 11-hydroxycorti costeroids 
were slightly higher in depression than in normal controls 
or recovered patients (Brooksbank and Coppen, 1967). The 
urinary excretion of 17-hydroxycorti^coster0ids was found to 
be elevated in depression (Ellman & Blacker, I969), but 
normal in mania (Carpenter & Bunney, 1971b). Ferguson et al., 
(1964) reported low urinary levels of 11-deoxy and 17-oxo- 
steroid excretion in depressive illness in female patients 
who returned to normal on recovery. These findings could not 
be confirmed for males by Coppen et al., (1967) but they
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reported decreased urinary excretion of oestrone and 
oestradiol during depression. Finally, Goodwin et al,,
(1968) reported a decrease in the excretion rate of 
aldosterone in the depressive phase and an increase in 
the manic phase. The weight of evidence suggests an 
increase in adrenocortical activity in depressive illness.
It seems probahl© that this is a "passenger" of the 
disorder not the "driver".
Thyroid activity
Investigations on the thyroid have shown no 
abnormalities or change in affective disorders (Coppen, 
1967). However, recent studies have shown that the 
administration of the peptide thyrotropin releasing hormone 
(TRH) to patients suffering from depressive illness may 
effect a rapid clinical improvement albeit of short 
duration (Kastin et al., 1972; Prange & Wilson, 1972;
Van der Vis Melsen & Wiener, 1972; Tiwary et al., 1972; 
Plotnikoff et al., 1971, 1972 ). Kastin et al.,
(1972), Prange ^  al., (l972) and Van der Vis Melsen and 
Wiener (1972) reported that the thyrotropin (TSH) response 
to TRH is diminished in depressed patients thus suggesting 
an abnormality in the hypothalamic/pituitary axis in some 
cases of depression. However, in a later report, Prange 
and his colleagues (1973) could not provide conclusive 
support for their earlier finding. Van der Vis Melsen and 
Wiener (l972) provided evidence that the therapeutic effects
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of TRH are not mediated by the pituitary-thyroid axis.
These findings support the concept that peptide hormones 
found in the hypothalamus may have a direct effect on the 
brain irrespective of their actions in releasing pituitary 
hormones (Plotnikoff et al., 1971, 1972). Henriques,
(1972) suggested that besides its direct action on the 
brain, the antidepressant effects of TRH may also be 
brought about by an unknotm quick acting substance secreted 
by the thyroid gland.
1.13*3. Biogenic Amines
An increasing number of publications implicate the 
biogenic amines (catecholamines and indolamines) in the 
aetiology of affective disorders.
Catecholamines
Bunney and Davis (1965) and Schildkrout (1965) put 
forward the "catecholamine hypothesis of affect", which 
states that depression is associated with low functional 
brain amines (noradrenaline and/or dopamine), while mania 
is associated with a high brain amine level. Low 
homovanillic acid levels have been reported in the GSP of 
depressive patients (Papeschi & McClure, 1971). Similarly, 
van Praag & Koff (l973) using the probenecid technique 
found a diminished dopamine turnover in the central nervous 
system of patients suffering from depression. However, 
Bunney et al., (l9^7) reported elevated urinary noradrenaline 
in psychotically depressed patients but not in those with
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neurotic depression, Perez-Reyes (1969) found the 
opposite pattern, i.e. urinary noradrenaline to be high 
in neurotic but not psychotic depression. Plasma 
concentrations of adrenaline and noradrenaline from 
depressed patients not on drug treatment were found to be 
significantly higher than in normal controls. Furthermore, 
the plasma catecholamines concentration decreased in 
consort with clinical improvement (Wyatt 1971).
In patients suffering from depressive illness, high 
concentrations of CSF noradrenaline (Peneker et al., 1966i) 
and normal CSF homovanillic acid levels (Mendels et al.,
1972) have been reported. Also, normal concentrations of 
noradrenaline have been found in brains of depressed patients 
who have committed suicide (Bourne & Israels, 1968;
Pare, 1969). The specific inhibitor of dopamine and 
noradrenaline synthesis, <x - methyl - p - tyrosine, when 
administered to manic patients was found to decrease 
catecholamine synthesis both centrally and peripherally and. 
to cause some clinical improvement (Bunney et al., 1972a); 
however, a catecholamine depletion in the brain by as much 
as 80fû, resulted in a swing to depression in only a small 
minority of patients (Wyatt et al., 1971 ). Clearly this 
is a most controversial region.
Indolamines
The "indolamine hypothesis of depression", postulates 
a correlation between depression and a shortage of
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functionally active 5-hydroxytryptamine (serotonin, 5-HT) 
in brain (Coppen, 1967; Van Praag, 1970). Thus a
decrease in 5-HT and 5-hydroxy-indolacetic acid (5-HIAA), 
the principal metabolite of 5-HT (figure 1.8.), has been 
found in the brains of patients who had suffered from 
severe depression and had committed suicide ( Shaw ^  al... 
1967; Bourne et al., 1968; Carpenter et al., 1969;
Pare ^  al., I969). The CSF concentration of 5-HIAA 
has been shown to be lower than normal in depressed and 
manic patients (Peneker et al., 1966.b| Coppen et al.,
1972a). Furthermore, the accumulation of 5-HIAA in CSF 
after probenecid administration, which blocks its egress 
from the CSF, is less in depressed patients than in non­
depressed controls (Tamarkin ^ t ^ . , 1970; van Praag &
Korf, 1971; van Praag & Korf, 1973). This finding was 
assumed to be indicative of a low turnover of 5-HT in 
brain tissues. Contradictions to the indolamine hypothesis 
are again not lacking. Normal CSF levels of 5-HIAA have 
been reported both in depression (Mendels et al., 1972) 
and mania (Ashcroft et al., 1966). Studies on controls
indicate a wide range of 5-HIAA values in normality 
& Korf
(van Praag (1973) and this scatter could provide an 
explanation for the contradictory findings.
It has been suggested (Lapin & Oxenkrug, 1969;
Curzon, 1969) that the reduction in levels of 5-HT and 
5-HIAA and tryptamine in depression could result from 
channelling tryptophan metabolism through the kynurenine
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pathway (figure ï.8). However, Fraser ^  (1973)
could not confirm this suggestion despite reports by 
Coppen et al., (1972a) that excretion rates of tryptamine 
are reduced during the depressive period but return to 
normal on recovery.
Coppen et al., (1971a) found that the CSF concentration 
of tryptophan, the precursor of 5-HT, is significantly 
lower in patients compared to a control group of neuro­
logical patients. Thus low tryptophan levels in lumbar CSF 
may account for the reduced brain 5-HT and 5-HIAA levels.
In a more recent investigation Coppen jet , (l972b) reported 
no significant difference in total plasma tryptophan between 
the depressive patients and the control group, whereas the 
concentration of plasma free-tryptophan was significantly 
lower in the depressive group than in controls. Consequently 
they suggested that the reduced plasma free-tryptophan levels 
may be the cause of the reduction in CSF tryptophan, although 
it is possible that there may also be an abnormality in its 
transport from blood to brain and CSF.
Ashcroft and his group (1972) have reformulated the 
"amine hypothesis for the aetiology of affective illness" as 
follows: "The activities of amine-mediated synapses in
brain are modified in affective illness either as a result 
of altered input into the neuronal systems from other centres 
or as a result of altered sensitivity of the postsynaptic 
receptors. It is the balance between transmitter avail­
ability at the receptor and receptor sensitivity which
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determines the functional state of the systems* One or 
more of the amine-mediated systems may be implicated and 
the pattern of involvement of the systems will be 
important in determining the characteristic pattern of 
behaviour and autonomic components comprising the clinical 
picture. Functional recovery of these systems in 
depression will follow either a rise in receptor sensitivity 
or a rise in transmitter output or both. True functional 
restoration of the systems will, however, occur only when 
both transmitter output and receptor sensitivity and the 
reactivity of the system to incoming stimuli are all 
restored to normal."
Goppen ^  , (1972b) suggested that affective
disturbance is associa-ted with an imbalance rather than a 
simple depletion of amines. A cholinergic-adrenergic 
hypothesis of mania and depression has been postulated by 
Janowsky and his group (1972). According to this hypothesis, 
a given affective state may represent a balance between 
central cholinergic and adrenergic neurotransmitter 
activity in those areas of the brain which regulate affect, 
with depression being a disease of cholinergic dominance 
and mania being an illness of adrenergic dominance.
Support for this hypothesis comes from animal experiments 
demonstrating antagonistic cholinergic and adrenergic 
central behavioural effects. Furthermore, reserpine, a 
drug which causes depression, has central cholinomimetric 
properties. Conversely, tricyclic antidepressants have
00
central anticholinergic properties, Inman, physostigmine 
and other centrally acting cholinomimetric agents which increase 
central acetylcholine levels (e.g. cholinesterase - inhibitors 
such as the fluorophosphate insecticides) counteract mania 
and cause depression in some individuals (Janowsl^ y, e_t al. 1973) * 
The biochemical hypotheses applied to affective 
disorders are numerous and sometimes controversial. There is 
an urgent need for a unifying concept.
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2.1; INTRODUCTION
Several methods have been used for the estimation of 
cyclic AÎ.1P in extracellular fluids (Table 2,1). For our 
studies 24-hour urinary and plasma cyclic AÎ»ÎP levels were 
determined by the enzymic radioisotopic displacement technique 
of Brooker ^  (1968 ) and later by the saturation assay
of Brown et al. (l9?l)*
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Table 2.1: Cyclic AMP Levels in Extracellular Fluids of Normal Humans
Amount of 
cyclic AI‘îP n Fluid Method Used Reference
7.1 ±  0.3 pmol/24h
(4.7 - 9.0) 12 Urine
2.3 ±  0.1 pmol/24h
(1.4 - 3.2) 18 Urine
5,6 j: 0,7 pmol/24h 10 Urine
1,1 - 2„0 pmol/24h 3 Urine
Enzymic radioisotopic 
displacement This study
Enzymic radioisotopic Abdulla and 
displacement Hamadah (l970)
Enzymic radioisotopic Paul et al. 
displacement (l970)
Enzymic radioisotopic Eccleston al. 
displacement (l970)
2.2 ±  0,1 pmol/24h
(1.5 - 3.8) 35
3.6 ±  0,4 praol/24h 
(1.7 - 6,0) 16
3.2 ±  0,2 pmol/24h
or 2,5 ±  0.1 pmol/g 12 
creatinine
Urine Saturation assay (a ) This study
Urine Saturation assay (a )
Urine Saturation assay (m )
3.3 —  0,2 pmol/24h 10 Urine Saturation assay (a )
2,7 - 5.6 pmol/24h 5 Urine Saturation assay (a )
2.2 ±  0,8 pg/mg
creatinine 25 Urine
6,5 ±  0,3 pmol/24h 15 Urine
2,7 + 0,5 piol/g 
creatinine
(2.3 - 3.5) 6 Urine
4.2 - 6,1 pmol/24h 5 Urine
Saturation assay (a ) 
Saturation assay (m )
High Pressure 
anion exchange 
chromatography
Activation of 
phosphorylase
2.0 - 7.0 pmol/24h 10 Urine Cyclic —  AT.3P— >ADP^A
Pi
Colorimetric 
estimation of Pi
1,1 - 8,6 pmol/24h 11 Urine Cyclic AiyiP^ ->ATP 
then radioactive 
phosphate exchange 
reaction
Brown et al,
(1972) ~  “
Murad & Pak 
(1972)
Jenner et al.
(1972)
Owen and Moffat
(1973)
Barlow & Wilkinson 
(1973)
Neelon et al. 
(1973)
Fichman and Brooker 
(1972)
Takahashi et al, 
(1966)
Butcher and 
Sutherland (1962)
Chase- ^  al. 
(1969a)
Continuation of Table 2.1s
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Amount of 
cyclic AlviP n Fluid
10 - 25 pmol/ml
25.9 ±  2.1 pmol/ml
15.0 pmol/ml
22.3 ±  2.2 pmol/ml 31
12.8 + 3.5 pmol/ml 12
5 - 25 pmol/ml
Method Used Reference
1.8 - 9.0 pmol/24h 8l Urine
6.9 ±  0.6 nmol/ml 17
Cyclic AMP-»^ATP-r>ADP Broadus ^  al.
(1970)rPi
3.2 ±  0.2 pmol/24h 21 Urine Taylor ^  al. 
(1910)
15.6 ±  2.5 pmol/ml 20 Plasma
Plasma
Plasma
15#8 —  2.8 pmol/ml 7 Plasma
8.0 — 16.0 pmol/ml 10 Plasma
Whole
Blood
Colorimetric 
estimation of Pi
Cyclic AMP->->ATP
^G-6-P 
[l - ^"^c]-glucosej 
14002
.Scintillation counting 
of trapped 14c02
Enzymic radioisotopic This study 
displacement
Cyclic A3IP->»ATP^ABP Broadus et al.
(1970)rPi
Colorimetric 
estimation of Pi
Cyclic AI'IP
Phosphorylase jL  Phospho-
(l) rylase (a )
Glycogen «- G—1-P Murad et al. 
(1969)
Colorimetric estimation 
of Glycogen
Plasma Radioimmunoassay Steiner et al.
(1970a)
Plasma Saturation assay (a ) This study
Plasma Saturation assay (a ) Barling e_t al.
(1974)
Plasma Radioimmunoassay Heath et al. 
(1973) ~ ~
Saturation assay (a ) Latner and
Prudhoe (1973)
Saturation assay (a ) Rabinowitz &
Katz (1973)
TLC chromatography 
and fluorimetry Hansen (1972)
Continuation of Table 2.1:
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Amount of 
cyclic Al'iP
31.1 ±3.5 pmol/ml
n Fluid
Cerebro­
spinal
fluid
Method Used
Phosphorylase
iPhosphorylase (a )
Reference
Murad ^  al.
(1969)
G-l-P -> Glycogen
5 - 22 pmol/ml
15 - 25 pmol/ml
11.0 ±  1.0 pmol/ml
11.0 1.1 pmol/ml
25 pmol/ml
3 0 - 5 0  nmol/ml
Cerebro­
spinal
fluid
Cerebro­
spinal
fluid
15 Cerebro­
spinal 
fluid
Cerebro­
spinal 
. fluid
Amniotic
fluid
Semen
Colorimetric estimation 
of Glycogen
Cyclic A3»IP_>_>ATP_y>ADP Broadus et al.
■ T
Pi (1970)
Colorimetric 
estimation of Pi
Radioimmunoassay
Steiner et al. 
(1970a)
Cramer ^  
Saturation assay (M) (1972)
0.8 nmol/ml Milk;
colostrum
Saturation assay (m )
Cyclic AMP->ATP-ÿ^ADP 
Pi
Colorimetric 
estimation of Pi
Cyclic AMP->-^ATP-^AD?
Pi
Colorimetric 
estimation of Pi
Ion exchange 
chromatography 
followed by paper 
chromatography and 
infra-red spectroscopy
Cramer ejb al.
(1973)
Broadus, et al.
(1971) “ “
Broadus et al.
(1971)
Kobata et al. 
(1961) -
20 pmol/ml Gastric
juice
Robison et al.
(1971)
(a ) Adrenal cortical binding protein (Brown et al., 1971) 
(M) Bovine muscle binding protein (Gilman 1970)
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2.2; MATERIALS
[s - j Cyclic AMP (6.5 Ci/mmcl and later 27,5 
Ci/mraol) was purchased from the Radiochemical Centre 
(Amersham). Cyclic AMP, cyclic GI»IP, cyclic II^IP, cyclic 
UMP, cyclic CÎ^ÎP, ATP, ADP, 5 * AMP, adenosine, snake venom 
(Crotalus atrox) bovine albumin (Cohn fraction V), 
2-raercaptoethanol, anion-exchange resin ‘Dowex - 1* 
chloride form (2^ cross linked, dry mesh 200-400) and 
cation-exchange resin *Dowex 5OW*, hydrogen form (8^ cross 
linked, dry mesh 100-200), were obtained from Sigma 
Chemical Co.
Before use both the anion-exchange and the cation- 
exchange resins were washed about ten times with N RaOH to 
remove alkali soluble impurities, then repeatedly with water, 
then with N HCl and finally with water to neutrality.
The scintillation chemicals were obtained from 
Nuclear Enterprises. Low potassium grade 1 scintillation 
vials were used throughout. All other chemicals used were 
ARALAR grade with the exception of ammonium sulphate which 
was enzyme grade.
Charcoal Norit GSX grade was purchased from Norit 
Clydesdale Co. Ltd. Lithium-heparin tubes were obtained 
from Abbot Laboratories Ltd. and stored at 0-4°C until use.
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2.3; GENERAL METHODS
2.3*1 Collection of Specimens;
(a) Urine
At the beginning of each collection period 
participants were asked to empty their bladders, this 
urine was discarded and timing started. 24-Hour urine 
samples were collected and pooled over 1 ml of chloroform 
(to inhibit bacterial growth), whereas 4-hourly urine 
specimens were pooled over 0.5 ml of chloroform. The 
pooled urinary output was thoroughly mixed, the volume 
measured, and a 10 ml sample pipetted into a'Uhiversai' 
container which was stored at -20®C until analysis. 
Creatinine estimations (g/24h) were used to check the 
completeness of urine collection. Individuals with suspect 
urine volumes and abnormal creatinine values were excluded 
from this study. Where possible more than one urine 
specimen was collected from each subject.
(b) Plasma
Blood (lO ml) was obtained by venepuncture (ante- 
cubital fossa) transferred into lithium heparin tubes, and 
gently mixed, then immediately centrifioged (MSB ’Minor*) for 
2 minutes at top speed (about 3,000 rpm). The plasma was 
carefully removed using a pasteur pipette and divided into 
two equal portions. One portion was snap-frozen (solid 
C02-cellosolve at -78°C), the other was diluted by mixing 
with an equal volume of 50 Tris buffer, pH 7*4, 
containing 8 mI4 theophylline and 6 mI5 2-mercaptoethanol
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and then snap-frozen* The aim was to achieve a frozen 
sample within 5-7 minutes of venepuncture. The samples 
were stored at - 20°C until determination of cyclic AMP,
2.3.2 Creatinine Assay;
Creatinine determinations were carried out ty the 
alkaline-picrate method of Bonsnes and Taussky (1945).
Urine was diluted a hundred-fold with distilled water.
To duplicate 3 ml samples of this diluted urine were added 
1 ml of 0.04 M picric acid, followed ly 1 ml of 0.75 M RaOH. 
After mixing and standing at room temperature for at least 
15 minutes the extinction was measured at 500 nmv 
Standards and duplicate blanks (3 ml water) were run in 
parallel. Figure 2.1 shows a standard curve for creatinine. 
The values of unknown samples were obtained by reference to 
the standard curve.
The normal daily excretion of creatinine ranges from 
0.8 -2.0g/24h, being as a rule nearer to the higher limit in 
men and to the lower limit in women. Under normal conditions 
the 24-hour creatinine excretion for an individual is more 
or less constant.
2.3.3 Protein Estimation;
The lOTfry technique (Lowry et al.. 1951) was used 
for protein measurements. Suitable dilutions of the protein 
preparations (0.5 ml containing less than 200 pg protein) 
were mixed with 0.5 ml of R RaOH and left at room temperature 
to achieve a clear solution. This was mixed with 6 ml of 
freshly prepared copper reagent (l litre of 2^ Ra2CÛ3 mixed
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Figure 2,1 : Standard curve for creatinine.
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with 20 ml of CUSO4.5H2O in 1^ K-tartrate) and left
to stand for at least 10 minutes. Folin-Ciocalteu reagent 
(0^5 ml, diluted to normal acidity) was added and immediately 
mixed (i.e. tube by tube). The extinction was read after 
at least 30 minutes at room temperature in the region of 
720 nm. Standards (Figure 2.2) and duplicate reagent blanks 
were run in parallel.
2.3.4 Radioactive Counting Procedures;
The scintillant used throughout this project had the 
following composition
bioxan System (Bruno and Christian. I96I);
Toluene ' TOO ml
1,4-bioxan 2,100 ml
2-Ethoxyethanol (cellosolve) 2,100 ml
1^ 2,5-Diphenyloxazole (PPO) 49 g
0.05/O l,4""bi8—^2— (4—methyl—
5 phenyloxazole)]benzene 
(dimethyl POPOP) 2,45 g
8^ Naphthalene 329 g
This ^stem could take up to 20^ water.
All radioactivity measurements were made using either 
a Packard Tri-Garb 3320 or Packard Tri-Garb 2425 automatic 
spectrometer at approximately 4°0. Settings (window 
40-1000; gain 55^) were adjusted to achieve optimum 
efficiency which, for tritium, was of the order 30^. The 
conversion of cpm to dpm was achieved by internal standard­
isation; 50 pi of tritiated toluene (4,000 dpm) was added 
to already monitored vials which were then recounted.
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Figure 2.2: Standard curve for protein estimation.
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2.4*1 Preparation of ITucleotide 3*5'-phosphodiesterase
Female ¥istar albino rats (250~300g) were killed by 
cervical fracture and the brains quickly removed as follows:- 
The head was cut off and held dorsal side uppermost, a 
mid-line cut was made through the interparietal and parietal 
bone to between the eyes (scissor points kept up), then the 
cranium levered off to expose the cerebral hemispheres and 
cerebellum. The brain was lifted out with a spatula, 
dropped into ice-cold Tris (60mM, pH 8) containing 
2-mercaptoethanol (5 mM). After weighing and adjusting 
volume to 3 ml per g fresh weight, the tissue was homogenised |g°vehjem 
and centrifuged for 30 minutes at 30,000 g (MSS High Speed 18,
8 X 50 rotor at 4°C, 15,500 rpm). Subsequent steps were 
carried out in the cold-room (0-4°C). Finely powdered 
ammonium sulphate was added gradually to the supernatant with 
stirring over a period of about 15 minutes to achieve 50/é 
saturation (0.38g/ml). The precipitate was collected by 
centrifugation (lO min at 30,00%), resuspended in Tris- 
mercaptoethanol (as above, i.e. 3 volumes per g fresh weight) 
and dialysed overnight with stirring against two changes of • 
this buffer. The preparation was divided into 0.5 ml aliquots, 
which can be kept at 0°G for 3-4 weeks or at —20^0 for 4-5 
months without appreciable loss of activity. Protein 
concentration was determined by the Lowry procedure.
The phosphodiesterase activity was measured by estimation of 
the inorganic phosphorus released on enzymic . breakdown of 
cyclic AÎ-ÎP in the presence of excess 5 '—nucleotidase (Butcher &
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Sutherland, 1962), or by use of [^ h]-adenosine release from 
tritiated cyclic AÎ'îP.
2.4*2 Determination of the Activity of Rat Brain Phosphodiesterase
(i) In this procedure (Butcher & Sutherland, 1962) the release 
of inorganic phosphate was measured after a known incubation 
time.
Phosnhodiesterase.^ Snake Venom^
Cyclic AMP TTTTT. T“— ^AMP ---:— Adenosine + Pi
(limiting) nucleotidase
(excess)
The initial reaction mixture (0.9 ml) contained 
0.36 pmol cyclic AMP
1.80 pmol MgSO^
35 praol Tris (pH 7*5)
50 \il of a suitable dilution* of the
phosphodiesterase preparation.
(* generally this was achieved by diluting the original 1:10 
with 50 mM Tris, pH 7*5, so that the 50 pi addition contained 
about 12 pg protein).
After incubating for 20 min at 30°C, 0.1 ml of Crotalus atrox 
venom solution (l mg/ml in 10 mM Tris buffer, pH 7*5) was 
added and the incubation continued for a further 10 min. -
The reaction was terminated after 30 min by the addition of
1.5 ml of ice-cold 6fo trichloroacetic acid and the precipitate 
formed spun-down using a bench centrifuge, (top setting) for 
about 5 min. The complete supernatant was poured off and to 
it added:- 1.5 ml of 5^ perchloric acid containing 0.6^  
ammonium molybdate, followed by 0.5 ml of freshly prepared
0.2^ ascorbic acid solution. After mixing and standing for
83
at least 30 minutes the extinctions were measured at 720 nm, 
together with appropriate controls and standards. Figure 2.3 
shows a typical standard curve for phosphorus estimation.
Using this procedure a specific activity of about 300 praol 
phosphate released/min/mg protein was obtained for the 
phosphodiesterase preparations.
(ii) Later, activity was measured by the breakdown of 
[^ h]-cyclic Al'iP to liberate tritiated adenosine. This 
procedure is described in section 2.5*2 the 'cold' cyclic AMP 
standard or unlaiown being replaced by 50 pl of 60 mM 
Tris-buffer, pH 8.0, containing 5 mid 2-mercaptoethanol,
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Figure 23; Standard curve for phosphorus.
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2,3 s ENZYiaiG RADIOISOTOPIC SISPLACIiSIENT TECHNIQUE
2.3.1* Sample preparation
Samples were thawed out immediately before preparation
for assay. To one ml urine, 0.2 ml, 0.3 M, zinc sulphate
*
and 0.2 ml, 0.3 M, barium hydroxide were added, well mixed 
( Mihirlimixer *) and centrifuged for 10 minutes (bench centrifuge, 
top setting). This precipitated proteins, phosphates, 
pyrophosphates and all nucleotides except cyclic AI-IP (Krishna
1968). Due to the amount of protein present in plasma, 
its purification was modified:- To 2 ml of plasma were added 
equal volumes of zinc sulphate and barium hydroxide* and the 
mixture centrifuged as above.
The supernatants were loaded drop by drop on to one 
column for urine and two for plasma. Each column consists of 
3 X  0.6 cm of *Dowex 3OK* resin, prewashed with at least 3 
volumes of distilled water, and with a filter paper disc on top 
to avoid resin disturbance. The loaded columns were eluted with 
glass distilled water. Cyclic AMP, freed of cations, appeared 
in the second to tenth ml of effluent as monitored by the 
appearance of tritium label or UV absorbance (Figure 2.4).
The third to the seventh ml (inclusive) of effluent were pooled 
and freeze-dried. The dried material was taken up in 30 pi of 
60 mM Tris-buffer, pH 8.0, containing 3 2-mercaptoethanol for 
plasma and 30-500 pi for urine.
To estimate the loss of cyclic AMP during this purification, 
tracer amounts of tritiated cyclic AMP (about 1000 dpm) were 
added to 1 ml of sample which was then passed through the
(* freshly prepared)
86
0.8
300
200
o
in
2
■100
0
Volume (ml )
Figure lA: Elution curve for the purification of cyclic AMP
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on a column ( 0.6 X 3.0 cm) of Dowex 50Y/ resin.
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procedure described above and the resultant $0 pi solution 
in buffer counted in I5 ml of scintillant. 20^ out of each 
batch of estimations were checked for recovery. Values in 
the range 44 to $1^ of the added [^ h] cyclic Aï»ÎP were obtained. 
Part of the loss was due to collection of the central region of 
the elution peak rather than the whole peak.
2.3.2. Cyclic AIvIP Assay
A purified sample (50 pi, containing 5-320 pmol of 
cyclic AIIP) was pipetted into the bottom of a 20 ml conical 
glass-stoppered centrifuge tube; to this was added an equal 
volume of substrate containing 6 pmol Tris-HCl, pH 8.0, 6 pmol 
MgCl2> 6 nmol 5* AI^IP and 8 praol tritiated cyclic AMP (about 
50 nCi). The reaction was started by the addition of 50 pi 
of an enzyme mixture which contains the brain phosphodiesterase 
(about 48 pg of protein/ml), Crotalus atrox venom (img/ml),
60 ml»l Tris—HCl, pH 8.0, and 5 2-mercaptoethanol. The amount 
of phosphodiesterase (about 2.4 pg/incubation tube) was 
previously determined so that it was just sufficient to hydrolyse 
.30-40^  of the tritiated nucleotide without the addition of 
nonr-radioactive cyclic Al'IP. The reaction was stopped, after 
10 minutes at 30^C, by the addition of 0.8 ml of 50^ (w/v) slurry 
of ‘Dowex 1 * resin. The mixture was left to equilibrate for 
10 minutes, then I5 ml of scintillant added and thoroughly mixed 
(‘Whirlimixer*) about 1 minute. After standing for a further 
10 minutes the mixture was spun (shielded bench centrifuge) at 
top-setting for 10 minutes and the supernatant transferred as 
fully as possible to scintillation vials for counting. The
*
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values of unknown samples were obtained by reference to a 
standard curve (Figure 2.5)* This curve is prepared by 
measurement of knoTm concentrations of cyclic ÈMP through 
the described procedureo
2*5*3# Specificity Characteristics of Brain Phosphodiesterase 
The rat brain phosphodiesterase preparation was 
investigated by replacing the cyclic A&IP standards with 
concentration ranges of each of the following:- cyclic Gl-IP, 
cyclic UMP, cyclic HÆP, cyclic CMP, adenosine, 5* AMP, ADP and 
ATP# The cyclic AMP assay was carried out as described in 
2#5#2#. and the results plotted (Figure 2.6).
2.3*4# Discussion of the Brooker et al. Assay for Cyclic
The assay is based on the competition between unlabelled 
cyclic nucleotide with labelled cyclic Aî^IP for conversion to 
3 '-nucleoside by a limiting amount of phosphodiesterase. % e  
amount of labelled adenosine formed is inversely proportional 
to the quantity of unlabelled cyclic M W  present (Brooker & 
Appleman, 1968 )#
Cyclic AMP concentrations in body fluids are obtained 
from the standard curve in conjunction with the calculated 
recovery factor for the *clean-up * procedure (2.5*1)#
The enzymic radioisotopic displacement assay for the 
measurement of cyclic AÎ^ P in body fluids is easily set up and 
maintained. The assay is sensitive enough for the
levels of the nucleotide in U r i n e H o w e v e r ,  determination of 
the much lower concentrations of cyclic AMP in plasma requires 
at least 2 ml to achieve a borderline sensitivity.
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It has been suggested by Eodbell (l971a) that as much 
as 5 - 25^ endogenous nucleotide could be lost by treatment 
of the body fluid with zinc sulphate and barium hydroxide.
However, Krishna (1968) argued that less than 1^ of the 
nucleotide is lost via this route. Radioactivity measurements 
on several samples in this study indicate a loss of 1 - 5^*
The venom used was found not to show any phosphodiesterase 
activity towards the cyclic Al^ P under the conditions of the assay, 
5* - AÎ-ÎP is included in the assay mixture to act, after hydrolysis 
by the venom, as a carrier for the minute quantities of labelled 
adenosine, the reaction product. Although the amount of the 
5* — AI^'IP used inhibits the phosphodiesterase to some extent 
(Brooker et al., I968), we found that as much as 1,5 mî-î 
51 - #IP still gave a functional assay system.
The reaction is stopped by the addition of anion exchange 
resin, which binds unhydrolysed cyclic AI»IP, and thus differentiates 
substrate from product. The removal of resin improves the 
sensitivity for urine measurement, the trapped nucleotide giving 
a distinct count rate in contradiction to the findings of Brooker 
et al, (1968 ), Resin removal by centrifugation is vital for 
attempts at plasma measurements.
Table 2,2 shows various experiments conducted to confirm 
the validity of the assay. Prior destruction of cyclic AI^IP 
with phosphodiesterase reduced the assay value to zero; boiling 
and then readdition of cyclic AMP agreed well with standards. 
Interference with the assay of cyclic AI*IP by other 
nucleotides is shown in Figure 2,6, Of the nucleotides tested
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Table 2.2; Validation for the Brooker, Thomas and Appleman Procedure
pmol of cyclic AMP 
^Measured Expected
1. 50 pi of purified urine 36 -
2. 20 pi of purified urine 16 14
3. 50 pi of purified urine
+ 80 pmol of cyclic AI<IP 110 ll6
4. 20 pi of purified urine
+ 80 pmol of cyclic A15P 90 94
5* 100 pi of freeze-dried plasma
(2 ml original plasma) 12 —
6. 50 pi of freeze-dried plasma
(l ml original plasma) 6*5 6.0
7. 100 pi of freeze-dried plasma
+ 80 pmol of cyclic AI# 87 92
8., 50 pi of freeze-dried plasma
+ 80 pmol of cyclic AMP 80 86
T 9. 50 pi of purified urine
pretreated with excess
phosphodiesterase 0 0
Î 10. 50 pi of freeze-dried plasma
pretreated with phosphodiesterase 0 0
Î 11. 50 pi of purified urine
+ 80 pmol of cyclic AI#
pretreated with phosphodiesterase 0 0
Î 12. 50 pi of freeze-dried plasma
+8 0  pmol of cyclic AMP
pretreated with phosphodiesterase 0 0
13# As in 11 except 80 pmol of
cyclic AI# added after boiling 75 80
14* As in 12 except 80 pmol of
cyclic AMP added after boiling 74 80
* The mean of 5 separate estimations.
Î Brain phosphodiesterase preparation (48 pg) was incubated 
for 10 minutes with the sample and then destroyed by 
boiling (lOO^C) for 5 minutes.
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cyclic CDIP and cyclic ÜI# showed negligible cross reaction 
at concentrations as high as 300 pmol/incubation. Cyclic 
H #  was found to have a third of the effect of cyclic AMP, 
and cyclic Gî»jP had about a tenth of the effect* Cyclic GMP 
has been detected in urine (Broadus et al*, 1971) but to a 
lesser extent than cyclic Aï# (0*4 - 3.0 pQ0l/24h)* Other 
cyclic nucleotides, including cyclic 31ÎP, are barely detectable 
in urine (Hardman, 1971)* Treatment of the body fluids with 
zinc sulphate and barium hydroxide removes a range of other 
possible interfering substances* There is now evidence for 
two distinct brain phosphodiesterases - one for cyclic AÎ# and 
one for cyclic GMP (Thompson & Appleman, 197l)> both activities 
would be expected in the rat brain preparation described 
(Section 2*4.1*).
One of the requirements of this type of assay is that
the enzyme used must have a Michaelis constant, which is not
appreciably higher than the concentrations which are to be
measured* The for the rat brain phosphodiesterase as used
in this study was 9*7 x 10 (Figure 2*7). This is in general
—V
agreement with the value of 8*3 x 10 M obtained by Somerville 
et al, (1970), and 8 x 10""^ M by Skidmore and Hindiey (l970). 
Thompson and Appleman (1971 ) have reported values of 5 x 
for the for cyclic AI# phosphodiesterase, and 1 x IC'^M for 
oyclio G&ÎP phosphodiesterase*
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Figure 2.7: Lineweaver -  Burk plot for rat brain 3, 5-cyclic AMP
phosphodiesterase.
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2.6: SATURATION ASSAY
2.6.1. Preparation of the Binding? Protein
The procedtire was modified from that given by Brown 
et al. (1971)S-* Bovine adrenals collected as soon as possible 
after slaughter, were transported packed in ice. Preparation 
of binding protein was carried out at 4^0 (cold room).
The adrenals were freed from the surrounding fat and the 
cortices were separated from the medulla and the capsule as 
follows: the adrenals were cut into halves which were pinned
on to a dissection board. The medulla was stripped away from 
the cortex with a pair of curved forceps, then the cortex was 
scraped off the capsule with a scalpel. The pooled cortices 
were disrupted in an MSE horaogenizer, with I.5 volumes of ice- 
cold Littlefields medium (O.25 H sucrose, 0.5 M Tris-HGl buffer, 
pH 7*4, 0.05 M magnesium chloride, 0.025 M potassium chloride).
The homogenate was centrifuged for 10 minutes at 10,000 ^  at 
4^G in an MSE High Speed I8 centrifuge (10,500 rpm, 8 x 50 rotor). 
The resulting supernatant was stored in 0.5 — 1.0 ml portions at 
—20®C. Immediately before use one such portion was thawed and 
an aliquot diluted; activity is lost on refreezing. Using this 
one freeze-thaw procedure negligible loss of binding activity was 
found after 3 months. The diluent used is 50 mM Tris, pH 7*4, 
containing 8 mM theophylline and 6 mM 2-mer cap to ethanol (’’Buffer”)
2.6.2. Binding Protein Dilution Curve (Fig. 2.8 )
This was set up for each preparation of binding protein 
to determine the dilution of binding protein to be used in 
subsequent assays. Serial dilutions of binding protein were
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Figure 2.8: Binding protein dilution curve (sem i-log plot )
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prepared (dilutions used were; 1:2, 1:4, 1:8, l:l6, 1:32,
1:64) and the incubation tubes (50 x 9**75 mm round bottom) 
were set up as follows 
100 pi "Buffer”
100 pi binding protein (each dilution)
50 pi [ j - cyclic AIvîP (0.36 pmol i.e. lOnCi)
The tubes content was mixed (’Whirliraixer*) and incubated 
(without shaking) in an ice-bath for 90 minutes.
2.6.3. Separation of Free and Bound Fractions
After this incubation 100 pi of a suspension of Ig/lO ml 
of charcoal in buffer containing 2^ (w/y) of bovine albumin was 
added to each tube. The suspension (initially at 0®C) was 
agitated (magnetic stirrer) for about 5 minutes and then, with 
continuous stirring, 100 pi portions were rapidly transferred 
using an ’Oxford’ pipette. Immediately after receiving the 
charcoal each tube was agitated for a few seconds on a ’Whirlimixer* 
then placed back in the ice-bath. The complete batch (in this 
study 24 tubes) took 3-4 minutes to complete; it was then 
centrifuged for 10 minutes at 4,000 rpm (MSE ’Multex’ 24 x 15 
angle head rotor) at room temperature. The batch was replaced in 
an ice-bath and 100 pi of the supernatants of each tube transferred 
to 6 ml scintillant and counted.
It is important to work to a precise time sequence as 
it is found that if tubes were not rapidly centrifuged but left 
to stand at room temperature reversal of the binding reaction 
occurs (Table 2.3). However, the rapid reversal of the binding 
reaction is slowed down by keeping the tubes in an ice-bath.
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Table 2.3: Reversal of Binding Reaction on Standing at Hoorn
Temperature 22^0).before Centrifugation ~
. / . \ ^ pH] - cyclic AI4P bound % Reversal of
ime ^min; (mean of 2 estimations) Binding
0 ( 10 sec) 36.0 0.0
1 34.0 5.6
2 34.0 5.6
5 27.0 25.0
 10 23.5 34.7
20 16.8 53.5
The binding protein dilution was plotted (Figure 2.8) 
as ^ bound (ordinate, linear scale) against dilution of the 
binding protein (abscissa, log scale). The 100^ binding value 
was obtained by setting up tubes containing everything but the 
charcoal (i.e. 100 pi of buffer added, instead of the Norit 
suspension, to the 25O pi incubation mixture). Ah aliquot 
(100 pi) was counted as above. Sample tubes were expressed 
as a percentage of this standard.
The dilution of the binding protein that gave 20 - 30^ 
binding of the tracer was read off Figure 2.8. This was the 
dilution to be used in the assay (Ekins and Newman, 1970).
2.6.4. Preparation of Sample
a. Urine
Samples were thawed out immediately before cyclic AI# 
determination and assayed for creatinine. Dilutions (l%10 to 
ls50) in ’Buffer* were prepared and 100 pi of the diluted 
samples were taken for estimation of cyclic AI'ÎP.
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b* Plasma .
Freshly thawed heparinised plasma (0.2 ml) was 
deproteinised by the addition of 0.2 ml, 0.3 M zinc sulphate 
and 0.2 ml, 0.3 M barium hydroxide (Krishna et al., 1968; 
see section 2.5.1). The supernatant was freeze-dried and 
the residue taken up in 100 pi ’Buffer*. Recovery values for 
this plasma procedure were checked by the addition of a known 
amount of pHJ - cyclic AMP to about 20^ of the plasma samples 
in each batch (see section 2.5.1). After freeze-drying and 
redissolving in ’Buffer’ the sample was counted. Normally 
about 90^ of the labelled nucleotide was recovered.
Both plasma and urine cyclic AMP in the appropriately 
prepared 100 pi samples was determined by the saturation method 
of Brown et al. (1971)♦
2.6.5* Protein Binding (Saturation) Assay for Cyclic MIP 
Each assay tube contained 300 pi for incubation 
50 pi of cyclic AICP standard (O-I5 pmol) Œ  
50 - 150 pi of unloiown.
50 pi of [^h] - cyclic AI4P (lOnCif 0.36 pmol i.e. 120 pg) 
100 pi of an appropriate dilution of binding protein 
(normally diluted l;l6).
'Buffer' to 300 pi.
The tubes content was mixed ( *%irlimixer ’ ) and incubated 
at O^C for 90 minutes (without shaking). At the end of the 
incubation period 100 pi of charcoal suspension was added and 
the procedure described in section 2.6.3 was followed.
The values of unknown samples were obtained by reference 
to a standard curve (Figure 2.9). The linear range was
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Figure 2.9: Cyclic AMP calibration curve for the protein 
binding assay. Each point represents the mean of seven 
separate determ inations. The vertical bars indicate 
± S.E.M. .
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1 - 15 pmol.
Control tubes containing 100 pi buffer instead of 
binding protein were prepared; these were used to monitor 
the efficiency of the charcoal in absorbing the free nucleotide 
and also as a check for non-specific effects. It was found 
that the Norit did not completely remove radioactivity.
In general aqueous standards or urine dilutions gave 40 —
60 cpm, plasma samples gave 90 - 100 cpm (scintillant alone 
gave 20 opra). These values were subtracted from standards 
and unknowns as appropriate.
2.6.6. Specificity Characteristics of the Binding Protein 
This was investigated by incubating dilutions of cyclic
CMP, cyclic GI4P, cyclic IMP, cyclic X31>1P, adenosine, 5* - AÎ^ ÎP,
ADP and ATP with [^ h ] cyclic AMP and binding protein under the 
specified assay conditions (figure 2.10).
2.6.7. Presentation of Results
Standard plots can be presented in a number of ways:—
a. Percentage of cyclic AMP bound (see section 2.6.3) as 
ordinate, against the log of concentration of unlabelled 
cyclic Al'IP (pmol per assay tube; figure 2.9) as the 
abscissa (Brown et al., 1971; Latner & Prudhoe, 1973; 
Zettner, 1973).
b. Percentage of cyclic A3IP bound as ordinate against the 
concentration of unlabelled cyclic AÎ*ÎP added (pmol per 
assay tube; figure 2.11) as the abscissa (Barling, 1974).
0. ordinate against concentration of unlabelled
cyclic AI'ZP (pmol per assay tube; figure 2.12) as 
abscissa (Weller et al., 1972), where Go is the amount
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Figure 2.11: Effect of plasma on the cyclic AMP response curve.
Three assays were set up with the same reagents: b-  q Assay
curve for standards in buffer; a l and e @ assays
supplemented with blank plasma ( 5 0 pi)  from two different 
subjects in place of an equal volume of buffer.
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of radioactivity bound in the absence of unlabelled 
cyclic AÎÎP and Cx is the amount of radioactivity 
bound in the presence of standard or unknown 
unlabelled cyclic AMP* 
d. Percentage of free [^h] - cyclic AI^IP as ordinate
against unlabelled cyclic M P  (pmol/incubation tube; 
figure 2.13) as abscissa (Rabinowitz & Katz, 1973)*
Of these four methods the former two give curves the 
latter two are linear. Plot (c) is now widely used giving 
a straight line of intercept 1.0 on the ordinate.
2.6.8. Standardization Problems
A major problem with the measurement of cyclic AMP in 
plasma is the presence of phosphodiesterase, which is active 
even in frozen samples (Brovm, personal communication). Thus 
unless the enzyme is inactivated the plasma concentration of 
cyclic AI-ÎP is found to fall by as much as 100^ after storage 
at - 20^0 for a month. Attempts to inactivate the enzyme by 
collecting blood into lithium-heparin tubes which are either 
coated with theophylline or contained a small volume of isotonic 
solution of this inhibitor, proved unsatisfactory in terras of 
reproducibility. Recently EDTA has been used with success 
(Oldham^ personal communication). To avoid excessive loss of 
cyclic AJ^îP heparinised plasma was snap-frozen within 5 - 7  
minutes of blood collection, stored at -20°C and deproteinized 
as described in section 2.6.4 within 24 hours. Recoveries 
were estimated by the addition of known amounts of p H  j - cyclic 
AMP to the freshly collected plasma. In deproteinized plasma 
cyclic AI'IP is stable for long periods of storage.
* Tovey ^  al., 1974
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Brown’s group (Barling et al., 1974) found that
dilution of heparinised plasma with an equal volume of .
’Buffer* allowed prolonged storage of samples at - 20^0
with minimum cyclic AMP loss. Thus by slight modification
of the saturation assay (i.e. up to 150 pi of diluted plasma)
direct measurement of cyclic AI*!P in plasma is made possible.
The previously described (section 2.6.4) deproteinization
however
procedure will remove plasma interfering factors^ These are 
still present but can be corrected by letting the plasma 
samples stand at room temperature for 24 hours in the absence 
of theophylline thus losing all measurable cyclic AMP. The 
effect of cyclic AMP free plasma (blank plasma) on the assay 
response curves is shown in figure 2.11. These assay curves 
are not identical showing that constituents in the plasma of 
different subjects may alter the curve to different extents.
The binding curve for plasma diluted with ’blank plasma* for 
an individual is concomitant with the standard curve of pure 
cyclic A3ÎP dissolved up in the same blank plasma. Thus the 
preparation of standards in blank plasma allows elimination of
interfering factors. The ideal is individual standard curves
/
but it is, in general, satisfactory to compromise with a 
standard curve made up with pooled blank plasma (Latner & 
Prudhoe, 1973). In urine interfering factors are conveniently 
removed by dilution, thus eliminating the need for the 
preparation of a blank urine.
Weller ^  (1972) encountered a similar problem in
studies of cyclic AîvIP determination in cerebral tissue. This 
was overcome by modifying Gilman’s assay (l970) by incorporating
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unlabelled internal standards in order to determine the 
extent of interference.
2.6.9* Discussion of the Protein Binding Assay for Cyclic AIÆP
The assay is based on the competition of variable 
unlabelled cyclic nucleotide with a fixed amount of labelled 
cyclic nucleotide for limited protein binding sites. The 
amount of tritiated cyclic AMP (cpm) still present in the 
supernatant (protein bound fraction) at the end of the assay 
is inversely proportional to the quantity of unlabelled cyclic 
AMP added.
Bovine adrenal binding protein was found to have a 
high affinity for cyclic AI# (0.83 x 10 see figure 2.14).
This is in good agreement with the value of 0.75 % 10 quoted 
by Walton & Garren (l970). In the assay procedure as described 
the lower limit of detection for cyclic M P  was 0.2 pmol. For 
measurement, the range used was greater than 1 pmol and less than 
15 pmol per assay tube.
Of the nucleotides tested cyclic CMP, cyclic GMP, cyclic 
UIP and cyclic IB# showed slight cross-reaction (figure 2,10). 
Cyclic II# seems to be about 10 times less potent than cyclic A>#, 
and cyclic CB#, cyclic GMP and cyclic UI# are at least 100 times 
less effective. Urinary levels of cyclic G&# are not 
sufficiently high to interfere with the assay of cyclic AJ># 
(Goldberg et al., 1969; Ishikawa et al., 1969), while cyclic 
UMP could not be detected in the urine (Hardman, 1971)# There ' 
are no published reports of cyclic IMP in urine. Adenosine at 
concentrations up to 30 nmol/incubation tube, 5' - AMP at 
concentrations up to 75 nmol/incubation tube and ADP and ATP
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Figure 2.14: Scatchard çAoi (ScatchardJ949 ) for the saturation assay of 
cyclic AMP. The resulting graph (solid line) is nota straight line because of the 
heterogeneity of the binding protein preparation (Zettner,1973). The broken line
7
shows an average slope of-*8.3x10 M, indicating the average affinity constant
7of this binding protein preparation to be 8.3x10 M, and the dissociation
8constant to be 1.2x10' M,
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at concentrations up to 100 nmo1/incubâtion tube did not 
appear to cross-react with the system. Thus for urine, 
after ten to fifty fold dilution, the assay may be taken 
as specific for cyclic AMP,
The partial competition of cyclic CICP, cyclic GMP, 
cyclic IMP and cyclic UMP but lack of competition by adenosine, 
5 * - AMP, ADP and ATP suggests that the specificity resides in 
the cyclic 3*,5* ring. Serial dilutions of binding protein 
were assayed with the intention of distinguishing non-specific 
effects (Ekins & Meiman, 1970). Though such data does not 
constitute complete evidence for assay specificity, parallel 
dilution curves on semilogarithraic plots with respect to a 
standard cyclic AMP range were observed.
Various experiments were conducted to check the 
validity of the assay (table 2,4). Treatment of urine with 
cyclic AMP phosphodiesterase reduced the cyclic AI^ IP content 
to zero; readdition of a loiown amount of cyclic AI'IP to this 
urine gave a value in accordance with aqueous standards.
Table 2.4: Protein Binding Assay for cyclic AI^îP in Urine
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Cyclic AMP (pmol/50ytl )
Measured Expected % Recovery
1. 50 pi of urine (1:50 dilution) 2.8 (3)
2. 50 pi of urine (l:50 dilution)
+ 7*5 pmol of cyclic AI«1P
*3. 50 pi of urine (ls50 dilution)
pretreated with phosphodiesterase 0.0 (3) 
*4* As 3 except 15 pmol of cyclic 
AÏÎP added after boiling
10.1 (3) 10.3
0.0
98
15.9 (3) 15.0 106
*Brain phosphodiesterase preparation (60pg) was incubated for 
10 minutes with the sample and then destroyed by boiling 
(100°C) for 5 minutes 
( ) Humber of estimations
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To check the reproducibility of the urinary cyclic 
AMP determinations, three separate urine specimens were 
collected# Each specimen was put through the dilution and 
assay procedure on 4 separate occasions (table 2.5)*
Table 2.5 : Check for Assay Reproducibility
Specimen Cyclic AICP (pmol/50pl urine) Interassay Coefficient
+ S.D. of Variation
1 78.0 i  4.0 (4) 5.1
2, 47.3 ± 5.7 (4) 12.0
3 47.9 -  8.1 (4) 16.9
Mean interassay coefficient of variation 11.4
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3.1 Diurnal Variation of Plasma and Urinary Cyclic AIÆP in
Normal Human Subjects.
Cyclic AI-ÎP has been implicated in a number of clinical 
conditions including pseudohypoparathyroidism (Chase et al.,
1969? Marcus , 1971; Murad and Pak, 1972), mania and
depression (Abdulla and Hamadah, 1970; Paul et al.. 1970 ;
Cramer et al.. 1972; Naylor £ t ^ . , 1974), bronchial asthma 
(Szentivanyi, I9685 Alston et al., 1974), and diabetes insipidus 
(Pichman and Brooker, 1972). In these conditions cyclic AIvIP 
levels have been studied mainly in urine and plasma. The 
interpretation of cyclic M W  levels as an aspect of clinical 
biochemistry must rely on a clear understanding of the "normal 
range" for this nucleotide. Thus the occurrence of diurnal 
variation of cyclic AI^IP in body fluids could produce a misleading 
interpretation if reliance is placed on data obtained from 
random specimens.
A number of hormones are known both to initiate their 
biological actions by altering the intracellular concentrations 
of cyclic AMP (section I.4) and to exhibit circadian rhythms 
(Conroy and Mills, 1970; table 3.1). It would therefore seem 
possible that cyclic AI# should exhibit a diurnal variation. . 
Cyclic Al# has been reported to exhibit such a pattern in 
mouse epidermis (Marks and Grimm, 1972), rat gastric mucosa 
(Domschke et al., 1972) and rat adrenal cortex (Moore and 
Quavi, 1971). In this latter case the rhythm disappeared after 
appropriate denervation in the hypothalamic region.
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Table 3*1 Hormones Exhibiting Circadian Rhythms 
(Conroy & Mills, 1970)
Hormone Peak Trough
Adrenaline 11.00 - 20.00 23.00 - 05.00
Nor adr enal ine 08.00 - 14.00 20.00 - 02.00
ACTH 06.00 18.00
*ADH Morning Night
MSE Early morning 18.00
TSH 20.00 - 08.00 11.00 - 20.00
* Goodwin, _et al. (1968) have reported considerable individual 
variation in the diurnal rhythm of urinary excretion of ADH.
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At present there is no detailed information on the 
diurnal variation of plasma cyclic AI>1P. The situation with 
regard to human urinary excretion of cyclic AI^IP is confused. 
Chase (1969) did not find any diurnal variation in
the excretion of cyclic AMP in four normal volunteers.
However, at the same time as this investigation, Murad and Pak 
(1972) reported circadian rhythms for both cyclic A>ÎP and 
cyclic GI>1P in an unspecified number of subjects. Recently 
Sagel et al. (1973; 16 normal volunteers) and Somerville
(1973; 5 normal volunteers) have found a diurnal
variation in urinary excretion of cyclic AMP.
Plasma and urinary levels of cyclic AMP were investigated 
in 8 male and 10 female volunteers and urinary levels alone 
were studied in a further 3 male and 7 female volunteers 
(doctors, nurses and students) aged 18 - 55 years (all but 
four being under 30 years). Serum levels of PTH and TSH were 
measured on 8 volunteers. There was no attempt to modify the 
diet and physical activity of the volunteers. In fact apart 
from 4-hourly attendance at the collecting centre they were 
asked to pursue normal activities. Disturbance of sleep was 
kept to a minimum, the 04*00 and 08.00 sample being collected 
at the bedside. Samples were obtained at 4-hourly intervals 
over a 24-hour period commencing at O8.OO. As we have 
evidence of a circadian rhythm associated with the menstrual 
cycle (section 3.2), repeat collections were made eight weeks 
later. On the second 24-hour study the volunteers were asked 
to avoid the ingestion of alcohol. Both plasma and urine
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( 2 .^1 )
samples were collebtedjand prepared for the assay as described 
in section 2.6,4, Cyclic ÈMF was determined by the saturaticn 
method of Brown et al. (l97l) section 2,6.5*
Figure 3*1 summarises data for plasma and urine from all 
subjects studied. The bimodal distribution observed for plasma 
led us to look for ti-TO groups within this population.
Consideration of the first 24-hour collection period indicated 
two distinct urinary patterns: 21 subjects (l4 female, 7 male)
showed maximum levels of cyclic ABîP in the morning (04.OO — O8.OO), 
whereas 7 subjects (3 female, 4 male) showed a peak in the 
afternoon (16.OO - 20.00). Plasma values also gave two patterns;
16 subjects (9 female, 7 male) showed a cyclic AMP peak at 
about midnight, whereas 2 subjects (l female, 1 male) had their 
peak value at noon. Plasma and urinary cyclic Aî«ÎP levels were 
remeasured in 10 of the subjects (6 female, 4 male) eight weeks 
after the first 24-hour survey and eight of these (5 female,
3 male) showed the same morning peak pattern as before (figure 3.2). 
The two exceptions had shifted from a morning peak to an afternoon 
peak pattern. The male had had a markedly higher alcohol intake 
on the first occasion; and the female was at the beginning of 
her menstrual cycle for the first collection but at the end of 
her cycle for the second.
Figure 3.3 summarises data for urine and plasma of the 
morning peak type, figure 3*4 shows the afternoon peak pattern. 
Figure 3.5 illustrates the reproducibility of an individual 
pattern for the urinary cyclic AI»iP in collections made at the 
mid-point of three consecutive menstrual cycles. Thé recovery
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Figure 3.1: Diurnal variation of urinary and plasma cyclic AMP 
levels in normal human subjects. Solid line shows variation in 
urinary cyclic AMP, broken line shows variation in plasma cyclic AMP 
levels; S.E.M. values are indicated by the vertical bars. Comparison 
of the paired data (Students t test ; Bailey, 1964 ) for minimum with 
maximum cyclic AMP in the 4h urine collection periods gives a difference 
significant at the level p< 0.05. For plasma the minimum value at 
16.00 h is lower than the 1200 h (p=Ol) and the 24.00h (p<002 ).
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Figure 3.2: Diurnal pattern for plasma and urinary levels of 
cyclic AMP in normal humans (mean of 8 ). Specimens were 
collected on two separate occasions eight weeks apart.
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Figure 3A : Diurnal rhythm-afternoon peak pattern - for plasma 
and urinary levels of cyclic AMP in normal humans. For urine (n=7 ) 
the 2400-0400h and 0800-1200h values are lower than the 1200- 
1600h (p<0.01 ). The plasma pattern is for 4 subjects ( 2 of these 
showing a pattern shift from one collection to the next ), the 
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Figure 3.5: Illustration of reproducibility of an individual diurnal 
pattern for urinary cyclic AMP. Specimens were collected from a 
normal volunteer at the mid-point of three consecutive menstrual 
cycles.
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values for the plasma procedure ranged between 70-80^.
The 24-hour urine values for each individual investigated 
on the two occasions varied by not more than 10%, with one 
exception (2'Jfo) of the female who was at different points 
in her menstrual cycle. All 24-hour creatinine values fell 
within the normal range. Variations in plasma levels of 
PTH and TSH were measured through the co-operation of &îr.
Brian Morris and I'Ir. Peter Hood. Their findings are depicted 
in figures 3*6 and 3.7.
The results obtained demonstrate diurnal rhythms for 
plasma and urinary cyclic AMP* The urinary excretion pattern 
was, in fact, similar whether the results were expressed as 
nmol/4h or nmol/mg. creatinine. This latter method of 
expressing data has been used by some workers (e.g. Murad and 
Pak, 1972), however in agreement with Curtis and Pogel (l970) 
we found a circadian rhythm for creatinine itself and hence 
find no purpose in presenting data obtained from the ratio of 
a variable with a variable.
The patterns obtained indicate two populations with regard 
to peak times. In our study the major group showed maicimum 
values in the early morning for both plasma and urinary cyclic 
AÎÆP, the minor group showed their peak values in the afternoon. 
Some individuals investigated fitted in with both these groups 
in that they showed a bimodal distribution. The urinary 
pattern does not seem simply to be a reflection of plasma 
concentration. Biddle and Hardman in their review (1971) 
point out a proportion of cyclic AICP in urine is formed in the
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Figure 3.7: Diurnal variations in plasma levels of TSH and 
cyclic AMP. Each point represents the value for eight normal subjects. 
Determinations were carried out on two separate occasions eight weeks 
apart.
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kidney (’'nephrogenous”) and is excreted directly without 
traversing the general circulation*
The pathways to the appearance of cyclic AI-DP in body 
fluids are still far from clear (Hardman ^  al*, 1971) and 
the mechanisms involved in the control of diurnal variation 
in cyclic MiP remain to be established* We chose PTH and 
TSH on the criteria that they affect cyclic M P  levels 
(Robison jet , 1971 ) and that assays exist in this 
Department. There is a need to investigate a variety of 
hormones including ADH (Jenner , 1972) and glucagon
(Park & Exton, 1972) before attempting to correlate 
patterns*
Our findings indicate the need for caution in interpreting 
cyclic Aî'IP levels in clinical disorders* It would seem that 
investigation of patterns of variation will be of greater 
value than the determination of the concentration of a random 
specimen*
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3,2 Variation of Urinary Cyclic AlEP during the Human Menstrual 
Cycle,
The plasma concentrations of luteinising hormone (LH) and 
follicle-stimulating hormone (PSH), show a marked rise at about 
mid-cycle (figure 3,8) and this leads to ovulation (Watson,
1973). In the corpus luteum LH activates adenyl cyclase leading 
to an increased progesterone synthesis (Marsh et , 1966), 
Oestradiol shows a peak plasma concentration about one day 
preceding the gonadotrophin peak (Dodson et al,, 1973)» and one 
action of this hormone is to restore uterine cyclic ÂMF levels 
in ovariectomised rats (Szego and Davis, 1967)* Eyan and Coronel
(1969) have reported that the injection of cyclic AMP in female 
Svriss mice prevented pregnancy and led to a considerable 
reduction in ovarian mass. The treated mice were still infertile 
5 weeks after cessation of the injections. However, the dose 
level was, to say the least, pharmacological (5 mg per day),
A further confusion is that the dibutyryl analogue was ineffective 
even at this massive dose level as was 5 '-AI'IP. These variations 
in hormonal levels associated with the menstrual cycle may 
influence urinary excretion of cyclic àMP and Taylor et al,
(1970) reported a mid-cycle rise of this nucleotide in three 
women,
Tîfelve normally menstruating women, two women with secondary
amenorrhoea, one pregnancy (second trimester) and six men were
range
investigated (the overall agejbeing 19-38 years). Five of those 
with a normal ovulatory cycle were classified as suffering from 
premenstrual tension. The classification was based on a 
questionnaire (see pp.129-130 ) which was compiled and assessed by
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HORMONES IN PLASMA
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Figure 3.8: Circadian variations in plasma levels of hormones 
associated with human menstrual cycle. The secretion of progesterone 
by the corpus luteum leads to a rise in basal body temperature. A 
temperature rise and the maintenance of a plateu provides some 
indication that ovulation has taken place. (Reproduced from a chart 
by Searle Diagnostic Hormone Assay Laboratory, High Wycombe, 
Bucks.. UK.).
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Questionnaire devised for the Assessment of Premenstrual Tension 
gyndrome ‘
Name •••••••«•••••«•«•.••••••••••••••••• Age  ....
Marital Status  .... . . . . . . No. of children ....•• i
1. Are your periods regular and normal? Y e s   .... .
N o   .....
2. How long does the period last? No. of da y s...... .
3. How many days between the periods? .....................
4. Do you experience feeling of tension Yes   . .......... ...
before or during the period? No . . . . . . . . . . . . . .
If yes,
(a) How many days before the
period? ..................
(b) How long does the tension
last?............................ ....................
(c) Is it relieved by the onset
of the period? .............
(d) Does the tension last
throughout the period? ...........
5* Do you feel pain before or during Yes  .... .
the period? No . .... .............
If yes, please specify  .... ..............
If you suffer from tension before or during the period
6. Do you feel slight irritation with  .....................
other people? .....................
7. Do you get bad tempered? . . ...............
8. Do you take it out on yourself ..................
or others? ....................
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9« Do you feel depressed and weepy? •••••••,
10. Do you entertain any suicidal ......
thoughts?
11. Do you imagine husband or boyfriend ........
does not want you, etc. - "No one .......
cares about mej" ........
12. Do you want to go out?................ ........
13. Do you feel bloated and ugly? ......
14. Do you put onweight? ......
15. How long have you had this tension? ........
16. Nhen in cycle does it start? ........
17. How does it affect you? ......
18. Hhat relieves the symptoms? .......
Menstrual History
1. At what age did menstruation start? .......
2. What pattern was it in the first .......
two years?   .... .
3. What pattern was it before you .......
started having tension, if any? .............
4* If you suffer from premenstrual .......
tension, has there been a difference .......
in the symptoms over the years?....... ......
Please specify  .... ...................
Comments
Please feel free to add any information you wish.
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Miss Mary L* Stokes, Consultant Gynaecologist at the South 
London Hospital for Women. To obtain a rough estimate of 
the time of ovulation first morning temperature charts 
(figure 3.9) were completed by some of the volunteers. Urines
(24-hours) were collected at weekly intervals for up to two 
months. Completeness of the collection was checked by 
creatinine estimation and the samples were stored at -20®C 
until cyclic AICP determination by the protein binding method 
of Brown et al. (l97l).
The results obtained for the twelve normally menstruating 
women are shown (two cycles) in figures 3.10 and 3.11. A 
peak (3*5 ±  0.3 pmol cyclic AîiP/24 hours) was obtained at day 
14 (where day one is defined as the onset of menstruation).
This maximum was significantly higher than the value on day 7 
(2.5 ± 0.2 pmol cyclic AI<üP/24 hours; P < 0.02) and on day 21 
(2.9 ±  0.2 pmol cyclic AMP/24 hours; P= 0.02). The pregnant 
female (3.7 ±  0.17 pmol cyclic AI'IP/24 hours; 6 samples) and 
the six males (3.1 ±  O.I5 pmol cyclic AMP/24 hours; 36 samples) 
showed no significant variation during six to eight weeks.
The two subjects with amenorrhoea excreted cyclic Al# (1.9 
+ 0.18 pmol cyclic AMP/24 hours; 9 samples) at a level comparable 
to the minimum in the menstrual cycle studies (table 3.1) but 
again there was no significant change in four weeks.
These findings indicate a maximum urinary excretion of 
cyclic AMP associated with temperature rise and thus, presumably, 
ovulation. Our results suggest that the premenstrual tension 
syndrome may be associated with a rhythm of greater amplitude 
(figure 3.11a) the significance of which is not yet understood.
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TOTAL POPULATION [n=12]
14 21 28 14
-r----- 1
21 28
DAY OF MENSTRUAL CYCLE
Figure 3.10: Urinary cyclic AMP excretion during two menstrual 
cycles. Each point represents the mean value for 12 normally 
menstruating women; the vertical bars indicate S.E.M. values. The 
shaded areas show periods of menstruation, and the arrows the 
time of first morning temperature shift (approximate time of 
ovulation).
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Figure 3.H: Urinary cyclic AMP excretion during two menstrual 
cycles. The shaded areas represent periods of menstruation. S.E.M. 
values are indicated by vertical bars.
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One hypothesis is a loss of fine control, i.e. an overswing.
We could find no evidence of a significantly low urinary level 
of cyclic Af'IP during premenstrual tension. However, this 
variation of cyclic AI^'IP excretion associated with the menstrual 
cycle again indicates the need for care in studying urinary 
cyclic #IP levels in clinical states.
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3*3 The Effect of«Oral Contraceptives on Urinary Excretion
of Adenosine 3'5'-Cyclic Monophosphate in Hormal Humans*
The precise mechanism whereby conception is prevented by 
the use of oral contraceptives is uncertain* Dufau. et al*
(1970) have shown that the oestrogen peak and the output of 
pituitary gonadotrophins, FSE and LH, which are largely 
responsible for the events of a normal menstrual cycle and 
pregnancy, are suppressed or diminished during the first cycle 
of the treatment with an oestrogen-progestagen contraceptive 
preparation* However, there is evidence that long terra 
treatment with oral progestational agents suppresses ovarian 
activity and ovulation but does not inhibit pituitary function 
(Loraine et al., I963). Oestradiol-17p (Szego and Davis, 
1967) and LH (Marsh et al*, I966) have been shown to exert 
their actions via cyclic AMP* As described in the previous 
section there is a mid-cycle peak in the urinary excretion of. 
cyclic AMP, in normally menstruating women, while volunteers 
with suppressed ovulation (secondary amenorrhoea and pregnancy) 
and males had little or no variation* It is therefore possible 
that the administration of oral contraceptives could suppress or 
abolish the nucleotide peak*
taking
Seven normal healthy women (l8-27 years)^oral progestagens 
were investigated* Five were using *Horilyn-l *, one ‘I^ Iyrovlar* 
and one *Minulyn*5 the dose for all drugs used was one tablet 
per day orally from day 5 to 25 of the cycle* Each tablet of 
♦Horilyn-1* contains 1 mg norethisterone (l7c<-ethinyl-19- 
nortestosterone) plus O.O5 rag mestranol (ethinyl oestradiol- 
3-methyl ether)* *Myrovlar* contains 1 mg norethisterone
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acetate and 0*05 mg ethinyl oestradiol, *Minulyn^ contains
2,5 rag lynesterol plus 0,05 mg ethinyl oestradiol. Six of 
the women had been taking oral contraceptives 6 to l8 months 
prior to this investigation. Tiro of these were followed up 
2 months after they had discontinued the ingestion of 
progestagens. One of the volunteers was investigated for two 
cycles prior to administration of oral contraceptives and during 
the first 3 cycles of treatment with ‘Norilyn-1*. Urines (24h) 
were collected at weekly intervals. Completeness of collection 
was checked by creatinine estimation and the samples were stored 
at -20®C until estimation of cyclic AMP by the protein binding 
method,
*
The results obtained are presented in figure 3.12; the six 
women who had taken progestagens for 6 to 18 months showed an 
excretion of cyclic AI^IP in the normal range (l*5 - 3.7 umol/24h), 
with no significant variation between the eight collections 
during two cycles. The two women (figure 3.13 A & B) showed no 
variation in cyclic AI-iP excretion during 2 cycles on progestagens, 
but two months after withdrawal of the contraceptive agents a 
marked mid-cycle peak in cyclic AMP excretion was obtained. The 
single volunteer (figure 3.13 C) investigated for two cycles 
prior to administration of *Morilyn-l*, showed a mid-cycle peak 
in cyclic AÎ5P excretion which disappeared during the third month 
of taking the oral contraceptive. Depressive symptoms caused 
the cessation of ingestion of the drug at this point.
This study indicates that during the administration of 
oestrogen-progestagen contraceptive preparations the mid-cycle
(* these should be compared with the pattern shoim in Figure 3.10),
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Figure 3.12 : Urinary cyclic AMP excretion during periods of
up to 8 consecutive weeks. Vertical bars represent 5.EJ4. values.
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Figure 3.13: Effect of oral contraceptives on urinary cyclic AMR 
Solid lines represent cyclic AMP excretion during cycles free from  
contraceptives agents; broken lines show cyclic AMP excretion 
during cycles on progestagens. The oral contraceptive agent was 
'minulyn' for F.J.Mc./myrovlar’ for RD. and 'norilyn-l'for H.H..
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urinary cyclic AÎ-ÎP .peak is suppressed. It is possible that 
ovarian activity and ovulation are mediated through an 
increased production of cyclic AI^IP in the ovary. It is 
interesting that depressive symptoms were absent in the 
volunteers taking oral contraceptives (figure 3,13 A & B) but 
premenstrual tension recurred after discontinuation of 
progestagens.
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3>4 The Effect of.Exercise and Diet on the Plasma Levels of
Cyclic Al'iP.
Cyclic #1P has been implicated in many biological systems 
(section 1.7) and because of its relation to P-adrenergic 
receptors it is thought that changes in muscular activity could 
result in changes in cellular cyclic AlCP. Prolonged physical 
activity - 90 minutes of football or stair climbing - was found 
to have no significant effect (Paul ^  al*? 1971b;
Owen, 1975; Murad and Pak, 1972). Williams et al. (1972) 
reported a marginal rise in cyclic AI^EP excretion in four 
volunteers after a 2 or 3 mile run (but no change in cyclic GÎ'ÎP). 
Paul (1971b) could not find any significant difference in
cyclic AI'IP excretion between 10 hyperkinetic children and an 
age-matched control group* He also reported that physically 
active and inactive depressed patients show similar (low) levels 
of cyclic AI'IP. No significant difference in urinary cyclic AI»IP 
levels were found between the normal and psychotic phases of 
two patients with periodic catatonia; one of whom exhibited 
episodes of prolonged stupor, whereas the other exhibited violent 
and destructive episodes. However, Eccleston and his group (1970) 
in an investigation of 3 volunteers who walked 5 or 10 miles in 
hilly country found a doubling in cyclic A5ÎP excretion (24h 
output) in two of these subjects. Heath ^  (1973), have
reported a rise in plasma cyclic AI»IP and in the urinary cyclic 
AMP/creatinine ratio after exercise in an unspecified number of 
subjects.
Twelve normal volunteers, 7 males and 5 females (age l8 
to 24 years) were investigated. No food was consumed by any of
143
the subjects for at least 12 hours prior to the investigation.
All volunteers were confined to bed for 8 - 9  hours before the 
collection of the first blood specimen (08*00 — 10.00 h).
After the first blood collection, four controls, two males and 
two females, remained in their beds for the rest of the period
of this investigation. Six volunteers (3 males, 3 females)
undenrent the Harvard step procedure (Consalazio et al., 1963) 
for up to 5 minutes (20 inch step for males, 17 inch for females; 
30 steps a minute); they then returned to bed till the end of 
the investigation. The remaining 2 male volunteers stayed in
bed and ingested a meal of 760 calories (Glaxo and Farley baby 
rice cereal, chocolate flavour, consisting of;
carbohydrates 80^
protein 10^
fat 3^
and milk; protein 3*3 g
fat 3.6 g ).
Within a minute after completion of exercise or food intake, a 
second blood specimen was collected. A specimen was taken from 
the members of the control group at the same time. Forty minutes 
later a third and final blood specimen was collected from all 
volunteers.
Plasma was isolated and frozen within seven minutes (see 
section 2.3.1). Part of each sample was deproteinised and 
freeze-dried (section 2.5.1) and the remainder was diluted with 
an equal volume of 50 mî& Tris buffer, pH 7.4, containing 
8 mM theophylline. Cyclic AI'IP was measured in 50 and 100 pi
144
aliquots of the appropriately prepared plasma by the protein 
binding technique.
The changes in plasma cyclic AMP resulting from exercise 
are shown in table 3.2. All six volunteers showed a 
significant rise in plasma cyclic AMP one minute after exercise 
(mean value 17*7 pmol/ml) compared with a mean of 9*2 pmol/ml 
plasma before exercise (P<0.001 ). However, this effect was 
only transient; 40 minutes later plasma cyclic AIuP had fallen 
back to almost pre-exercise level (11.2 pmol/ml plasma). The 
four controls did not show any significant change throughout the 
period of this investigation. Only tifo of the originally 
arranged four volunteers consumed the 760 calories meal. They 
showed no significant change in plasma cyclic Al^IP levels.
The influence of haemolysis was checked by dividing blood 
samples into two parts. One part was used to obtain plasma 
under careful conditions, the other was freeze-thawed twice to 
get massive haemolysis. This latter sample showed considerably 
higher cyclic AMP content (eg. 9 pmol/ml rising to 35 pmol/ml). 
Thus haemolysis must be avoided in this estimation.
It is clear from this investigation that a transient rise
in plasma cyclic AÎ‘ÎP is associated with vigorous exercise. This
is in agreement with the findings of Heath _et al. (1973).
However, no significant variation could be detected in pre— and
post—exercise urine samples. This finding contradicting that
with
of Eccleston ^  (l970) but agreeing^several studies;-
Paul et al., 1971b; Moffat and Owen, 1972; Murad and Pak, 1972; 
Williams et al., 1972. The consumption of a large meal (760 
calories) did not influence plasma cyclic AÎ'^ÎP levels in the two 
subjects studied.
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Clearly a larger study is needed to establish the effect 
of exercise and diet on cyclic AI# levels in plasma. This 
limited sample does, however, show that conditions must be . 
carefully controlled both in terms of muscular activity 
immediately prior to venepuncturing and in the avoidance of 
haemolysis.
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3.5 In vitro Studies on the Effect of Vitamins on Cyclic 3*3*- 
I\)ucleotide Phosphodiesterase Activity.
A significant fall in the intracellular concentration of
cyclic AICP, including the central nervous system, has been
postulated to account for depressive illness (Abdulla and Hamadah,
1970). It has been suggested that some antidepressant drugs may
act through the inhibition of phosphodiesterase (Abdulla and
Hamadah, 1970; Eamsden, 1970) thus allowing the concentration of
( >
cyclic AMP in the cells to build up to a normal level.
Vitamin deficiency is known to precipitate depressive illness , 
(slater and Roth, 1969) and the administration of the vitamin B 
complex has been proved effective in the treatment of some psychotic 
states.
In this study the in vitro effects of a number of vitamins 
on phosphodiesterase activity were investigated. For each 
compound tested, six reaction mixtures comprising three tests and 
three controls were prepared. Phosphodiesterase activity was 
measured essentially as previously described (section 2,5.2).
Each test mixture contained 50 pl/^H/~cyclio AI5P, 50 pi of the 
compound dissolved in Tris-buffer, pH 8.0,
and 50 pi of the rat brain preparation. The controls contained 
all but the test compound. The phosphodiesterase activity was 
measured by the breakdown of /^î^—cyclic Aî'ÎP to liberate tritiated 
AI‘îP and thence /^I^-adenosine.
The results are given in table 3.3. Of the vitamins 
examined only ascorbic acid and cyanocobalarain were inhibitory 
at concentrations lower than millimolar. These findings are in
agreement with tho^e of Weinryh et al. (1972) on vitamin B22 
and Moffat et al. (1972) on vitamin C.
Table 3*3? Inhibition of Phosphodiesterase from Rat Brain
Brug/Vitamin Minimum Inhibitory Concentration (Molar)
Ascorbic acid 1 X 1 0 “ 4
Cyanocobalamin 4  X 10" ^
Theophylline 1 X 10“ ^
Caffeine 1 X 10“ ^
Nicotinamide
-2
4  X 10
Pyridoxine hydrochloride
-2 
4 X 10
Nicotinic acid
-2
4  X 10
Riboflavin No activity at 
1 X 1 0 -^
Tocopherol acetate No activity., at 
1 X 10
Na-Pantothenate No activity, at
5 X 10~
14Ü
CHAPTER IV
Cyclic AI'IP Levels in Depressive Illness and the Effect of 
Electro-Convulsive Therapy.
4.1 Comparison of Plasma and Urinary Levels 
of Cyclic AICP between Normal Volunteers 
and Patients suffering from Depressive
Illness .. .. .. .. .. «. 150 - 155
4.2 Diurnal Variation of Urinary Cyclic AîoP
in Depressive Illness .. .. .. .. I56 — I6I
4.3 Effect of Electro-Convulsive Therapy on
Urinary and Plasma Levels of Cyclic AÎ»ÎP l62 — 172
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4*1 : Comparison of Plasma and Urinary Levels of Cyclic AMP
between Normal Volunteers and Patients suffering from
Depressive Illness.
Abdulla and Hamadah (1970) reported from a London study 
that the cyclic AÎ5P urinary output was significantly lower in 
a depressed group of 21 female patients (0.52 _+ 0.08 pmol/24h) 
compared with 18 female controls (2.3 ±  0.1 pmol/24h). There 
was the suggestion that the level was raised in mania. At 
about the same time Paul £t al. (l970) working at NIH., Bethesda 
gave findings of similar pattern (psychotic depression 3*6 Hh 
0.2 pmol/24h; controls.5*6 + 0.7 pmol/24h; manic 9*9 ±  1*9 
pmol/24h). In a later study Paul et al. (l971a>) reported a 
marked but transient elevation in urinary cyclio AJ»IP at the time 
of the switch from depression into mania.
Abdulla and Hamadah (l970) suggested a causal relationship 
"that intracellular cyclic AÎ-ÎEP deficiency is related to 
depressive illness and that a striking increase leads to mania". 
This was controversial, thus Eccleston and his colleagues (l970) 
suggested that muscular activity was the key rather than the 
clinical states of depression and mania (see previously 3*4)* 
Brown _et al* (1972) in a longitudinal study on a group notable 
for its small sample size, diversity and lack of controls, and 
their more recent single patient study (Hullin et al.. 1974), 
could not show any correlation betrreen cyclic AMP excretion and 
"mood" (see l.ll). Jenner et al* (1972) similarly reported a 
failure to correlate cyclic Al-iP excretion and "mood" in an 
undefined number of depressed patients. Their paper included a 
more detailed account of a study on a patient with a regular 48h 
cycle of mania and depression. In this case there was excellent
151
correlation both with urinary cyclic AÎCP and ADH. It was 
suggested that ADH is the * driver * and cyclic AI^îP the 
‘passenger* - this pattern reflecting pituitary or hypothalamic 
function.
Hansen (1972) has reported that cyclic Al# in blood is 
significantly lower in a group of depressed patients compared 
with controls. He suggests, however, that this is a reflection 
of changes in ATP concentration. His methodology is idiosyncratic 
and his reported blood levels for cyclic AMP (2.3 pg/ml) are 
,3 orders of magnitude higher than other workers. Robison et al. 
(197O21) found no correlation between clinical condition and cyclic 
AMP level in cerebrospinal fluid pooled from a manic group, or a 
depressed group, or a *neurological * control group. Cramer et al. 
(1972, 1973) supported this lack of correlation in a study of 
’baseline* CSP samples. However, administration of ’probenecid’ 
led them to conclude that the * turnover’ of cyclic AMP in brain is 
significantly greater in the manic group than in the depressed or 
the ’neurological’ control group. The measured level in a body 
fluid such as CSP is a resultant of the dynamic interplay between 
input and removal.
Thus the years pass but the controversy is not resolved.
The various investigations have the common feature of small sample 
size. In this study cyclic Al# levels in urine and plasma have 
been investigated. Ethical criteria prevented the use of CSP.
The urinary levels of cyclic At# were measured in 47 normal 
volunteers (l3 males; 34 females)' ranging from I8 - 59 years of 
age; and in 35 female (24 - 67 years) inpatients suffering from 
depressive illness. Plasma levels of cyclic AMP were measured
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in 50 normal subjects (32 males; 18 females) of age range 
18 - 59 years; and 11 female (37-64yrs) inpatients who were 
diagnosed as suffering from endogenous depression. All 
patients received antidepressants or tranquillisers or both, 
the doses of which were fixed throughout the period of the 
study. All participants avoided certain foods which might 
affect indole and catecholamine excretion (Paul et al., 1970); 
no attempt was made to modify physical activity.
Twenty-four hour urine specimens (08.OO — O8.OO) and
venous blood samples were collected on two separate occasions
from the majority of the subjects. In 11 of the patients
(7 endogenous depression and 4 reactive depression) the 24—hour
urinary excretion of cyclic Al# was measured both during the
depressed phase and after recovery. Plasma and urine samples
were collected (section 2.3.1) and prepared for assay as
previously described (2.5.1; 2.6.4). Cyclic Al# was determined
by either the enzymic radioisotopic displacement technique
the
(2.5.2) or, later,by/protein-binding method (2.6.5).
Table 4.I summarises data for plasma and urine for all 
subjects studied. There was no significant difference in the 
levels of either urinary or plasma cyclic Al# between the male 
and female normal volunteers. The nucleotide levels were 
consistently lower in the depressed group as compared with 
controls, irrespective of the measurement technique employed. 
Moreover, patients diagnosed as suffering from endogenous 
depression showed significantly lower (P<0.001) urinary excretion 
for cyclic Al# (0.9 ±  0.1 pnol/24h) than the patients suffering 
from reactive depression (1.9 ±  0.2 yniol/24h). The latter were
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not significantly different from normal subjects (2.2 _+ 0.1 
}imol/24h). On improvement the 11 depressed patients showed 
an increase in urinary cyclic AI# excretion. This increase 
was not significant at the 10^ level for the reactive 
depression group but was highly significant (P<0.00l) for the 
endogenous depression group (Table 4*2).. The lower levels of 
plasma and urinary cyclic Al# in patients suffering from 
endogenous depression could not be attributed to a reduction in 
muscular activity, as both physically inactive and agitated 
patients in this group showed similarly low levels of cyclic 
Al#. In any case, studies on controls (3.4) indicated that 
vigorous exercise produced a transient increase in plasma cyclic 
Al# levels which was not detected in the urine.
This present study thus confirms Abdulla and Hamadah*s 
(1970) earlier report; added weight being given by the use of 
a ’blind* procedure involving the analysis of ’coded* urines, 
the code being resolved only after the completion of results. 
Recently two other groups, Naylor et al. (1974) and Sinanan 
et al. (1975) provided further evidence in support of these 
findings.
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Table 4*2; Comparison between Cyclic AI# Excretion in Depressed 
Patients before and after Improvement.
• Cyclic Al# yimol/24b Urine 
Group Depressed. Phase Improved Phase n Reference P <
Endogenous
Depression 1.0 + 0.2 2.2 + 0.3 7 This Study 0.001
Reactive
Depression 2.0 + 0.4 2.9 + 0.3 4 NS
Abdulla &
Depression 0.5 + 0.008 1.3 + 0.02 15 Hamadah 0.001
(1970)
Naylor
Depression *4.5 + 0.4 *6.0 + 0.6 12 et al. 0.02
11974)
* pmol cyclic AI#/g creatinine..
156
4*2; Diurnal Variation of Urinary Cyclic Al# in Depressive Illness.
An important and significant symptom of depressive illness is 
the daily fluctuation of mood and of the total state. A worsening 
of depression in the morning has been associated with endogenous 
depression while a worsening in the evening has been thought as 
characteristic of reactive depression (Winokur ±t , I969) * In 
depressive illness alterations in the circadian rhythms of plasma 
and urinary corticosteroids (Bridges & Jones, I966), urinary sodium 
and chloride excretion (Elithorn et al., I966), salivary electrolyte 
excretion (Palmai & Blackwell, 1965) have been reported® • Murad and 
Pak (1972) have reported a diurnal rhythm for the urinary excretion 
of cyclic AMP in normal humans, a finding repeated and extended to 
include plasma in section 3*1* The purpose of this study is to 
demonstrate possible alterations in circadian rhythm of cyclic Al# 
in depressive illness before and after improvement.
Eleven women, of age range 37 - 67 years, who were inpatients
as suffering from 
at Tooting Bee Hospital and had been diagnosed/either endogenous
depression (7) or reactive depression (4) were investigated. All
patients received tricyclic antidepressants and a night sedative,
and some were also given tranquillisers. The doses were fixed
throughout the period of study. Seven of the patients were also
treated with E.G.T. Urine samples were collected at 4-hourly
intervals over a 24-hour period commencing at 08.00 h on two
occasions. The first collection was obtained from the patients
after they were stabilised on drugs (approximately one week after
admission), and the second on improvement one to five months later.
For natients who received E.G.T. the second collection was carried
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out at least two weeks after completion of this treatment (Hamadah 
et al., 1972), Urine samples were collected (2.3*1) and prepared 
as described in section 2.6.4* Cyclic Aî# was determined by the 
protein-binding method (2.6.5)*
During the depressed phase of endogenous depression the 
diurnal pattern observed was of the form shown in figure 4*1* The 
maximum being at O8.OO - 12.00 h for the group. After improvement 
the group pattern became bimodal with peaks at O4.OO - 08.00 and 
16.00 - 20,00 h. As well as this qualitative change in pattern 
there was a quantitative change in that the 24-hour output increased 
by 115^ (Table 4*3)* The reproducibility of the ^depressive 
pattern' is indicated in figure 4*2 in which the same patient was 
investigated at various dates during a depressed phase of three 
months duration.
The reactive depressive group showed no qualitative pattern 
change, maintaining maxima at 24.00 — 04*00 and 12.00 - 16.00 h 
both when depressed and after improvement (Figure 4*3). 
Quantitatively there was no significant increase in the 24-hour 
urinary output of cyclic Aï# (Table 4*3).
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Figure 4.1: Diurnal variation of urinary cyclic AMF 
levels in patients suffering from endogenous depressio 
(n=7). The broken line shows variation in cyclic AMP 
excretion during the depressed phase; the variation ir 
the urinary levels of the nucleotide after improvemeni
it-^ I
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Figure 4.2 : Diurnal variation in the urinary cyclic AMP 
excretion of a single patient suffering from endogenous 
depression Specimens were collected on 3 separate 
occasions during the depressed phase.
500
A
E300
200
2400 24.0C08.00 16.00
TIME (hours)
Figure 4.3 : Diurnal variation of urinary cyclic 
AMP levels in patients suffering from reactive 
depression (n=4). The broken line shows variation 
in cyclic AMP excretion during the depressed phas 
the solid line represents variation in the urinary 
levels of the nucleotide after improvement.
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4.3: Effect of Electro-Convulsive Therapy on Urinary and Plasma
Levels of Cyclic MIP*
Significantly decreased urinary and plasma levels of cyclic 
AÎ«ÎP have been shown in patients with dépressive illness (sections 
4*1 and 4*2). Abdulla and Hamadah (l970) have suggested that 
depressive illness is the manifestation of a fall in the intra­
cellular levels of cyclic AI'IP in all tissues, including those of 
the central nervous system.
The levels of cyclic MIP in tissues and body fluids will 
reflect such processes as rates of synthesis, brealcdown and 
secretion. Thus affecting one or more of these processes may 
change cyclic AI^IP concentrations. The tricyclic antidepressants 
(e.g. imipramine, desipramine, amitriptyline) inhibit cyclic M T  
phosphodiesterase (Abdulla and Hamadah, 1970; Ramsden, 1970;
Beer ^  , 1972; Weinryb et al., 1972) and their administration
leads to an increase in urinary level of cyclic Aî‘îP. Studies by 
Kodama et al., (1971) also showed that these compounds stimulate 
adenyl cyclase activity in brain slices.
Cerebral cortex slice studies have also indicated that 
electrical stimulation increases the concentration of cyclic AKP 
(Kakiuchi ^  al., 1969; Shimizu ^  al*? 1970; Reddington e_t al., 
19731. A similar finding has been reported in the superior 
cervical ganglion of the rabbit (McAfee ^  , 1971).
Putative transmitters: noradrenaline, 5“*hydroxytryptamine
and histamine (Kakiuchi & Rail, 1968 a,b; Kakiuchi £t al., 1969; 
Chasin et al., 1971, 1973), adenine ribose compounds (Sattin & 
Rail, 1970) and certain depolarising agents such as ouabain, 
veratridine and batrachotoxin (Shimizu et al., 1970; Huang et al.,
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1972) have been found to increase cyclic MIP levels in 
respiring brain slices. Adrenaline, isoproterenol, 
noradrenaline and to a lesser extent dopamine, have also been 
shoim to increase the endogenous cyclic AI# in the brain when 
injected in vivo (Burkard, 1972). Electrical stimulation of 
brain slices results in a release of neurohumoral agents from 
the tissue including noradrenaline, 5-hydroxytryptamine (Katz 
& Chase, 1970) and adenosine (Mcllwain, 1971) any of which may 
act as intermediates in the increase of cyclic AMP concentration 
by electrical stimulation.
Electrotherapy has a long history (possibly 
back to the Roman lünperors - see Alexander and Selesnick, 19^7)* 
Cerletti and Bini first used E.C.T. in 1938 and its simplicity 
of procedure and favourable results (e.g. in involutional 
melancholia) led to it rapidly replacing insulin - shock treatment. 
Extensive clinical experience (Lehmann, 19^5) and a number of 
controlled studies (Greenblatt et al., 1964) agree that 
approximately 80^  of depressed patients experience significant, 
sustained improvement or disappearance of symptoms in the course 
of an E.G.T. series given at intervals of one to a few days.
Urinary levels of cyclic AI# were investigated in 14 women 
(ages 24 - 6l) and plasma levels were measured in a further 7 
women (ages 37 - 64), all of whom were inpatients at Tooting Bee 
Hospital diagnosed as suffering from depressive symptoms and 
requiring E.C.T. Patients with heart or kidney diseases were 
excluded. The only additional criteria for selection were the 
willingness and the ability of the patients to co-operate in the
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investigation..
Throughout the period of the study the patients were 
given a diet that lacked foods which might affect indole and 
catecholamine excretion (Paul et al., 1970). No alcohol was 
permitted and tea and coffee intake was stabilised. Patients 
were clinically assessed on the day before E.G.T., on the day 
of the treatment, and on the following day to detect any sudden 
or pronounced change in 'mood*. All participants received 
antidepressants or tranquillisers, or both, the doses of which 
were fixed throughout the period of the study.
E.G.T. was administered between 09.30 and 11.00 hours on 
Tuesdays and Rridays, All patients received 0.6 mg of atropine 
sulphate as premedication half to one hour before treatment.
In 18 patients, who were investigated over a total of 28 treatments, 
the convulsion was modified by the intravenous injection of 60 - 
70 mg of methohexitone sodium and 25 — 50 mg of suxamethonium 
chloride immediately before E.G.T. In two patients (investigated 
over seven treatments) the convulsion was modified by the intra­
venous injection of 250 mg of thiopentone sodium and 30 — 50 mg of 
suxamethonium bromide. The E.G.T. was administered with an 
*Ectonus * mark 3, A.G. mains model (Ectron Ltd) . The electrodes 
(Ectonus head-band) were lightly soaked in iEctronolyte* solution 
and applied bitemporofrontally. The rotary control was used to 
apply the potential in a series of increasing steps, reaching a 
maximum of I40 V; the current was passed for about one second.
The patients were well oxygenated with 100% oxygen.
During this study three patients received all the preliminary
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treatment” but for various reasons, including instrument failure, 
no shock was delivered. As they had experienced the anticipatory 
anxiety and had received atropine sulphate, methohexitone sodium, 
suxamethonium chloride, but not the electric shock they were 
regarded as controls on these occasions. A fourth patient, who 
received the atropine sulphate but panicked before further treatment 
could be given and refused it, was regarded as a separs-te control.. 
Thus the controls for urinary cyclic Al# (Table 4*4) were achieved 
by chance rather than design. It was felt to be unacceptable on 
ethical grounds to enlarge this control group.
Ti-renty-four hour specimens of urine (07.OO - 07.OO hours) 
were collected for up to three days before the first E.C.T. to 
establish a baseline for each individual patient and to determine 
the day-to-day variation of cyclic Al# excretion. Ti\renty-four 
hour specimens were also collected on the day of E.C.T., for two 
days after E.G.T. and, where appropriate, on the days between 
subsequent treatments. Venous blood samples were collected on the 
day before E.G.T., (between 09*30 - 11.00 hours) and on the day of 
E.G.T., about one minute before treatment (i.e. after the 
administration of atropine sulphate but before muscle relaxant 
and anaesthetic). Blood samples were also collected at 10, 30,
90 and 180 minute intervals after the administration of the electric 
shock.
ITrine and blood specimens were collected as described in 
section 2.3*1 and prepared for assay according to sections 2.5*1 
and 2.6.4 respectively. Urinary levels of cyclic Al# were 
determined by the enzymic radioisotopic displacement technique
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(section 2,5*2) whilst plasma levels were determined "by'the 
saturation assay (section 2.6,5).
The changes in urinary and plasma cyclic AÎ<ÎP resulting 
from the administration of E.G.T, in a typical case are shown 
in figure 4*4 (a and b). Twelve of the 13 patients who received 
E.C,T,.. (Table 4*4) showed a significant rise in urinary cyclic 
AMP excretion on the day of the treatment. The mean value for 
the 13 patients (26 treatments) was 14,2 pmol/24h on the day of 
treatment compared with a mean of 4*2 pmol/24h for the period 
before E*C,.T, (F<0,001). In general the excretion of cyclic 
AJÎP fell on the following day but not necessarily to the pre- E«C,T. 
level. The four controls were markedly different in that they 
showed a fall in the urinary excretion of cyclic AKP on the day 
of (abortive) treatment, (Table 4*4)* The plasma levels of cyclic 
AIvîP did not show any significant variation during the 24 h prior 
to the treatment (Table 4*5). However, five out of seven patients 
who received E.G.T* showed a marked rise in plasma cyclic A3IP,
This increase was obtained within 10 minutes of administration of 
the electric shock, when the mean value was I8.6 pmol/ml plasma, 
compared with 10,3 pmol/ml plasma at one minute before E.G.T. The 
plasma level was still raised 30 minutes after treatment but had 
fallen to pre- E.G.T. level by 3 hours (Table 4*5)* It was noted 
that the three patients who did not respond to E.G.T. in terms of 
cyclic AI'IP increase also showed no clinical improvement, whereas 
those who showed an increase in cyclic AiiP were psychiatrically 
assessed as improved.
Brown et al. (1972) reported that E.G.T. does not affect.
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Urinary Excretion of cAM? (pmol cAMP/24h) Change in cAIÆP Excretion
Case No, on Day of E,G,T, compared
Before E.G.T,* Day of E.G.T, After E.G.T,* with Before E,G,T.
E.G.T, Group
1 3.6 7.8 4.3 +120
2 2.6 6.9 2.9 +170
(1.4 8.3 7.5 +480
3 (3.9 14.5 15.1 +280
(6.5 21,2 6.6 +230
(6,6 23,0 14.4 +250
4 9.1 24.8 4.7 +170
5 12.2 28.6 5.7 +130
6 (2,4 4.3 1.5 +80
,(1.5 6.8 3.5 +370
7 ( 1.9 3.6 2 .0 +90
( 2,0 3.7 3.6 +90
8 (3.8 6.9 4.6 +80
(4.6 27.0 4.2 +490
9 ( 1.2 3.5 3.1 +180
( 5.2 21.5 19.1 +310
10 6,2 38.1 25.2 +520
11 (2,0 2.3 2 .1 +20
(2.1 2 .0 1.9 0
( 1.7 2 ,8 2.3 +60
4 12 ( 2,3 14.4 4.5 +540
(,4.5 28.3 2.2 +530
(4.9 20,0 2 .0 +310
$ 13 (2.0 29.7 4.4 +1,360
(1.9 3.9 13.2 +110
(1,2 14.1 2 ,2 +1,070
Mean Values 4.2 (0,4; n = 51) 14.2 (2.1; n = 26) 6,3 (0,7; n = 44) +310 (50; n = 26)
Control Group (No E,G,T,)_
4 26,1 24.6 20,3 -6
5 9.3 7.9 5.0 -16
14 5.1 3.7 0.9 -27
:flO 3.0 1.0 0,9 -67
•Mean values ( for up to three days, where appropriate),
••Mean values with S.E. of mean and number of samples in parentheses.
^Patient received thiopentone sodium instead of methohexitone sodium. 
Patient received 0,6 mg atropine sulphate only.
Comparison of the paired data from cyclic AMP excretion on the day of E.G.T. with excretion on the 
day of E.G.T. gives a significant difference P 0.001. For cases 9 - 13 a double-blind procedure 
was used; only after assaying all specimens was the code disclosed.
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cyclic AIÆP excretion# This was a single patient study and 14^ 
of the group here investigated (Tables 4.4; 4.5) showed no
significant increase in the plasma and urinary levels of cyclic 
MIP after E.G.T. A rise in plasma and urinary cyclic Af«lP levels 
after E.G.T. could be due to one or more of the following factors: 
anticipatory anxiety, premedication, anaesthesia, the administra­
tion of muscle relaxant, hypoxia, or electrical stimulation. The 
failure of the four controls to show any increase in cyclic AI^IP 
excretion suggests that E.G.T. was the major factor responsible 
for the rise in urinary and plasma cyclic A>IP concentrations 
observed in this investigation. This conclusion is supported by 
the results of other studies. The work of Gox and Potkonjuk 
(1969) and Robison ^  (l970) suggests that atropine would have
little or no effect at the dose level used. Wilson (19^9) showed 
that barbiturates lower cyclic AÎÆP levels in the rat brain, and 
Havens et al, (1959) showed that thiopentone and suxamethonium 
reduce the post-convulsive levels of catecholamines in the plasma 
of patients undergoing E.G.T., and hence probably also lower cyclic 
AMP levels (Robison et al., 1971).
The procedure used in E.G.T. needs to be carefully controlled 
to prevent hypoxia, which can result in various biochemical changes. 
Thus Havens et al. (1959) showed that the post-convulsive plasma 
level of adrenaline bears an inverse relation to the degree of 
oxygenation of the patient, while hypoxia leads to a definite 
increase in the level of cyclic AI'îP in mouse and rat brain (Goldberg 
et al., I97O; Hitzion et al., 1970). In this study the patients 
were well oxygenated, and the lack of increase in cyclic AMP level
171
in the three suxamethonium treated controls again points to 
convulsive electric shock as the causative factor.
T h e  m ech anism  b y  w h ic h  e l e c t r i c a l  s t i m u l a t i o n  in c r e a s e s  
t h e  l e v e l  o f  c y c l i c  ÈMP i n  b r a i n  r e m a in s  t o  be e s t a b l i s h e d .
Direct administration of noradrenaline, 5—hydroxytryptamine, 
histamine (Chou et al., 1971; Chasin et al., 1971; Reddington 
et al., 1973) and adenosine-ribose compounds (Sattin and Rail,
1970) to respiring guinea pig cerebral cortex slices causes 
activation of adenyl cyclase. Excitation of slices with 
electrical stimulation results in a release of neurohumoral 
agents from the tissue including noradrenaline, 5~hydroxytr5Tptamine 
(Katz and Chase, 1970) and adenosine (HcIIwain, 1971; Zanella 
and Rail, 1973) any of which may act as intermediates in the 
effect of electric shock on cyclic AI5P content. Since the response 
produced by histamine and 5’-hydroxytryptamine is additive with 
that of electrical stimulation (Reddington et al., 1973; Williams 
and Rodnight, 1974) these agents are made less plausible as inter­
mediates in the effect of E.G.T. on cyclic AICP level. Currently 
the most likely suggestion is that depolarisation results in 
increased release of adenine-ribose compounds and noradrenaline 
which then stimulate cyclic AMP formation (Zanella and Rail, 1973; 
Reddington et al., 1973).
T h is  s tu d y  h a s  shovm  t h a t  E . G .T .  p ro d u c e s  a n  in c r e a s e  i n  
b o th  p la s m a  an d  u r i n a r y  l e v e l s  o f  c y c l i c  Al'IP. T he  d i r e c t  
s t i m u l a t i o n  o f  s l i c e s  o f  g u in e a  p i g  c e r e b r a l  c o r t e x  r a p i d l y  
p ro d u c e s  a  g r e a t l y  in c r e a s e d  l e v e l  o f  c o r t i c a l  c y c l i c  Aï»!?
(R e d d in g to n  e t  a l . , 1973; Z a n e l l a  e t  a l . , 1973), F u r t h e r m o r e ,
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e v id e n c e  h a s  b e e n  o b ta in e d  to  s u p p o r t  t h e  s u g g e s t io n  t h a t  
c y c l i c  AMP m e d ia te s  t h e  p h y s i o l o g i c a l  a c t io n s  o f  n e u ro ­
t r a n s m i t t e r  s u b s ta n c e s  i n  t h e  c e n t r a l  n e rv o u s  s y s te m  (P lo r e n d o  
I97I; G re e n g a rd  a n d  K u o , 1970). P o s s i b l y ,  t h e r e f o r e ,  
th e  a n t id e p r e s s a n t  a c t i o n  o f  E .G .T .  i s  m e d ia te d  th r o u g h  a n  
in c r e a s e d  p r o d u c t io n  o f  c y c l i c  AÎ'IP i n  t h e  b r a i n ,  w h ic h  i s  
r e f l e c t e d  i n  t h e  in c r e a s e  o b s e rv e d  i n  t h e  p la s m a  and  u r i n e  o f  
E . G .T .  - t r e a t e d  p a t i e n t s .
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5.1. The Use of Plasma and Urine for Studying Changes in
Cyclic AI'IP associated with Depressive Illness
Affective disorders are a group of illnesses associated 
with biochemical changes in the central nervous system. The 
first biological fluid which comes to mind in studying these 
changes is cerebrospinal fluid, especially as there is good 
evidence of ready exchange between brain extracellular fluid 
and the cerebrospinal fluid. Blood and especially urine are 
more remote from metabolic changes in brain tissue, the signal 
to noise ratio will be decreased by the action of all the other 
tissues. However in studies on patients, whereas blood and 
urine may be readily available, the procedure of lumbar puncture 
in the interest of establishing a biochemical hypothesis may be 
considered unethical. Blood and urine were used in this study 
as a matter of necessity. If, as suggested by Abdulla and 
Hamadah (l9?0),depressive illness is a systemic disorder 
remoteness from the central nervous system becomes unimportant.
The major problem in interpretation is that the sources 
of normal plasma cyclic AÎ'IP are far from clear. There is 
evidence to indicate that under appropriate hormonal stimulation 
both liver and kidney are capable of adding cyclic AÎ'IP to 
plasma (Broadus jet , 1971 )« Albano and Bro^m (l974) 
showed that in vitro stimulation of rat adrenals by ACTH causes 
an increase in the intracellular cyclic AI»1P which is then 
released into the perfusing fluid. Similar findings were 
obtained in vivo by Peytremann et al., (l973). Studies
r/D
in vitro, with rat testes have shown that after stimulation 
with human chorionic gonadotrophin, the intracellular cyclic 
AI'IP concentration reaches a maximum and then declines as 
cyclic AMP is extruded into the surrounding medium (Dufau 
1973). Cramer and Lindl (1974), in an in vitro 
study^ have shown that cyclic AMP is released from the 
peripheral sympathetic ganglion of the rat following 
stimulation of its intracellular formation by biogenic amines 
such as adrenaline and histamine. They suggested that under 
physiological conditions the release or overflow of cyclic 
AÎ'îP after stimulation by neurohormones could have some 
distinct peripheral function, or could serve to remove and 
thus effectively inactivate any excess in nucleotide that is 
not bound to protein kinases in the nervous system, Cramer 
et al. (1972b) have evidence of the vivo release of cyclic 
AI'IP from the central nervous system.
This investigation (Chapter 4) has shown that the 
plasma and urinary cyclic AIIP levels correlate with mood 
changes in patients suffering from depressive illness,
Cramer et al. (l972a) suggested that the * turnover ^ of cyclic 
Al'iP in brain as measured in cerebrospinal fluid with and 
without probenecid correlates with mental condition, i.e. 
higher in mania than in depression. Other workers (Abdulla 
and Hamadah, 1970; Paul £t aJ., 1971b) have provided evidence 
that the urinary levels of cyclic AI'IP in manic depressive 
patients correlate with clinical change and improvement.
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This is not without controversy but recently support has 
come from Naylor ejt al. (1974) in Dundee and from an
extensive survey by Sinanan ^  (l975 ) in Dublin.
Plasma cyclic Aî-iP is derived from a number of tissues 
including the central nervous system; it is not yet feasible 
to draw up a balance sheet; however, Broadus ^  (l970)
have presented evidence that approximately 50ÿ of the 
urinary cyclic AÎ5P is derived by direct glomerular filtration 
of plasma while the other 50/6 is nephrogenous in humans under 
basal conditions.
5.2, Factors affecting the Plasma and Urinary Levels of
Cyclic in Normality and Depressive Illness
In this study human plasma and urinary levels of cyclic
AI'IP were found to be affected by the following factors: 
diurnal rhythms, menstrual cycle (in turn affected by oral 
contraceptives), exercise and depressive illness (in turn 
affected by E . G . T . ) .
As discussed in Chapter 3.1, there seem to be two 
populations with regard to diurnal patterns of cyclic A3IP 
in both plasma and urine from controls. The two patterns 
do not seem to be mutually exclusive. It would be worthwhile 
investigating a normal group in more depth with regard to 
this patterns. A somewhat superficial evaluation suggested 
that introverts tend to the afternoon peak whereas extraverts 
have a morning p e ^  of cyclic Al*iP. It is possible that an 
evaluation of cyclic AMP patterns in normal subjects in
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conjunction with other evidence (e.g. history of affective 
disorders in close relatives) may be of prognostic value.
Patients suffering from reactive depression had a 
bimodal diurnal pattern for urinary cyclic Af-lP with similar 
timing to that of the controls. This group of patients did 
not show any qualitative change in the urinary cyclic Aî-îP 
rhythm on clinical improvement. However^ the patients 
suffering from endogenous depression had a diurnal pattern 
for urinary cyclic AI-iP with a single peak (O8.OO - 12.00); 
on clinical improvement the group pattern tends towards the 
normal bimodal rhythm.
The mechanisms involved in the control of diurnal 
variation of cyclic AÎ'IP are not yet established. However, 
a number of hormones are known both to initiate their 
biological actions by altering the intracellular concentrations 
of cyclic AJ-IP and to exhibit circadian rhytiiras (table 3.1).
Thus it is possible that diurnal patterns in plasma and 
urinary cyclic ydIP could reflect the sum of the hormonal- 
patterns. This only shifts the problem back to what controls 
the hormonal patterns and we are led back to hypothalamic 
function. There may also be non-hormonal effects to consider. 
In this study diurnal variations in plasma TSH and PTH were 
measured (figures 3.6 and 3.?)* The TSH pattern showed quite 
a good correlation with the plasma cyclic AMP pattern, whereas 
the pattern for PTH, a hormone acting predominantly on the 
kidney, showed a correlation with the diurnal rhythm of 
urinary cyclic #IP. This latter finding has been mentioned
by Sagel et al. (l973). There is need to investigate a 
larger number of hormones before a causal relationship 
can be established. Thus at present there is lack of 
information on ADH which could well affect urinary patterns 
(jenner jet , 1972). Dietary factors can influence 
hormonal levels e.g. glucagon and insulin. In the rat 
adrenal cortex cyclic /dlP circadian rhythm has been shown 
to be under hypothalamic control, as the rhythm disappears 
after appropriate denervation of the hypothalamic region 
(Moore and Quavi, 1971). In gastric mucosa the periodicity 
of cyclic AI'IP content seems to be connected to changes in 
gastric secretion (Dornschice e_t , 1972). In mouse 
epidermis the periodicity in cyclic AM? may be related to 
the control of mitotic activity. It has been suggested that 
cyclic AI'IP depresses mitotic activity whereas cyclic GMP is 
an enhancer (Hadden 1972).
Hormonal involvement in the control of circadian rhythm 
of urinary cyclic Al'lP.is further strengthened by studies of 
changes of this nucleotide during the human menstrual cycle.
As shown in section 3.2 when women with normal ovulatory 
cycles were investigated a mid-cycle peak in cyclic AI-IP was 
obtained.
Muscular activity can have no more than a minor influence 
on the diurnal patterns as strenous physical exercise was 
found to cause only a transient increase in plasma cyclic 
AÎ1P and this rise was not reflected in the urine. In any case 
the diurnal peak position tends to coincide with minimal
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physical activity,
in this investigation plasma and urinary levels of 
cyclic AI'IP were found to be significantly lower in patients 
suffering from endogenous depression compared to controls 
and patients suffering from reactive depression, Abdulla 
and Hama.dah (1970) presented a cause and effect relationship 
in that they suggested that depressive illness is the result 
of a lowering of cyclic AI# in all tissues including those 
of central nervous system. During a depressive phase for 
an endogenous group the cyclic AI'îP levels are low whereas on 
clinical improvement the nucleotide level rises towards 
normality; this does not show which is passenger and which 
is driver. Jenner jet (1972) proposed that ADH leads 
and cyclic AMP follows in a dramatic example of the regular 
switch from mania to depression. Thus pituitary or hypo­
thalamus may be the driver. Hansen (l972) suggested that 
the lowering of blood cyclic A14P in depression is a reflection 
of a decrease in ATP concentration. If this is the case 
we are back to a central feature of metabolic control, let 
alone the possibility of compartmentalization. Lack of 
exercise has 8,1 so been proposed as the cause of lower 
excretion of cyclic AÎ'îP in patients, i.e. a change in life 
style which comes from the change in mood (Eccleston jet , 
1970). However, physical activity as a main contributor 
to changes in plasma and urinary cyclic A31P in depressive 
illness has now been eliminated. Thus physically active and 
inactive depressed patients show similar (low) levels of
1UU
cyclic M'lP (this study; Paul et al,, 1971h), and Perry 
^  (1973) could not find a significant difference in
urinary cyclic AhIP levels between the normal and psychotic 
phases of two patients with periodic catatonia.
The quest for a single precipitating factor in a 
group of related illnesses such as cancer or depression may 
be as fruitless as the search for the ‘Philosopher’s Stone’ .’ 
The finding of this study supported by several other 
investigations is that plasma and urinary cyclic AMP is 
decreased in endogenous depression. It would seem fruitful 
to try to arrive at reasons for this decrease ;
(a.) Lack of stimulus, i.e. hormone; this would tie in with 
the catecholamine hypothesis of mental illness and the 
fact that some patients do respond to monoamine oxidase 
inhibitors.
(b) Faulty hormone receptors, and/or adenyl cyclase.
(c) An overactive phosphodiesterase - such cases should 
respond to tricyclic antidepressants if a major action 
of these drugs is the inhibition of this enzyme.
(d) A faulty cyclic AÏ'IP-dependent protein kinase receptor,
active
and/or jcentre, and thus a lack of physiological response 
in the presence of normal cyclic AdIP concentrations.
Further investigations on these various factors are 
required before more conclusive evidence can be presented to 
support the role of cyclic AÎ-ÏP in depressive illness.
E.G.T. has been shoim to cause significant increase in
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both plasma and urinary levels of cyclic AMP (section 4.3).
As discussed in greater detail in 4.3 electric 
shock seems to be the cause of the rise in plasma and 
urinary cyclic AÏCP. The mechanisms by which electrical 
stimulation increases the level of cyclic AÎÆP in brain 
remains to be established. Direct administration of 
noradrenaline, 5-hydroxytrj’ptamine, histamine (chou et al.,
19715 Chasin ejb al., 1971? Reddington ejt 1973) and 
adenosine-ribose compounds (Sattin and Rail, 1970) to 
respiring guinea pig cerebral cortex slices causes 
activation of adenyl cyclase. Excitation of slices with 
electrical stimulation results in a release of neurohumoral 
agents from the tissue including noradrenaline, 5-hydroxytrypt- 
amine (Katz and Chase, 1970; Sssman, 1973) and adenosine 
(Mcllwain, 1971; Zanella and Rail, 1973) any of which may 
act as intermediates in the effect of electric shock on 
cyclic MIP content. However, the response produced by 
histamine and 5-hydroxytryptamine is additive with that of 
electrical stimulation (Reddington et al., 1973; Williams 
and Rodnight, 1974) suggesting separate modes of action. 
Currently the most likely suggestion is that E.C.T. causes 
depolarisation of synaptic structures thus resulting in an 
increased release of noradrenaline and adenine-ribose 
compounds (Rodnight, 1975; Hcllwain, 1972; Shimizu and 
Daly, 1972 j Euroda and Mcllwain, 1973). These in turn 
increase intracellular concentrations of cyclic AMP by
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s t i m u l a t i o n  of* a d e n y l c y c la s e  th r o u g h  r e c e p t o r s  lo c a t e d  
on t h e  p o s t - s y n a p t i c  m em brane ( S c h u l t z  and  D a ly ,  1973a); 
f u r t h e r  a d e n o s in e  c a n  a c t  a s  a  p r e c u r s o r  f o r  ATP ( s e c t io n  
1,8). E l e c t r i c a l  s t i m u l a t i o n  h a s  a ls o  b e e n  sho^m to  
in c r e a s e  c e r e b r o v a s c u la r  p e r m e a b i l i t y  (E ssm an ,, 1973), and  
th u s  r a i s e d  l e v e l s  i n  b lo o d  an d  u r i n e  may r e f l e c t  in c r e a s e d  
le a k a g e  a s  w e l l  as p r o d u c t io n ,
Zanella and Rail (1973) have presented evidence that 
the major part of the extra cyclic AI>ÎP formed on depolar­
isation with electrical pulses is due to adenosine release; 
however other workers question the importance of this 
nucleotide in the mechanism. The diverse actions of cyclic 
Al# are mediated by protein kinases (see figure 1.6), and 
this raises the problem that adenosine is an effective 
kinase inhibitor (Wei1er and Rodnight, 1973; Ueda et al., 
1973) blocking the protein phosphorylation response to 
histamine in slices (Reddington et al., 1973). Exogenous 
adenosine does not prevent protein phosphorylation following 
electrical stimulation or the administration of serotonin 
and noradrenaline (Williams and Rodnight, 1974)> and 
currently the weight of evidence is against its involvement 
in protein phosphorylation mediated by E.G.T. (Rodnight,
1975)» N o r a d r e n a l in e  and  p o s s ib ly  d o p am in e  ( T h i e r r y  e t  a l . , 
1973; H ungen an d  R o b e r t s ,  1973; W i l l i a m s ,  1974) r e m a in  
th e  m o s t l i k e l y  m e d ia t o r s  o f  t h e  p h y s i o l o g i c a l  re s p o n s e  to  
E . G .T .
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Certafnly E.G.T. can have a marked effect on the 
clinical course of depression (section 4.3) as well as on 
cyclic Al# levels in plasma and urine. Where does E.C.T, 
act? : the brain is insulted (the exorcist might suggest
the devils are driven away) but the precise sites of 
action are still a mystery.
5.3. Possible Physiological Role of Cyclic AI# in the
Nervous System
In the rabbit superior cervical ganglion system, it 
has been shoi-m (Greengard et al., 1972) that alterations in 
cyclic AlviP content of the postganglionic nerve cell results 
in hyperpolarisation leading to a modulation of cholinergic 
transmission. It was suggested that the link between the 
increase in cyclic A l#  and the membrane hyperpolarisation 
might be a cyclic A M P -stimulated protein kinase.
Williams (1974) has shown that a noradrenergic 
mechanism involving an increase in cyclic A I # ,  results in 
raised protein phosphorylation in the synaptic region of 
guinea pig neocortical neurones. He suggested that this ' 
phosphorylation is involved in the modulation of synaptic 
transmission. Such a supposition was supported by the 
relatively long time of turnover of the protein phosphorylated 
on anplication of electrical pulses (ti. = 5 min), which is 
comparable in some respects to the dopamine-dependent 
modulation of cholinergic transmission (Libet and Tosaka,.
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1970) snd the suggested time course of noradrenaline 
effects on central neurones (Salmoriagjhi, I966).
Changes in the phosphorylation state of the post- 
synaptic nerve cell membrane mediated by cyclic AI#- 
dependent protein kinases were suggested by Greengard and 
Kuo (1970) and Routtenberg et al. (1975) to be part of the 
molecular basis of learning and memory.
It is generally accepted that the associative 
processes occurring in the bra.in during learning result in 
the repetitive activation of new neuronal pathways, with 
the progressive development of persistent changes in the 
properties of their component synapses (Kety, 1972)i These 
changes presumably involve molecular variations affecting 
the efficiency of synaptic transmission (Glassman et al., 
1972).
Drugs that affect the release of noradrenaline or 
enhance its effects, have been shoim to affect memory 
consolidation processes (Kety, 1972). Bilateral lesions 
of the locus coeruleus in rats, which cause a reduction in . 
the neocortical noradrenaline concentration, stops the 
learning process (Anzelark et al., 1973). Similarly, 
lesions in both the dorsal and median midbrain raphe nuclei 
in rats, which cause a reduction in the forebrain serotonin 
and possibly noradrenaline (Hole and Lorens, 1975) result 
in a deficit in learning. The coerulocortical pathway is 
one of two noradrenergic pathways which are considered to
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function as ‘reinforcement* systems in the consolidation 
of memory (Gilbert, 1975)* The firing of Purkinje cells 
is inhibited by noradrenaline via cyclic A!# (Hoffer ^  al., 
1972), and Gilbert (1975) has recently presented evidence 
that this inhibition is involved in the system, for 
learning and storage of information with regard to movement. 
Thus cyclic A #  is implicated in the modulation of processes 
involved in learning and memory consolidation. Indeed the 
behavioural changes occurring on the destruction of the 
noradrenergic pathway have been compared (Stein et al.,
1972) to those associated with schizophrenia. Endogenous 
6-hydroxydopamine can cause such destruction and Altsman 
et al. (1972) have suggested that this is the primary lesion 
in the onset of this disorder.
It is well established (Kety, 1972) that drugs like 
reserpine which deplete nerve endings of their catecholamine 
content, lead to a depression in behaviour (ptosis) when 
administered to rat or mice in vivo and this effect is 
reversed by cyclic Al# and its dibutyryl derivative (Abdulla 
and Hamadah, 1970). On the other hand drugs like 
D-amphetamine which both block re-uptake (Glowinski and 
Axelrod, I965) and increase the release of noradrenaline 
(Zianie , 1972) have the opposite effect to the
reserpine-like drugs when given in vivo, counteracting 
drowsiness and leading to hyperactivity and aggressiveness. 
Item such studies Schildkrout (19^5) has proposed that the
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biochemical lesion of depressive illness is a reduction 
in the availability of endogenous amines. A more recent 
hypothesis for the aetiology of affective illness 
formulated by Ashcroft jet (1972) states that the 
activities of amine mediated synapses in brain are modified 
in affective illness either as a result of altered input 
into neuronal systems from other centres or as a result of 
altered sensitivity of postsynaptic receptors. Evidence 
for.such a modification include a report of increased adenyl 
cyclase sensitivity, to noradrenaline in rat brain, following 
a lesion in the noradrenergic pathway (Palmer, 1972; Weiss 
and Strada, 1972). Janowsky _et aJ. (1972) postulated a 
cholinergic-adrenergic hypothesis of depression which states 
that the affective state may represent a balance between ■ 
central cholinergic and adrenergic neurotransmitter activity 
in those areas of the brain which regulate affect, with 
depression being a disease of cholinergic dominance and mania 
being an illness of adrenergic dominance. Cyclic has 
been shoum to affect behaviour, its lipid soluble dibutyryl 
analogue producing catatonia and convulsions when injected 
into the lateral ventricles of rat brain (Cessa jet , 1970) * 
,This present investigation shows cyclic Al# to be 
related to behavioural changes. This relationship is based 
on the following findings;-
(i) - Both plasma and urinary levels of cyclic Al# were
significantly lower in patients suffering from
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endogenous depression compared to normals,
(ii) A correlation between cyclic AMP excretion and mood 
was obtained, thus patients suffering from endogenous 
depression excreted least cyclic iil# in the morning 
when depression was most severe.
(iii) The low levels of urinary cyclic AMP observed during 
the depressed phase increased quite significantly on 
clinical improvement,
(iv) Aipproximately 80SG of depressed patients experienced 
significant and sustained improvement, or disappearance
of s^-mptoms, in the course of an E.C.T. series (Kety et al. 
1967). In this investigation 06% of the patients who 
received E.C.T. showed an increase in plasma and 
urinary level of cyclic Al# accompanied by improvement 
in clinical condition. The 14^ of the cases that did 
not show any change in cyclic Al# levels did not show 
clinical improvement.
(v) Women suffering from premenstrual tension, a syndrome 
with symptoms characteristic of depressive illness, 
showed fluctuations in urinary cyclic AJ#. This 
fluctuation was smoothed by the administration of oral 
contraceptives with concomitant relief of the tension.
A number of recent publications provide strong support 
for the biological dualism of cyclic i\J# and cyclic GI# in 
the mediation of a number of biological processes, Watson 
et al. (1973) suggested that cyclic Al# and cyclic GI# mediate
the intracellular signals which determine whether antigen- 
sensitive cells follow an inductive or non-inductive 
(paralytic) pathway. Cyclic A T# and cyclic GMP have also 
been implicated in cell division (Hadden et al., 1972;
Moens et al,, 1975 ), mobility (Estensen _et , 1973) and 
differentiation (Silverman and %stein, 1975)* An increase 
in the cellular cyclic GI# is thought to represent an 
active signal for cell proliferation whereas an elevation 
of cyclic AÎ# concentration may limit or inhibit cell 
division. The contractile forde of the heart is regulated 
by these tTTO nucleotides, cyclic Al# mediating the positive 
inotropic response (Robison ejfc al., I965) and cyclic GI# 
mediating the negative response (George ^  , 1973).
Costa and his colleague (1975) provided evidence for an 
increase of cyclic A l # /cyclic G I#  ratio as the earliest 
detectable biochemical change in the adrenal medulla during 
the trans-synaptic induction of tyrosine-3-monoox;;,’-genase.
In t h e  c e n t r a l  n e r v o u s  s y s te m  c y c l i c  A l#  h a s  b e e n  shown to  
m e d ia te  n o r a d r e n e r g ic  a n d  d o p a m in e r g ic  re s p o n s e s  w h e re a s  
c y c l i c  G I#  m e d ia te s  m u s c a r in ic  re s p o n s e s  to  a c e t y l c h o l i n e  
( T a y lo r  e t  a l . , 1975)* G re e n g a rd  a n d  h i s  g ro u p  (1974) 
p r o v id e d  e v id e n c e  f o r  t h e  in v o lv e m e n t  o f  c y c l i c  G I#  i n  
s y n a p t ic  t r a n s m is s io n  i n  s y m p a th e t ic  g a n g l i a *
In view of this evidence and Janowsky‘s cholinergic- 
adrenergic hypothesis of depression it is possible that the 
low levels of cyclic Al# seen in the endogenous depression
c o u ld  be a c c o m p a n ie d  b y  r a i s e d  c e l l u l a r  c y c l i c  GMP l e v e l s ;  
th u s  t h e  lo w e r in g  o f  t h e  c y c l i c  # I P / c y c l i c  GMP r a t i o  c o u ld  
a c t  a s  a  t r i g g e r  m ech an ism  f o r  end o g en o u s  d e p r e s s io n .
I t  i s ,  to  s a y  t h e  l e a s t ,  u n f o r t u n a t e  t h a t  f i v e  y e a r s  
a f t e r  th e  i n i t i a l  p u b l i c a t i o n s  t h e r e  i s  s t i l l  c o n t r o v e r s y  
o v e r  w h a t  i s  a p p a r e n t ly  e a s i l y  v e r i f i a b l e  -  th e  l e v e l s  o f  
c y c l i c  iUCP i n  b o d y  f l u i d s  i n  m a n ia  and  d e p r e s s io n .  C e r t a i n l y  
we c a n  e x p e c t  th e  d is c o v e r y  o f  o t h e r  seco n d  m e s s e n g e rs , w i t h  
s t r e s s  a t  p r e s e n t  on c y c l i c  GMP an d  i t s  r e l a t i o n s h i p s  t o  
c y c l i c  A l # .  F u tu r e  w o rk  on p a t i e n t s  s h o u ld  in c lu d e  
an  i n v e s t i g a t i o n  o f  c y c l i c  A l # / c y c l i c  G I#  r a t i o s ;  c y c la s e  
r e c e p t o r  s e n s i t i v i t y  i n ,  f o r  e x a m p le , p l a t e l e t s ;  p h o sp h o ­
d ie s t e r a s e  a c t i v i t y  ( i n c l u d i n g  is o e n z y m e  p a t t e r n s ) .  I t  
w o u ld  be o f  v a lu e  to  e x a m in e  b r a i n  p r o t e i n  k in a s e s  b u t  t h i s  
i s  n o t  f e a s i b l e  i n  human s t u d i e s .  As w as  in d ic a t e d  i n  a  
r e c e n t  b r i e f  r e v ie w  i n  t h e  L a n c e t  (1975) t h e r e  a r e  m any c lu e s  
t o  f o l l o w .
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The EflFect of an Ovulatory Dose of Human Chorionic Gonadotrophin on 
Preovulatory Adenosine 3h5'-Cyclic Monophosphate Concentrations 
in Rabbit Ovarian Tissue*
A. K. GOFF and P. W. MAJOR
S e c t i o n  o f  P h a r m a c o l o g y ,  A c a d e m i c  D i v i s i o n  o f  M e d i c i n e ,  U n i v e r s i t y  o f  S h e f f t e l d ,  
S h e f f i e l d  S 1 0 2 T N ,  U . K .
In bovine corpus-luteum tissue and rabbit ovarian tissue i n  v i t r o  evidence suggests that 
(yclic A M P  is an intermediate in the action of luteinizing hormone on steroidogenesis 
(Marsh &  Bavard, 1966; Dorrington &  Kilpatrick, 1967).
Injection of luteinizing hormone or human chorionic gonadotrophin also promotes 
ovulation in oestrus rabbits, and the effect of the latter on concentrations of cyclic A M P  
i n  v i v o ' m . oestrus rabbits has now been investigated. The animals were anaesthetized with 
Nembutal (2ml) and 37 %  urethane (ethyl carbamate). The ovaries were freeze-clamped 
/« j/Vm and transferred to liquid Nz. Cyclic A M P  was extracted and assayed by thë hSethod 
of Brown e t  a l . (1971). Basal concentrations (± s.e.m .) of 1.75 ±0.25nmol/g of tissue 
were found in oestrus rabbits. Cyclic A M P  concentrations rose to a peak of 7.3 ± 
0.93 nmol/g of tissue 30min after the injection of human chorionic gonadotrophin and 
they remained high for about 4h. Concentrations of cyclic A M P  then fell and had reached 
values similar to those found in controls by 8h after the injection of human chorionic 
gonadotrophin and remained low throughout the ovulatory period, 10-12h after admin­
istration of the gonadotrophin.
ATP concentrations were also measured, as described by Lowry e t  a l . (1964); these 
tended to fall from 1.2±0.09/imol/g of tissue (control) to 0.52±0.03)umol/g of tissue at 
8 h after the injection of human chorionic gonadotrophin, but a significant increase to 
1.03 ±0.02jLcmol/g of tissue was observed at the onset of ovulation (lOh).
Uiese results show that human chorionic gonadotrophin can increase cyclic A M P  
production and that changes of cyclic A M P  concentrations occur in rabbit ovaries 
i n  ü/üo with a dose of the hormone that produces the ovulatory response. They also sup­
port the view that cyclic A M P  may mediate the steroidogenic action of luteinizing hor­
mone, since the direction and duration of these changes was similar to changes observed 
in steroid production after mating (Hilliard e t  a l . , 1964).
This work was supported by a grant from the Medical Research Council.
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Diurnal Variation of Plasma and Urinary Adenosine 3' : 5'-Cyclic 
Monophosphate Contents in Normal Human Subjects
HELEN HOLMES and K A M E L  H A M A D A H
T o o t i n g  B e e  H o s p i t a l ,  L o n d o n  S W \ 1  B E L ,  U . K .
and G O R D O N  C. H A R T M A N  and DENNIS V. PARKE
D e p a r t m e n t  o f  B i o c h e m i s t r y ,  U n i v e r s i t y  o f  S u r r e y ,  G u i l d f o r d ,  S u r r e y ,  G U I  5 X H ,  U . K .
A  number of hormones are known to initiate their biological actions by altering the intra­
cellular concentrations of cyclic A M P  (Robison e t  a l . , 1971), and to exhibit circadian 
rhythms (Conroy &Mills, 1970). It would therefore seem likely that periodic changes of
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cyclic A M P  could occur in plasma and urine. Cyclic A M P  has been reported to exhibit 
diurnal variation in mouse epidermis (Marks & Grimm, 1972), rat gastric mucosa 
(Domschke e t  a l ,  1972) and rat adrenal cortex (Moore & Quavi, 1971). In this last case 
the rhythm disappeared after appropriate denervation in the hypothalamic region.
At present there is no available information on the diurnal variation of plasma cyclic 
AMP. The situation with regard to human urinary excretion of cyclic A M P  is confused. 
Chase e t  a l  (1969) did not find any diurnal variation in the excretion of cyclic A M P  in 
four normal volunteers. However, Murad &  Pak (1972) reported circadian rhythms for 
both cyclic A M P  and cyclic G M P  in an unspecified number of subjects.
Plasma and urinary concentrations of cyclic A M P  were investigated in eight men 
and ten women, and urinary concentrations alone were studied in a further three men 
and seven women aged 18-55 years. There was no attempt to modify the diet and physical 
activity of these volunteers, and disturbance of sleep was kept to a minimum. Samples 
were obtained at 4h intervals over a 24h period commencing at 08:(X)h.
Blood was obtained by venepuncture (antecubital fossa), and heparinized plasma was 
isolated and snap-frozen (solid CO 2) within 5min. These plasma samples and portions 
from each 4h urine specimen were stored at -20°C until determination of cyclic AMP. 
Samples were thawed immediately before assay. Then 0.2 ml portions of plasma were 
deproteinized by the addition of 0.2ml of O.SM-ZnSO^ and 0.2ml of 0.3M-Ba(OH)z 
(Krishna e t  a l ,  1968). The deproteinized supernatants were freeze-dried and the residues 
were taken up in 0.1 ml of buffer [50mM-Tris-HCl buffer, pH 7.4, containing theophylline 
(SmM) and 2-mercaptoethanol (6m\i)]. The urine samples were assayed for creatinine 
and a range of dilutions was prepared (1:10 to 1:50) in the buffer specified above. For 
both plasma and urine, cyclic A MP in the appropriately prepared 0.1ml samples was 
determined by the saturation method of Brown e t  a l  (1971). Recovery values for the 
plasma procedure were checked by the addition of a known amount of cyclic [8-H^ ]- 
A M P  and were found to be in the range 70-80%.
Fig. 1(a) summarizes data for plasma and urine from all the subjects studied. The 
bimodal distribution observed for plasma led us to look for two groups within this 
population. Consideration of the first 24 h collection period indicated two distinct urinary 
patterns : the majority (14 female, seven male) showed maximum concentrations of cyclic 
A M P  in the morning (04:00-0:800h); the minority (three female, four male) showed 
a peak in the afternoon (16:00-20:00h), Plasma values also gave two patterns: 
16 subjects (nine female, seven male) showed a cyclic A M P  peak at about midnight 
(24:00h), whereas two subjects (one female, one male) had their peak value at noon 
(12:00 h). Plasma and urinary cyclic A M P  concentrations were remeasured in ten of the 
subjects 8 weeks after the first 24 h survey, and eight of these showed the same moming- 
peak pattern as before. Fig. 1(6) summarizes data for urine and plasma of the moming- 
peak type, and Fig. 1(c) shows the aftemoon-peak pattern. The 24 h urine values for each 
individual investigated on the two occasions varied by not more than 10%, with one 
exception (27 %) of the female who was at different points in her menstrual cycle. All 
24h creatinine values fell within the normal range.
The patterns obtained indicate two groups with regard to peak times, and some indivi­
duals fitted in with both in that they showed a bimodal distribution. The urinary pattern 
does not seem simply to be a reflection of plasma concentration, but this is not surprising 
if a proportion of urinary cyclic A M P  is formed in the kidney and is excreted directly 
(Liddle & Hardman, 1971). Our findings indicate the need for caution in interpreting 
cyclic A M P  concentrations in clinical disorders. It would seem that investigation of 
patterns of variation will be of greater value than the determination of the concentration 
of a random specimen.
We thank Mr. Brian Shipton, the staff of Tooting Bee Hospital and the students of ‘Third 
Court’ for their help in this study. This work was supported by a grant from the South-West 
Metropolitan Regional Hospital Board.
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Diurnal Variation of Urinary Adenosine 3':5'-Cyclic Monophosphate 
Content in Depressive Illness
K A M E L  H A M A D A H  and HELEN HOLMES
Tooting Bee Hospital, London S W \1  SBL, U .K .
and G O R D O N  C  H A R T M A N  and DENNIS V. PARKE
Department o f  Biochemistry, University o f  Surrey, Guildford, Surrey G U I  5 X H , U .K .
An important and significant symptom of depressive illness is the daily fluctuation of 
mood and of the total state. A  worsening of depression in the morning has been associated 
with endogenous depression, whereas a worsening in the evening has been thought as 
characteristic of reactive depression (Winokur et al., 1969). In depressive illness altera­
tions in the circadian rhythms of plasma and urinary contents of corticosteroids (Bridges 
& Jones, 1966), urinary Na+ and Cl“ excretion (Elithom et al., 1966), salivary flow and 
salivary electrolyte excretion (Palmai &  Blackwell, 1965) have been reported. Abdulla 
&  Hamadah (1970) observed abnormally low excretion of cyclic A M P  in patients suf­
fering from depression. Murad &  Pak (1972) have reported a diurnal rhythm for the 
urinary excretion of cyclic A M P  in normal humans, a finding repeated and extended to 
include plasma in a study reported by us in the preceding paper (Holmes et al., 1974). 
The purpose of the present study is to demonstrate possible alterations in the circadian 
rhythm of cyclic A M P  in depressive illness before and after improvement.
We have investigated 11 women, of age range 37-67 years, who were inpatients at 
Tooting Bee Hospital and had been diagnosed either as endogenous depression (seven 
patients) or reactive depression (four patients). All patients received tricyclic antidepres­
sants and a night sedative, and some were also given tranquillizers. The doses were fixed 
throughout the period of study. Seven of the patients were also treated with electro- 
convulsive therapy. Urine samples were collected at 4h intervals over a 24h period com­
mencing at 08 : OOh on two occasions. The first collection was obtained from the patients 
after they were stabilized on drugs (about 1 week after admission), and the second on 
improvement 1-5 months later. For patients who received electroconvulsive therapy 
the second collection was carried out at least 2 weeks after completion of this treatment 
(Hamadah et a l., 1972). Urine samples were stored at —20°C until cyclic A M P  determi­
nation by the protein binding method of Brown et al. (1971).
All patients in the endogenous-depression group changed from a maximum value for 
urinary cyclic A M P  at 08:00-12: OOh when depressed to maxima at 04:00-08 : OOh and 
16:00-20:00h when improved (Table 1). On the other hand all members of the reactive- 
depression group maintained maxima at 24:00-04:00h and 12:00-16:00h both when 
depressed and after improvement (Table 1). A  comparison of the 24h urinary cyclic 
A M P  values for the two occasions showed, on improvement, a rise of 115 %  in the endo­
genous-depression group and 45% in the reactive-depression group. Comparison of 
paired data (Student’s t test) showed the former to be significant (P<0.001).
These results indicate a pattern change in the urinary excretion of cyclic A M P  during 
clinical improvement in patients suffering from endogenous depression but not in those
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Table 1. D i u r n a l  v a r i a t i o n  o f  t h e  u r i n a r y  c y c l i c  A M P  c o n t e n t  i n  p a t i e n t s  w i t h  d e p r e s s i v e  
i l l n e s s
The results presented are the means ± s.e.m . of the determinations (seven for endogenous 
depression, four for reactive depression). Inter-assay coefficient of variation for the cyclic 
A M P  determination in urine = 9.6%.
Amount of cyclic A M P  in urine (nmol/4h urine)
Endogenous depression Reactive depression
During After During After
Time (h) depression improvement depression improvement
24:00-04:00 150+37 300 + 38 350 ±30 520±18
04:00-08:00 170+49 440 ±97 250±48 420 ±70
08:00-12:00 240 ±48 360 ±46 340 ±108 480 ±70
12:00-16:00 180 + 29 270 ±42 410 ±147 550 ±123
16:00-20:00 140+17 430 ±68 310±57 520 ±93
20:00-24:00 140+9 350 ±50 350 ±100 420 ±78
Total for 24h 1000+145 2150±311 2010±388 2910±317
%  increase of the mean 
24h value =115 
(significant at the level P <0.001)
%  increase of the mean 
24h value = 45 
(not significant at the level 
P = 0.1)
with reactive depression. During the depressed phase urinary cyclic A M P  excretion is 
significantly lower in the endogenously depressed patients than in the normal group 
described by Holmes e t  a l . (1974) (P <0.001 for either the whole normal group or for the 
female members of the group). These findings may prove to be of diagnostic and prog­
nostic value.
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Variation in Urinary Adenosine 3':5'-Cyclic Monophosphate Content 
during the Human Menstrual Cycle
KA M E L  H A M A D A H  and HELEN HOLMES 
T o o t i n g  B e e  H o s p i t a l ,  L o n d o n  S W Y l  S B L ,  U . K .  
and M A R Y  L. STOKES
S o u t h  L o n d o n  H o s p i t a l  f o r  W o m e n  a n d  C h i l d r e n ,  L o n d o n  S W 4  9 D R ,  U . K .
and G O R D O N  C. H A R T M A N  and DENNIS V. PARKE
D e p a r t m e n t  o f  B i o c h e m i s t r y ,  U n i v e r s i t y  o f  S u r r e y ,  G u i l d f o r d ,  S u r r e y  G U I  5 X H ,  U . K .
The plasma concentrations of luteinizing hormone and follicle-stimulating hormone 
show a marked rise at about mid-menstrual cycle and this surge leads to ovulation 
(Watson, 1973). In the corpus luteum luteinizing hormone activates adenylate cyclase, 
leading to an increased concentration of cyclic AMP, which in turn leads to increased 
progesterone synthesis (Marsh e t  a l . , 1966). Oestradiol shows a peak plasma concentra­
tion about 1 day before the gonadotrophin peak (Dodson e t  a l . , 1973), and one action of 
this hormone is to restore uterine cyclic A M P  concentrations in ovariectomized rats 
(Szego & Davis, 1967). There is evidence that the administration of pestrogen-progesta- 
gen contraceptive preparations initially suppresses both the oestrogen peak and the out­
put of follicle-stimulating hormone and lutenizing hormone (Dufau e t  a l . , 1970), but the 
gonadotrophins may return to their pre-administration concentration on long-term 
treatment (Loraine e t  a h , 1963). These variations in hormonal concentrations associated 
with the menstrual cycle may influence urinary excretion of cyclic AMP, and Taylor e t  a l .
(1970) reported a mid-menstrual cycle rise in the excretion of this nucleotide in three 
women.
Twelve normally menstruating women, two women with secondary amenorrhoea, 
one pregnancy (second trimester), five women receiving high-progestagen oral contra­
ceptives and four men were investigated (the overall age range being 19-38 years). Five
4,0
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2.0,
o
I
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14 21 2870 21 28147
Day of menstrual cycle 
Fig. 1. U r i n a r y  c y c l i c  A M P  e x c r e t i o n  d u r i n g  t w o  m e n s t r u a l  c y c l e s
o , Overall pattern (12); vertical bars indicate s.e.m . values ; a  , non-pre-menstrual-tension 
subgroup (7); □, pre-menstrual-tension subgroup (5). The shaded areas indicate periods 
of menstruation.
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of those with a normal ovulatory cycle were classified as suffering from pre-menstrual 
tension. Urines (24h) were collected at weekly intervals for a period of up to 2 months. 
Completeness of collection was checked by creatinine determination and the samples 
were stored at —20°C until cyclic A M P  determination by the protein binding method of 
Brown e t  a l . (1971).
The results obtained from the 12 normally menstruating women are shown (two cycles) 
in Fig. 1. A  peak (3.5 ±0.3 /xmol of cyclic AMP/24h urine) was obtained at day 14 (where 
day 1 is defined as the onset of menstruation). This maximum was significantly higher 
than the value on day 7 (2.5±0.2/imol/24h urine; P<0.02) and on day 21 
(2.9±0.2jamol/24h urine; P  = 0.02). The five women receiving oral contraceptives (2.9 
±0.12/xmol of cyclic AMP/24h urine; 32 samples), the pregnant female (3.7±0.17/xmol/ 
24 h urine ; six samples) and the four males (3.1 ±0.15 /tmol/24h urine ; 27 samples) showed 
no significant variation during 6-8 weeks. The two subjects with amenorrhoea excreted 
cyclic A M P  (1.9±0.18jumol/24h urine; nine samples) at a rate comparable with the 
minimum in the menstrual-cycle studies, but again there was no significant change in 
4 weeks.
These findings indicate a maximum urinary excretion of cyclic A M P  associated with 
ovulation. Our results suggest that the pre-menstrual tension syndrome may be associated 
with a rhythm of greater amplitude (Fig. 1), the significance of which is not yet under­
stood. This variation of cyclic A M P  excretion associated with the menstrual cycle again 
indicates the need for care in studying urinary cyclic A M P  contents in clinical states.
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The Effect of Electro-convulsive Therapy on 
the Urinary Excretion of Adenosine 3':5'- 
Cyclic Monophosphate
B y  K. H a m a d a h , H e l e n  H o l m e s  and G. B a r k e r  
( T o o t i n g  B e e  H o s p i t a l ,  L o n d o n  S W l l  S B L ,  U . K . )  and 
G. C. H a r t m a n  and D. V. P a r k e  ( D e p a r t m e n t  o f  
B i o c h e m i s t r y ,  U n i v e r s i t y  o f  S u r r e y ,  G u i l d f o r d ,  S u r r e y ,  
U . K . )
Abdulla & Hamadah (1970) have suggested that de­
pressive illness is due to a severe fall in the intracellular 
concentration of cyclic A M P  (adenosine 3':5'-cyclic 
monophosphate) in all tissues. They also report that 
urinary excretion of cyclic A M P  is lowered in depres­
sive illness, but an increase in the urinary excretion 
occurred after administration of tricyclic anti­
depressants.
Electrical stimulation has been found to increase 
the concentration of cyclic A M P  in cerebral-cortex 
slices (Pull &  Mcllwain, 1972), and electro-convulsive 
therapy has long been accepted as an effective form 
of treatment in some types of depression. We have 
therefore measured the urinary excretion of cyclic 
A M P  in 14 female patients (aged 24-61 years) under­
going electro-convulsive therapy for depressive ill­
ness. The administration of antidepressant or 
tranquillizing drugs and of potential dietary inhibi­
tors of phosphodiesterase (e.g. methylxanthines in 
tea and coffee) was stabilized (Paul e t  a l . , 1971). 
Patients were well oxygenated through the period of 
electro-convulsive therapy, as it has been noted that 
hypoxia in guinea-pig brain slices results in a marked 
increase in the output of adenosine derivatives (Pull 
&  Mcllwain, 1972).
Urines (07:00-07:00h) were collected and stored 
at —20°C, and the cyclic A M P  content was deter­
mined by an enzymic radioisotope-displacement 
technique (Brooker e t  a l . , 1968). It has been suggested 
that this method may lack the specificity inherent in 
the protein binding assay (Brown e t  a l . ,  1 9 1 1 ) , but 
this has not been our experience with determinations 
in urine.
Twelve of the patients showed a significant rise in 
the excretion of cyclic A M P  on the day of electro- 
convulsive therapy (14.2 compared with 4.2/xmol/ 
24h before the therapy). Four controls (failed 
electro-convulsive therapy) showed no significant 
increase. This finding is not in agreement with the 
single-patient study made by Brown e t  a l . (1972), 
but we have found that about 10% of our patients 
showed no significant increase in the excretion of 
cyclic A M P  on the day of electro-convulsive therapy.
The role of cyclic A M P  as a transmitter in the 
central nervous system is under investigation (Green­
gard, 1972). It is possible that the antidepressant 
action of electro-convulsive therapy is mediated 
through an increased production of cyclic A M P  in 
brain, and that this is refiected in an increased urinary 
excretion.
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Effect o f Electric Convulsion Therapy on Urinary 
Excretion of 3', 5' Cyclic Adenosine Monophosphate
K. HAMADAH, HELEN HOLMES, G. B. BARKER, G ,C. HARTMAN, D. V. W. PARKE
Sum m ary
Electric convulsion therapy (E.C.T.) was used in the 
treatm ent o f  13 wom en inpatients suffering from  de­
pressive sym ptom s. Twelve o f  the patients showed a 
significant increase in urinary excretion o f  3 ,  5 cyclic 
adenosine monophosphate (cAMP) on the day o f  treat­
m ent, whereas four controls who received all or part o f  
the prelim inary treatm ent but no electric shock showed a 
reduction. The results o f this study are consistent with  
the hypothesis that the antidepressant action o f  E.C.T. 
is mediated through an increased production o f  cAMP 
in brain tissue.
Introduction
Abnormally low excretion of 3', 5' cyclic adenosine mono­
phosphate (cAMP) has been reported in patients with depressive 
illness (Abdulla and Hamadah, 1970; Paul et a/., 1970). Abdulla 
and Hamadah suggested that depressive illness is due to a severe 
fall in the intracellular level of cAMP in all tissues, including 
those of the central nervous system. Several factors have been 
found to influence cAMP levels in body fluids and tissues. An 
increase in the urinary level has been noted after the administra­
tion of tricyclic antidepressants, and these have been shown to 
be inhibitors of cAMP phosphodiesterase (Abdulla and Hama­
dah, 1970; Ramsden, 1970). Recent studies by Kodama e t  a l .
(1971) on brain slices suggest that imipramine, desipramine, and 
amitriptyline stimulate the formation of cAMP. Electrical 
stimulation has also been found to increase the level of cAMP 
in cerebral cortical slices (Kakiuchi e t  a l . , 1969; Shimizu e t  a l . ,  
1970), and this response was synergistic with that of histamine or 
noradrenaline but was prevented by previous treatment with a 
methylxanthine such as theophylline (Kakiuchi e t  a h , 1969; 
Sattin and Rail, 1970).
Electric convulsion therapy (E.C.T.) has long been accepted 
as an effective form of treatment in some types of depression, 
and we therefore decided to examine the effect of E.C.T. on the 
urinary excretion of cAMP.
Tooting Bee Hospital, London S.W.17 
K. HAMADAH, M.B., D.P.M., Psychiatrist 
HELEN HOLMES, B.sc., Research Assistant 
G. B. BARKER, M.B., D.P.M., Consultant Psychiatrist
University o f  Surrey, Guildford, Surrey
G. C. HARTMAN, dip.tech.. Lecturer in Biochemistry
D. V. W. PARKE, PH.D., F.R.I.C., Head of Biochemistry Department
Patients and Methods
The investigation was carried out on 14 women inpatients at 
Tooting Bee Hospital suffering from depressive symptoms who 
were judged clinically to require treatment with E.C.T. The 
only additional criteria for selection were the willingness and the 
ability of the patients to co-operate in the investigation. Patients 
with heart or kidney diseases were excluded. The age range was 
from 24 to 61 years. Throughout the period of the study the 
patients were given a diet that lacked foods which might affect 
indole and catecholamine excretion (Paul e t  a h , 1970). No 
alcohol was permitted and tea and coffee intake was stabilized. 
Patients were clinically assessed on the day before E.C.T., on 
the day of treatment, and on the following day to detect any 
sudden or pronounced change in mood. All participants 
received antidepressants or tranquillizers, or both, the doses of 
which were fixed throughout the period of the study.
E.C.T. was administered regularly between 09.30 and 11.00 
hours on Tuesdays and Fridays. All patients received 0 6 mg of 
atropine sulphate as premedication half to one hour before 
treatment. In 11 patients, who received a total of 19 treatments, 
the convulsion was modified by the intravenous injection of 
60-70 mg of methohexitone sodium and 25-50 mg of suxametho­
nium chloride immediately before E.C.T. In the last two patients 
in the E.C.T. group, who received a total of seven treatments, 
the convulsion was modified by the intravenous injection of 
250 mg of thiopentone sodium and 30-50 mg of suxamethonium 
bromide. The E.C.T. was administered with an Ectonus mark 
3 A.C. mains model (Ectron Ltd.). The electrodes (Ectonus 
head-band) were lightly soaked in Ectronolyte solution and 
applied bitemporofrontally. The rotary control was used to 
apply the potential in a series of increasing steps, reaching a 
maximum of 140 V; the current was passed for about one second. 
The patients were well oxygenated with 100% oxygen.
On three occasions patients received all the preliminary 
treatment but for various reasons, including instrument failure, 
no shock was delivered. As they had experienced the anti­
cipatory anxiety and had received atropine sulphate, metho­
hexitone sodium, suxamethonium chloride, but not the electric 
shock they were regarded as controls on these occasions. A  
fourth patient, who received the atropine sulphate but panicked 
before further treatment could be given and refused it, was 
regarded as a separate control. Thus the controls (see Table) 
were achieved by chance rather than design. It was felt to be 
unacceptable on ethical grounds to enlarge this control group.
Twenty-fbur-hour specimens of urine (07.00-07.00 hours) 
were collected for up to three days before the first E.C.T. to 
establish a baseline for each individual patient and to determine 
the day-to-day variation of cAMP excretion. Twenty-four-hour 
soecimens were also collected on the day of E.C.T., for two 
days after E.C.T., and, where appropriate, on the days between 
subsequent treatments. The total urinary output over each
674/72
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Ejfect of E.C.T., on Urinary 3', 5' Cyclic Adenosine Monophosphate
Urinary Excretion of cAMP (ixmol cAMP/2' Ihr)
Before E.C.T.* D ayofE .C T . After E.C.T.*
Case No,
% Change in cAMP Excretion 
on Day of E.C.T. compared 
with Before E.C.T.
E.C.T. Group
1 ............................ 3 6 7-8 4-3 -+120
2 . .  . .  . . 2 6 6-9 2-9 -f 170
f l -4 8-3 7-5 +  480
I 3-9 14-5 15-1 +  280
1 6-5 21-2 6-6 +230
16-6 23-0 14-4 +  250
9-1 24-8 4-7 +  170
5 ............................ 12-2 28-6 5-7 +  130
/2 - 4 4-3 1-5 +  80
1 1-5 6-8 3-5 +  370
7 ............................ /1 - 9 3-6 2-0 +  90
12-0 3-7 3-6 +  90
8 . .  . .  . . /3 - 8 6-9 4-6 +  8)
14-6 27-0 4-2 +  49 '
9 ............................ f l - 2 3-5 3-1 +  18'.
15-2 21-5 19-1 + 31.'
1 0 ............................ 6-2 38-1 25-2 +  52'.
1 1 ............................ /2 - 0 2-3 2-1 +  20
12-1 2-0 1-9 0
f l-7 2-8 2-3 +  60
1 2 t ............................ 2-3 14-4 4-5 +  540
U -5 28-3 2-2 +  530
(4-9 20-0 2-0 +  310
1 3 + ............................ J 2-0 29-7 4-4 +  1,360
) 1-9 3-9 13-2 +  110
11-2 14-1 2-2 +  1,070
Mean vainest • • 4-2 (0-4; n =  51) 14-2 (2-1; n =  26) 6-3 (0-7 ; n =  44) +310 (50; n = 26)
Control Group {No E.C.T.)
4 # • • • • • 26-1 24-6 20-3 — 6
9-3 7-9 5-0 - 1 6
5-1 3-7 0-9 - 2 7
10§ 3-0 1-0 0-9 - 6 7
♦Mean value (where appropriate).
tPatient received thiopentone sodium instead of methohexitone sodium.
$Mean values with S.E. of mean and number of samples in parentheses.
§Patient received 0 6 mg atropine sulphate only.
Comparison of the paired data for cAMP excretion before E.C.T. with excretion on the day of E.C.T. gives P <0-001. For Cases 9-13 a double-blind procedure was used. 
Only after assaying all specimens was the code disclosed.
24-hour period was pooled over 1 ml of chloroform, thoroughly 
mixed, and a 10-ml sample stored at — 20°C until analysis. The 
completeness of the collection was checked by determination of 
the creatinine content as described by Varley (1969). cAMP 
was determined by the enzymic-radioisotopic displacement 
method essentially as described by Brooker e t  a l . (1968).
Results
The changes in cAMP excretion resulting from the administra­
tion of E.C.T. in a typical case are shown in the Chart. Twelve 
of the 13 patients who received E.C.T. (see Table) showed a 
significant rise in urinary cAMP excretion on the day of treat­
ment, when the mean value for the 13 patients (26 treatments) 
was 14 2 (xmol/24 hr compared with a mean of 4 2 (Amol/24 hr 
for the period before E.C.T. (P <0 001). In general the excre­
tion of cAMP fell on the following day but not necessarily to 
the pre-E.C.T. level. The four controls showed a fall in the 
urinary excretion of cAMP on the day of (abortive) treatment 
(see Table).
D iscussion
A  rise in urinary cAMP excretion after E.C.T. could be due to 
one or more of the following factors: anticipatory anxiety, 
premedication, anaesthesia, the administration of muscle 
relaxant, hypoxia, or electrical stimulation. The failure of the 
four controls to show any increase in cAMP excretion suggests 
that E.C.T. was the major factor responsible for the rise in 
cAMP excretion observed in this investigation. This con­
clusion is supported by the results of other studies. The work of 
Cox and Potkonjuk (1969), and of Robison e t  a l . (1971) suggests 
that atropine would have little or no effect at the dose level used. 
Wilson (1969) showed that barbiturates lower cAMP levels in
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Daily urinary cAMP excretion in a patient who received 
E.C.T. on days 4 and 8.
the rat brain, and Havens e t  a l . (1959) showed that thiopentone 
and suxamethonium reduce the postconvulsive levels of catechol­
amines in the plasma of patients undergoing E.C.T. and hence 
probably also lower cAMP levels (Robison e t  a l . , 1971).
The procedure used in E.C.T. needs to be carefully controlled 
to prevent hypoxia, which can result in various biochemical 
changes. Thus Havens e t  a l . (1959) showed that the post- 
convulsive plasma level of adrenaline bears an inverse relation 
to the degree of oxygenation of the patient, while anoxia leads 
to a definite increase in the level of cAMP in mouse and rat 
brain (Goldberg e t  a l . , 1970; Ditzion e t  a l . , 1970). In the present 
study the patients were well oxygenated, and the lack of increase 
in cAMP level in the three suxamethonium-treated controls 
again points to convulsive electric shock as the causative factor. /
The mechanism by which electrical stimulation increases thf
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level of cAMP in the brain remains to be established. Although 
the direct administration of the monoamines noradrenaline and 
histamine into rat cerebral cortex causes prolonged activation of 
adenyl cyclase (Chou e t  a l . , 1971) the E.C.T.-induced increase 
in brain cAMP content cannot be completely explained by the 
action of these amines, since electrical stimulation of guinea-pig 
cerebral cortex produces an accumulation of cAMP over and 
above that produced by either noradrenaline or histamine (Rail 
and Sattin, 1970). Currently the most plausible suggestion is that 
depolarization results in increased release of adenine-ribose 
compounds, which then stimulate cAMP formation (Rail and 
Sattin, 1970).
This study has shown that E.C.T. produced an increase in the 
urinary excretion of cAMP, which may be due to increased 
tissue levels of cAMP or to an increased rate of elimination. The 
direct electrical stimulation of slices of guinea-pig cerebral 
cortex, however, rapidly produces a greatly increased level of 
cortical cAMP (K^uchi e t  a l . , 1969; Shimizu e t  a l . , 1970), 
and, furthermore, evidence has been obtained to support the 
suggestion that cAMP mediates the physiological actions of 
neural transmitter substances in the central nervous system 
(Florendo e t  a l . , 1971; Greengard and Kuo, 1970). Possibly, 
.therefore, the antidepressant action of E.C.T. is mediated 
through an increased production of cAMP in the brain, which is 
reflected in the increase observed in the urine of E.C.T.-treated 
patients.
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